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Abstract  
 
Drug safety is a major cause of attrition in contemporary drug development. Many promising 
candidate drugs are terminated in the developmental process or withdrawn in the post-
approval stage because of adverse drug reactions (ADRs). Among these, cardiovascular (CV) 
ADRs occur with a high incidence. Affecting the heart, blood vessels and blood components, 
CV ADRs can lead to hypertension, heart failure, cardiac arrhythmias and thrombosis. The 
prompt identification of CV toxicity would reduce both the delay and cost of drug 
development and increase patient safety.  
Drug-induced vascular injury (DIVI) in pre-clinical toxicology studies involves damage to 
endothelial (EC) and smooth muscle cells (SMC) in small and medium sized vessels, but little 
is known about the mechanisms of DIVI. Damage includes microhaemorrhage, endothelial 
junction disruption, SMC necrosis and inflammation. DIVI is often observed preclinically, 
driving a need to study this in human tissue. 
The aim of this thesis was to develop and characterise an in vitro human model that would 
allow the study of DIVI in human tissue during drug development. 
The first stage was to effectively reproduce DIVI in an animal model. To reduce the utilisation 
of live animals, a vessel explant was used. To determine whether DIVI was recapitulated ex 
vivo von Willebrand factor (VWF) release, one of the hallmarks of DIVI, was analysed using 
four drugs reported in the literature to produce DIVI. The same four drugs were then tested 
in human EC and SMC for the following features of DIVI: (1) VWF release; (2) EC monolayer 
disruption; (3) inflammation; (4) EC and SMC death. Both ex vivo in rats and in vitro in humans, 
the drugs did not exhibit common characteristics and each expressed DIVI features in 
different ways.  
The human in vitro model was also assessed in a co-culture of EC and SMC, and in the presence 
of a flow-mimetic that reproduces in vivo-derived hemodynamics. It was concluded that DIVI 
cannot be fully recapitulated in vitro in such a reductionist cellular model, suggesting that 
exposure to the complex microenvironment of the vasculature may be required for the 
lesions to develop, or that DIVI may, in fact, not be relevant to humans at all.  
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1. Introduction  
 2 
 
1.1 Timeline of drug production  
 
The research and development (R&D) process of a new drug takes on average 15 years, costs 
over 1 billion dollars and only 0.01 % of compounds are successful in making it to market1. In 
spite of years of effort to improve R&D efficiency and performance, bringing a new drug to 
market still remains a very expensive and time-consuming process1,2.  
 
The drug development pipeline can be divided into different stages (Figure 1.1)3. The first 
stage is the discovery phase, which is aimed at finding a promising drug candidate, which 
means that numerous compounds will be synthesised and screened before a lead series 
emerges. This is proceeded by the preclinical phase, which usually takes 3-6 years to complete 
and is conducted through in vitro studies and animal work, usually using rodents and dogs. If 
successful, the compound proceeds to clinical phases I, II and III, which usually require 1, 2, 
and 3 years, respectively, for completion, though this depends on the disease indication3. The 
clinical phase I trial examines the pharmacokinetics and safe dosage range. The drug is 
administered at low doses to a small group of closely monitored healthy volunteers (20 to 
100). On average, about two thirds of phase I compounds will progress to the next phase. 
Phase II is conducted on a larger cohort, perhaps 100 to 300 volunteers, who suffer with the 
condition for which the new drug has been developed. In these studies, the drug efficacy, 
method of delivery and the dosing intervals are assessed. Simultaneous animal and human 
studies continue to evaluate further its safety. At phase II, compounds can be discontinued 
due to adverse clinical side effects, or lack of efficacy. Phase III trials include a greater number 
of volunteer patients (usually thousands) with the aim to assess the drug therapeutic effect 
in a disease population and determine low-incidence adverse reactions3. If the drug 
successfully completes all clinical phases it is then submitted for regulatory approval and 
marketed. Phase IV runs alongside commercialisation of the drug, enabling monitoring on a 
larger scale for potential serious but rare side effects over the longer term. (Figure 1.1).  
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Figure 1.1 Drug development process. It includes preclinical and clinical research, after which a drug is marketed. The process 
can take up to 15 years on average to complete and can cost over 1 billion dollars. Author’s own drawing.  
 4 
 
In the past, the drug development process was not as stringent as it is today. During the 1950s 
and 1960s, the widely used hypnotic drug, thalidomide, was introduced to the market and 
administered to thousands of pregnant women to treat morning sickness, and was thought 
to be safe when it was marketed in 1957. Over 10,000 children were born with severe limb 
deformities4. In response to this and other accidents, stricter regulations were introduced 
making the drug development process more stringent to increase patient safety.  
 
Drug development  is associated with a high level of attrition, especially in early discovery and 
also in its II and III phases, which are also the most costly5,6. The success rates of developing 
a drug vary considerably depending on the different therapeutic areas: for example, 
cardiovascular (CV) has a ~20 % rate of success, compared with oncology and central nervous 
system disorders have ~5 % and ~8 % success, respectively7. 
 
Drug attrition can happen for several reasons: for example, in 1991, pharmacokinetics, and 
particularly bioavailability, were the most significant cause of attrition, accounting for ~40 % 
of all attrition. By 2000, these factors had dramatically reduced to less than 10 %, as efforts 
had been made to improve the prediction of pharmacokinetics and bioavailability7.In 2000, 
the major causes of attrition were lack of efficacy, accounting for around 30 % of failures, with 
safety accounting for a further 30 %8–11. Presently, failures due to efficacy and safety issues 
remain high7,10,11. This demonstrates the need to develop more predictive animal models and 
experimental medicine paradigms that are prognostic of the outcomes.  
 
At present, promising candidate drugs are often terminated in the developmental process or 
withdrawn in post-approval stage because of adverse drug reactions (ADRs)12,13. ADRs are 
defined as “a response to a drug which is noxious and unintended, and which occurs at doses 
normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the 
modifications of physiological functions”14. ADRs are one of the leading causes of morbidity 
and mortality in healthcare. Previous studies show that ADRs happen in 6.5 % - 20 % of 
hospitalised patients15, and that ADRs are themselves one of the more frequent causes of 
hospitalisation16. 
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1.2 Cardiovascular adverse drug reactions 
 
CV ADRs occur with a high incidence, accounting for 45 % of all ADRs17. Phase I clinical trials 
are very safe from a CV point of view, which may reflect that the preclinical studies were 
effective17. However, when drugs are administered for longer periods of time and to larger 
patient groups, high-risk ADRs such as arrhythmias, coronary artery disorders, embolism and 
thrombosis are detected, suggesting that subtle events are either not identified in earlier 
clinical trials or not believed to be biologically significant. It is important however to consider 
the complexity of the patient condition, as later stage trials involve disease subjects, who may 
have a weakened immune system and lower CV output and thus it is challenging to predict 
the effect of the drugs in these patients from healthy volunteers.  
Therefore, prompt identification of CV toxicity is of fundamental importance to i) reduce 
delays and costs of drug development, ii) increase the number of new drugs registered, iii) 
reduce the number of withdrawals, and above all iv) improve patient safety. 
 
1.2.1 Cardiac ADRs 
 
Cardiac arrhythmias are the most commonly reported CV ADRs. Between 1990 and 2006, one-
third of all drug withdrawals occurred because of drug-induced Torsades de Pointes (TdP), a 
potentially fatal arrhythmia18. Over the last decade, progress has been made into 
understanding the molecular mechanisms of TdP with a physical read-out and biomarker of 
drug-induced TdP, i.e. the prolongation of the QT interval on the electrocardiogram and 
addressed by assessing the blockade of the human Ether-à-go-go- related gene (hERG) 
potassium (K+) channel (Kv11.1)19. The availability of the biomarker, coupled with an 
understanding of the major molecular mechanism that underlies this ADR, has minimised the 
TdP risk through in vitro and in silico screening during early discovery. 
 
In contrast, myocardial ischaemia, myocardial necrosis, heart failure and coronary artery 
disorders are not always identified during early drug development, and are reported at the 
post-approval stage17, suggesting that current preclinical and clinical testing is failing to detect 
these liabilities. High-profile examples are the withdrawal of rofecoxib (Merck & Co., Inc.) in 
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2004 and valdecoxib (Pfizer, Inc.) in 2005, drugs that were associated with an increased risk 
of potentially fatal CV events20,21.  
 
Cardiac valve dysfunction, epicardial and endocardial disorders, and disorders affecting blood 
components are also not often reported during drug development and are more likely 
reported post-approval. This might be since these CV events are difficult to assess in 
preclinical models or are not deemed to be biologically significant at early stages, as the 
aetiology of drug-induced cardiac dysfunction is poorly understood, but then ADRs emerge 
when drugs are administered for longer periods of time to larger patient populations with a 
wide variety of co-morbidities. In principle, the risk of heart failure, cardiomyopathy and 
coronary artery disorders can be assessed by monitoring left ventricular function and 
coronary blood flow. There are sensitive and predictive imaging technologies such as 
ultrasound and magnetic resonance imaging to measure changes in cardiac function that 
might precede myocardial damage. However, these technologies are not routinely performed 
in preclinical studies unless triggered by other signals22. In addition, we are still unable to 
predict other serious ADRs, such as pericardial and endocardial disorders for which only 
histopathological examination is currently available. 
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1.2.2 Vascular ADRs 
 
Drug-induced vasculitis is an inflammation of blood vessels that causes thickening, 
weakening, narrowing and scarring23. It is caused by a number of drugs, including antibiotics, 
psychoactive agents and anti-tumor necrosis factor-α (TNF-α) agents23. The pathogenesis of 
drug-induced vasculitis is unclear and there is no standard treatment. In addition, the only 
approach to stop the ADRs is treatment cessation. 
 
Other vascular adverse events have been described as a serious consequence of some of the 
newer tyrosine kinase inhibitors (such as imatinib mesylate, which targets the abnormal gene 
BCR-ABL, used in the treatment of chronic myeloid leukaemia)24. These issues were initially 
unnoticed, but as clinical experience with these drugs evolved, vascular toxicity had become 
clearer with ADRs including pulmonary hypertension, acute and chronic arterial and venous 
occlusion, vasospastic phenomena and platelet dysfunction observed. 
 
1.2.3 Translational problems between pre-clinical to clinical trials for cardiovascular drugs 
 
One of the difficulties with preclinical evaluation of compounds is the limited translatability 
cross-species. There are numerous differences between animal species used in preclinical 
studies and humans and this is the reason why mice, rats, dogs, monkeys, guinea pigs, and 
zebrafish are used in preclinical studies. Despite over 95 % genome homology between mice 
and humans, there is great disparity between gene redundancies and regulation of gene 
expression levels. 
 
There are also intraspecies differences. For example, laboratory mice have been developed 
as inbred strains and therefore will have a highly homogeneous genetic composition. A study 
reported that some mouse strains are fully resistant to Ebola virus, whereas other mice die 
without reporting specific symptoms25. This points to the complexity of in vivo models. 
 
There have also been examples whereby mouse models have not accurately represented the 
human condition. For example, genetically engineered mouse models of cystic fibrosis 
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develop intestinal diseases similarly to humans but do not show the pulmonary complications 
that are a major part of the morbidity of human cystic fibrosis26. Therefore, preclinical in vivo 
studies need to be conducted in more than one species to give more confidence. 
 
A comparative study of the vasculature of a range of mammals revealed that the peripheral 
vasculature of the human resembled that of the monkey closely, was similar to that of the 
dog, and was dissimilar to that of the pig, rat, guinea pig and rabbit27. Moreover, it is known 
that vessel distribution between species greatly differ. Coronary collateral flow in certain 
species is the most important factor involved in the rate and extent of cell death within an 
ischaemic area in myocardial infarction28,29. In species such as the pig, where there is no 
coronary collateral circulation, coronary occlusion will result in a region of severe ischaemia 
causing irreversible injury and cell death in the absence of reperfusion. In contrast, the dog 
has extensive collateral connections, which will reduce ischaemia, slow down cellular injury 
and may deliver sufficient blood to allow survival of the original ischaemic area. Although the 
rat is widely used in drug experimentation, its collateral flow status in myocardial ischaemia 
has not been extensively studied, however one study has shown that the rat is unique among 
species in that it has both extracardiac and intracardiac coronary collateral vessels30.  Another 
study measured collateral flow during myocardial ischaemia in eight species and found it to 
be in this order: high (guinea pig); significant (dog and cat); minimal (rat); and zero (ferret, 
baboon, rabbit and pig)31. It has been speculated that the level of collateral flow in ischemia 
in humans depends on the age and pathology of each individual but is generally low31. These 
examples highlight the differences between species and the difficulty in finding a 
representative model of the human physiology.  
 
Species differences in CV pathophysiology have been observed also with compounds that are 
toxic in animals and not in humans, such as caffeine that causes arteritis in rats32. 
Furthermore, there are differences in the human and laboratory animal immune system33. 
For example, interleukin-8 (IL-8), a chemokine responsible for the migration of neutrophils to 
the site of inflammation, is absent in the mouse, but present in humans. In most cases, there 
are limitations to the preclinical models used in drug development and this is the reason why 
numerous approaches are employed throughout the process. 
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1.3 Drug-induced Vascular Injury  
 
Drug-Induced Vascular Injury (DIVI) is often reported with candidate drugs that reach the 
preclinical in vivo stage of development34,35 and can cause considerable delays in the drug 
developmental process because compounds that cause DIVI in preclinical studies are often 
stopped from further development or the entire process delayed35,36. DIVI is also reported 
with drugs that are routinely used and the vascular complications will depend on the specific 
drug mechanism, e.g. anti-VEGF therapeutics that block endothelial growth in the treatment 
of certain types of cancers have an impact on vascular injury. 
 
DIVI is difficult to detect due to the absence of specific and sensitive biomarkers cross-species, 
and the lack of in vitro models that are currently available to screen candidate drugs for DIVI 
risk during development. As such, DIVI is crudely defined through nonspecific cell death, 
vasoactive and inflammatory markers (section 1.3.1). So far DIVI has been documented in 
pathology (through histochemistry) and in vivo through changes in physiological cues. 
Furthermore, there remains speculation as to whether DIVI exists in humans, since no clinical 
observations have been reported as several drugs known to cause DIVI preclinically have 
caused no CV ADRs representative of DIVI. These will be discussed in more detail below. 
Besides histological methods, the non-invasive detection of DIVI in animals or humans is 
currently not possible due to the absence of biomarkers. The need to confirm that a candidate 
drug is safe for administration to humans, when toxicity is observed preclinically, remains. 
 
1.3.1 Histopathological signs of DIVI 
 
DIVI is characterised by arterial lesions. The anatomy of the large vessels consists of three 
tunicae: (1) intima, composed of endothelial cells (EC); (2) media, composed of smooth 
muscle cells (SMC) and bounded by a porous internal and external elastic lamina; and (3) 
adventitia, composed mainly of fibroblasts that in large vessels are surrounded by vasa 
vasorum (small blood vessels), and adipose tissue, macrophages, mast cells, and nerve 
terminations (Figure 1.2). 
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Figure 1.2 Structure of the arterial wall. The arterial wall is composed of three layers: tunica intima (endothelial cells and internal elastic lamina), 
tunica media (smooth muscle cells and external elastic lamina), and tunica adventitia (perivascular adipose tissue cells, fibroblast cells, collagen 
fibers and nerve endings). Image on the left is taken from203, image on the right is the author’s own drawing. 
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DIVI was first identified using histology in the late 1970s37, characterised by arterial lesions in 
selected vascular beds that are induced within hours of drugs administration in rats, mice, 
dogs, pigs, and monkeys. A lesion is defined as a histopathologic change, characterised by 
haemorrhage, inflammation, endothelial activation (the endothelium remains intact but gaps 
are formed between EC) and SMC necrosis to the vessel structure (Figure 1.2). This can range 
from barely noticeable (in mild lesions) to severe, resulting in significant tissue or organ 
dysfunction or failure38. 
 
Common histopathological signs of DIVI in rats and dogs are shown in Figure 1.3. In the rat, 
DIVI mostly affects mesentery arteries and generally only large calibre arteries with an 
external diameter of 100-800 μm38–46. In these studies following 24 hours of drug treatment, 
lesions are characterised by mild to moderate perivascular accumulation of mononuclear 
inflammatory cells, with necrosis and haemorrhage within the tunica media. Although the 
endothelium was generally intact, there was significant loss of SMC, and the red blood cells 
(RBC) were observed in the cavities vacated by dead SMC39. The lesions typically diminished 
over 3-14 days as leukocytes (mainly macrophages, T-cells and B-cells) adhered to the 
endothelium and fibroplasia (the process of forming fibrous tissue) occurred. This process has 
been shown in arterial lesions where damage evoked by dopaminergic agonists such as 
dopamine and fenoldopam undergo regeneration or repair39. In this study, lesions induced by 
dopamine were repaired in all rats as observed morphologically by 14 days after exposure to 
dopamine39. Lesions induced by fenoldopam also had undergone significant repair by 28 days, 
however these arteries had a thickened media surrounded by adventitial fibrosis. The 
presence of scar tissue could lead to narrowing of blood vessels, reduced physiological blood 
flow or reduced ability of the vessel to dilate causing secondary problems. However, it has 
been noted that vessel repair tended to depend on the specific experimental design and the 
literature is conflicting on this point34. 
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Figure 1.3 Haematoxylin and eosin staining of rat and dog arteries. (A) Mesentery artery of 
a control rat with no vascular injury present; (B) Mesentery artery of a rat 24 hours after 
treatment with fenoldopam showing perivascular accumulations of mononuclear cells 
(arrow) along with haemorrhages in the media (*)38; (C) Coronary artery of a control dog; (D) 
Coronary artery of a dog treated with a K+ channel opener showing RBC infiltrate into the 
vessel wall (arrow)203. Scale bars represent 200 μm. Taken from38,203. 
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In studies conducted in the dog, in all vessels investigated, DIVI primarily affected 200-500 
μm epicardial segments of the left and right coronary arteries47,48,57–63,49–56. The histology and 
time frame were similar to that seen in the rat, consisting of necrosis of the tunica media with 
accumulation of RBC. In advanced lesions, all vascular tunicae shown in Figure 1.2 were 
involved and in addition haemorrhage and accumulation of mononuclear and 
polymorphonuclear leukocytes, and proliferation of fibroblasts occurred in the tunica 
adventitia. Studies in dogs reported petechial and ecchymotic haemorrhages predominantly 
on the epicardium of the right atrium and coronary arteries of the atrioventricular groove35. 
Microscopically, arterial lesions were characterised by distensive haemorrhagic necrosis with 
inter-endothelial separation and adhesion of leukocytes and platelets. Images taken with 
scanning electron microscopy (SEM) showed severe EC and SMC damage, with RBC occupying 
cavitations in the SMC and leukocytes adhering to the lumen in the inter-endothelial gaps 
(Figure 1.4). Similarly to the rat model, it was shown that lesions in dogs resolved with time. 
For example, dogs treated with the opener of KIR (inward rectifier) 6.X ATP sensitive K+ 
channels minoxidil the lesions were evaluated at 1,3,10 and 34 day post-dosing and it was 
observed that substantial repair of the arterial lesions occurred such that by day 34, all 
sections of extramural coronary artery were apparently normal61.   
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Figure 1.4 Scanning electron microscope images of a control dog and a dog treated with 
SK&F 95654. A represents a dog control coronary artery, where EC (e) are flattened and 
demarcated by closely apposed, raised, irregular plasmalemmal ridges (arrowheads). 3200x. 
B represents a dog treated with SK&F 95654 for 24 hours, where EC (e) appear more rounded 
with gaps present at the intercellular boundaries. Numerous inflammatory cells (arrowheads) 
adhere to the surface, often lying at the intercellular boundaries. 800x. Taken from61. 
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In larger mammals (e.g. pigs and monkeys), studies have shown that DIVI lesions are similar 
to those described in the dog and consist of medial necrosis with cellular debris and 
inflammation in the intima, media and adventitia64,65. Interestingly, arterial lesions have been 
also described in the small and large intestines and testis. In some affected vessels, 
inflammatory cell infiltrates were accompanied by intimal proliferation in more severe 
lesions, marked fibrinoid necrosis was present in the tunica media, with loss of the internal 
elastic lamina. Necrotic vessels had edema and numerous inflammatory cells in the tunica 
adventitia and surrounding tissues. In severely affected vessels, the lumen was often occluded 
by intimal proliferation, inflammatory cells, necrotic debris, and thrombus formation. Veins, 
venules, arterioles, and capillaries were usually unaffected.  
 
A timeline of the lesion development in the different species described is depicted in Figure 
1.5. 
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Figure 1.5 Timeline of the development of the lesions in DIVI in rats, dogs and monkeys. 
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Spontaneous or background lesions such as arteritis in control animals have been reported in 
almost a quarter of studies performed during drug development in rats and dogs and 
confound the identification of DIVI47,49,66. These spontaneous lesions usually develop with age 
in hypertensive rats, and have also been reported in dogs57.  
 
One method to differentiate spontaneous lesions from DIVI may be to assess the nature and 
distribution of the lesions. Spontaneous arteritis usually occurs in medium to small arteries in 
many organs, in addition to the mesentery and coronary arteries; haemorrhage in the tunicae 
media and adventitia is absent in spontaneous arteritis whereas is always present in DIVI47. 
 
In addition, polyarteritis nodosa, an idiopathic vasculitis, affects small to medium-sized 
arteries in several vascular beds in humans67,68. Rash is a common manifestation of human 
drug-induced vasculitis, where eosinophils are prominent in biopsies69,70. Neither rash nor 
eosinophils are common in DIVI. 
 
The tissue specificity of DIVI can be linked to differences in flow in different vascular beds 
(refer to Introduction 1.7) and depends on the mechanism of the specific drug. 
Currently, there are multiple biomarkers available for DIVI (summary tables of these 
biomarkers are provided later in this chapter), however there is not a robust marker that 
translates across species and is observed in all vascular beds. Moreover, the current available 
biomarkers are assessed post-mortem using histopathology, providing limited utility as a 
clinical diagnostic. The ideal marker would ideally have the following characteristics: (1) it 
should be specific and sensitive, and correlate with the severity of damage; (2) it should 
detectable very early, before any histopathological damage; (3) it should return to baseline 
values when there is no further cell and/or tissue damage; (4) it should be accessible in the 
circulation for easy monitoring without requiring an intrusive biopsy; and finally (5) it should 
be translational, i.e. it should bridge across species. 
 
1.3.2 Physiological signs of DIVI 
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Many of the potent vasodilators, such as the opener of KIR (inward rectifier) 6.X ATP sensitive 
K+ channels minoxidil, phosphodiesterase (PDE) III inhibitors, and hydralazine are associated 
with significant haemodynamic changes, sufficient to induce marked reflex tachycardia, and 
CV lesions51,52,61,71,72. These drugs progress to clinical studies where patients are monitored 
for changes in blood pressure and heart rate, and doses that cause marked decreases in 
systemic vascular resistance, hypotension, and reflex tachycardia are avoided. However, 
other drugs do not induce significant systemic changes, but rather cause local increases in 
blood flow in selected vascular beds62,73,74. This will be explored more in detail in the 
mechanisms of DIVI (section 1.5.1). 
 
1.4 Drugs that cause DIVI 
 
1.4.1 Approved or approvable drugs responsible for vascular injury in animals  
 
Many drugs associated with DIVI in preclinical animals are known vasodilators. In the past, it 
was generally accepted that as long as therapeutic doses of candidate drugs in humans did 
not cause marked hypotension and reflex tachycardia, these drugs progressed to clinical 
studies34,51,61,75. Therefore, some drugs reported to produce DIVI in animal models have been 
developed and are currently on the market, as no adverse events in humans were observed76. 
However, recent studies have suggested that vascular injury is not always associated with 
profound systemic hemodynamic changes in blood pressure and heart rate, meaning that 
these parameters are of little clinical value to monitor vascular injury in humans56,74. 
Therefore, there is a need to identify whether DIVI occurs in humans, and if so, work toward 
generating tools to assess this adverse event both preclinically and clinically. 
 
DIVI incidence has been reported with at least six different pharmacological classes of drugs 
in preclinical species. Examples of approved or approvable drugs that cause arterial toxicity 
in animals but not in humans are summarised in Table 1.1 and include: PDE III and IV 
inhibitors, DA1 and A1 agonists, K+ channel openers, and ET receptor antagonists. This is not 
an exhaustive list and other compounds have also been shown to induce DIVI. Table 1.1 also 
illustrates the drugs that have been selected for the experiments within this PhD thesis (inside 
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the red box). Four drugs with different mechanisms of action have been selected: bosentan, 
an ET receptor antagonist, fenoldopam mesylate, a DA1 agonist, minoxidil sulfate, an opener 
of KIR (inward rectifier) 6.X ATP sensitive K+ channels and rolipram, a PDE IV inhibitor. The 
drugs in Table 1.1 are considered safe in humans, as no evidence of clinical risk has been 
reported. The reason for selecting drugs from four different pharmacological classes was to 
understand whether a common underlying mechanism of DIVI exists among them. A 
summary of the commercial uses, dosage and half-life of these drugs in humans is also 
presented in Table 1.1, and experiments conducted in animals with these and other drugs 
reported to cause DIVI in animals are listed in Table 1.2. 
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Drug Pharmacological 
class 
Commercial use Dosage in humans  Half life Reference 
Bosentan ET receptor 
antagonist 
Treatment of pulmonary 
artery hypertension 
62.5 mg/125 mg (tablets) 5 hours 35,62,77,78 
Fenoldopam 
mesylate 
DA1 agonist Treatment of hypertension 10 mg/ml (intravenous) 5 minutes 76,79,80 
Minoxidil sulfate K+ channel opener Treatment of resistant 
hypertension and alopecia 
2.5 mg/10 mg (tablets) for 
hypertension; 2-5 % 
solution (topical) for 
alopecia 
3-4 hours 50,57,81,82 
Rolipram PDE IV inhibitor  Antidepressant (only used in 
preclinical and clinical 
research) 
n/a 3 hours 83 
Cilomilast PDE IV inhibitor  Under development to treat 
respiratory disorders 
n/a 7 hours 34 
Hydralazine ? Treatment of hypertension 25 mg/50 mg (tablets) 
200 µg/min (intravenous) 
7 hours 34 
Adenosine A1 receptor agonist Treatment of tachycardia 6 mg/second (intravenous) 10 seconds 34 
Nicorandil K+ channel opener Treatment of angina 5-10 mg (tablets) 1 hour 34 
  
Table 1.1 Approved or approvable drugs that cause arterial toxicity in animals. The drugs used in this thesis are highlighted in the box. 
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Drug Pharmacological 
class 
Physiological 
signs 
Histopathological signs  Species Administration 
route 
Dosage Time 
course 
Reference 
Bosentan ET receptor 
antagonist 
No significant 
change in 
blood pressure 
nor heart rate 
n/a n/a n/a n/a n/a 35,62,77 
SB209670 ET receptor 
antagonist 
No significant 
change in 
blood pressure 
nor heart rate 
Medial haemorrhage and 
necrosis of extramural 
coronary arteries 
Dog Continuous 
infusion 
50 
µg/kg/min 
5 days 62,77 
Dopamine DA1 agonist Increase in 
blood pressure 
(mediated by 
D2, D3, D4 
receptors) 
Lesions of small calibre 
mesentery arteries, medial 
necrosis but little 
hemorrhage 
Rat Continuous 
infusion 
5 
µg/kg/min 
24 
hours 
39 
Fenoldopam 
mesylate 
DA1 agonist Decrease in 
blood pressure  
Perivascular accumulations 
of neutrophils in adventitia, 
haemorrhage and necrosis in 
media 
Rat Continuous 
infusion 
1-100 
µg/kg/min 
4,8,24 
hours 
38,39,76,84,85 
Minoxidil 
sulfate 
KIR 6.X (K+ 
channel) opener 
Decrease in 
blood 
pressure, 
reflex 
tachycardia 
Coronary/mesentery arterial 
injury, necrosis, 
hemorrhages 
Rat, 
dog, 
monkey 
Oral gavage 10-100 
mg/kg 
Up to 
1 year 
37,50,57,81 
CI-1044 PDE IV inhibitor  Decrease in 
blood pressure 
Hemorrhage and necrosis in 
the mesentery with 
periarterial inflammation 
Rat Oral gavage 10-60 
mg/kg 
Up to 
3 days 
86 
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Rolipram PDE IV inhibitor No significant 
change in 
blood pressure 
nor heart rate 
Necrosis in coronary and 
mesentery arteries, and 
inflammation 
Rat Oral gavage 10-100 
mg/kg/da
y 
Up to 
2 
weeks 
83 
SCH 351591 
and SCH 
534385 
PDE IV inhibitor No significant 
change in 
blood pressure 
nor heart rate 
Hemorrhage and necrosis in 
the mesentery but also 
pancreas, kidney, liver and 
stomach. Lesions 
characterised by fibrin 
deposition and perivascular 
inflammation 
Rat, 
monkey 
Oral gavage 3-80 
mg/kg/da
y 
Up to 
3 
month
s 
87,88 
SK&F 95654 PDE III inhibitor  Decrease in 
blood pressure 
Perivascular accumulations 
of neutrophils in adventitia, 
haemorrhage and necrosis in 
media 
Rat, 
dog 
Oral gavage 200 
mg/kg 
4,8,24 
hours 
38 
 
 
  
Table 1.2 Drugs responsible for causing DIVI in animals. 
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1.4.2 Selected DIVI drugs  
 
This section provides more background information on the four drugs studied within this 
thesis.  
 
Bosentan, is currently used to treat pulmonary artery hypertension, and is an oral dual 
endothelin receptor antagonist given at a dose of 1.2 mg/kg in humans and reaching a plasma 
concentration of 3366 ng/ml, acting on both ETA (Ki=6.5 nM) and ETB (Ki=343 nM) receptor 
subtypes but with a greater effect on ETA78 (Figure 1.6). Metabolic products of bosentan have 
not yet been investigated. Although histopathological signs of DIVI have not been described 
with bosentan in preclinical models, the drug has been chosen as it has been suggested as 
potential DIVI-related drug by several reviews36,77. Endothelin is a peptide predominantly 
produced by the endothelium and to a lesser extent by SMC and fibroblasts78. There are three 
endothelin isoforms, ET-1, ET-2, and ET-3, encoded by three distinct genes89. ET-1 is the most 
abundant isoform in the human CV system. ET-1 and ET-2 activate two receptors, ETA and ETB 
with equal affinity (Ki value ET-1 and ET-2 on ETA = 0.4±0.2 nM; on ETB = 0.2±0.0 nM), whereas 
ET-3 has a lower affinity for the ETA subtype90 (Ki value on ETA = 820±260 nM; on ETB = 0.4±0.2 
nM). ETA and ETB are ubiquitously distributed on various cell types and are part of the G-
protein-coupled receptor (GPCR) family. Only the ETB subtype is expressed on EC, whereas 
SMC express both subtypes91. The two receptor subtypes exhibit contrasting CV actions under 
normal physiologic conditions. After release from EC, endothelin causes vasoconstriction, 
mainly via ETA receptors on SMC that are the main subtype in the vascular tunica media in 
large arteries and veins90. Binding of ET-1 to ETB receptors on EC stimulates the production of 
nitric oxide (NO) from L-Arginine, resulting in relaxation of SMC. This receptor distribution 
offers an explanation as to the phenomenon that ET-1 causes transient vasodilation (initial EC 
ETB activation), followed by prolonged vasoconstriction through ETA on SMC.  
In dogs, continuous administration of SB209670, a dual endothelin antagonist, for five days 
at 50 µg/kg/min was associated with minor but sustained increases in heart rate, slight 
decreases in arterial pressure, and signs of DIVI as shown by medial haemorrhage and 
necrosis of extramural coronary arteries in the right atria77 (Table 1.2). The lesions in the right 
atrium were associated with the highest density of endothelin receptors62. 
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Radio ligand protein binding was used to quantify both endothelin subtype receptors in 
untreated healthy dog heart. The results showed a two-fold higher density of endothelin 
receptors in atrial regions versus ventricular regions and a 6-fold higher density of endothelin 
receptors in coronary arteries compared to that in atria or ventricles. Endothelinreceptor 
subtype characterization showed that ETB receptors were three times more prevalent in right 
compared to left coronary arteries and in situ hybridization confirmed the abundance of ETB 
in SMC in right coronary arteries, whereas ETA receptor density was comparable in right and 
left coronary arteries in SMC. It was concluded in this study that the disproportionate 
distribution of ETB receptors within right coronary artery predispose dogs to exaggerated 
pharmacological responses and subsequent damage to right coronary arteries by endothelin 
and/or endothelin receptor antagonists. In vitro studies in dog92 and pig coronary arteries93, 
in rabbit veins94 and in rat systemic circulation95 indicated that the physiological effect of ETB 
receptor signalling (vasoconstriction/vasodilation) can differ between species and vascular 
bed, and this occurs because GPCRs are known to have multiple functional roles96,97, which 
could explain differences in DIVI in terms of site and resolution of the lesions among different 
species.  
 
 
 
Fenoldopam is a selective DA1 agonist (Ka of 0.018±0.008 µM and efficacy of 0.46±0.11 as 
opposed to DA Ka of 0.58±0.17µM and efficacy of 1.0), that has been shown to increase 
Figure 1.6 Mechanism of action of bosentan. ET-1 released from EC causes prolonged 
vasoconstriction of SMC via ETA (mainly) and ETB receptors on SMC by increasing 
intracellular. ETB receptors on EC mediate transient vasodilation of SMC via production of 
NO in EC. Bosentan is a dual antagonist on ETA and ETB receptors that causes vasodilation. 
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vascular levels of cyclic adenosine monophosphate (cAMP) in the rabbit mesentery artery80 
(Figure 1.7). Fenoldopam produces significant falls in systolic and diastolic blood pressures 
and is currently used as an antihypertensive agent in humans. A study has also revealed that, 
in addition to being a DA1 agonist, fenoldopam is also an antagonist at ɑ2-adrenoceptors98. 
Fenoldopam was evaluated for its ability to inhibit both ɑ1- and ɑ2-adrenoceptors in rabbit, 
dog and guinea pig vessel explants enriched with those receptor subtypes98. In rabbit isolated 
aortic rings, fenoldopam was a weak antagonist of ɑ1-mediated contraction induced by 
noradrenaline. In contrast, in isolated dog saphenous venous rings where ɑ2-adrenoceptors 
mediate vascular contraction, fenoldopam was found to be a potent antagonist. Fenoldopam 
has no significant affinity for DA2, 5HT1 and muscarinic receptors. It was found to have a 
moderate affinity for 5HT2 receptors (pKA of 5.84±0.04 and efficacy of 0.57±0.04 as opposed 
to pKA of 6.65±0.12 and efficacy of 2.66±0.41 of 5HT80. 
 
Fenoldopam induces mesentery arterial lesions in rats but not dogs nor monkeys85. In a study 
in rats, fenoldopam did not induce arterial lesions in rats infused intravenously with the drug 
for 1 or 4 hours at 50 µg/kg/min, however at 5 and 100 µg/kg/min for 24 hours, fenoldopam 
caused medial necrosis and haemorrhage85. The endothelium of affected arteries was intact, 
except in areas of severe medial damage. The internal elastic lamina and connective tissue 
within the arterial wall were also unaffected. Haemorrhagic areas showed aggregates of RBC 
occupying the space of necrotic SMC. Several other studies observed similar effects38,99,100. 
Importantly, studies in conscious spontaneously hypertensive rats found that fenoldopam 
produced a dose-dependent reduction in arterial blood pressure and increases in renal and 
mesenteric blood flow, providing evidence for the role of local flow changes in the 
pathogenesis of DIVI101. In the clinic, fenoldopam reaches a plasma concentration of 30 ng/ml 
when administered at 0.8 µg/kg/min as a continuous IV infusion. 
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Minoxidil is an agent used to treat resistant hypertension for patients who have not 
responded to conventional multidrug antihypertensive regimens, and is also used to treat 
alopecia as it increases local blood flow82. It is administered at a maximum dose of 100 mg/day 
in adults, at which the plasma concentration observed is 2441 ng/ml. The antihypertensive 
activity of minoxidil is due to its sulphate metabolite, minoxidil sulfate. It is thus administered 
as a prodrug. Minoxidil acts by opening adenosine triphosphate (ATP)-sensitive K+ channels 
in vascular SMC (Figure 1.8), and specifically it is an opener of KIR (inward rectifier) 6.X ATP 
sensitive K+ channelsThe predominant site of minoxidil is arterial, and venodilation does not 
occur with minoxidil treatment (likely due to a higher density of channels in arteries as 
opposed to veins)82. The mechanism by which minoxidil induces hair growth has also been 
related to the action on K+ channels82. In animals, minoxidil has been studied in mice, rats, 
dogs, pigs and monkeys and its effects have been investigated for up to one year37,52. 
Minoxidil was found to cause hypotension, tachycardia, and increased blood flow to several 
tissues, especially to the heart, together with coronary arterial injury, right atrial 
haemorrhagic lesions and subendocardial necrosis in dogs52. The specific lesions observed in 
the right atrium in dogs were absent in the other species37. In the same study, when the 
Figure 1.7 Mechanism of action of fenoldopam. Physiologically, adrenaline and 
noradrenaline activate both α1 and α2 receptors, causing vasoconstriction of SMC. Dopamine 
activates DA1 receptors, causing an increase in cAMP and subsequent vasodilation. 
Fenoldopam acts as an agonist of DA1 receptors and as a weak antagonist of α1 and a potent 
antagonist to α2 receptors, inducing vasodilation.  
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treatment continued for up to one year, some dogs did not show prolonged lesions, 
suggesting a potential resolution of the injury.  
 
 
 
Rolipram is a phosphodiesterase (PDE) IV inhibitor (Ki of 0.6 µM), one of the 30 PDE forms 
responsible for hydrolysing cAMP, and therefore causes an increase in calcium (Ca2+) and 
consequent vasodilation102 (Figure 1.9). Although rolipram is highly specific for the PDE IV 
enzymes, it is non-selective within the PDE IV multigene family. Therefore, at therapeutic 
doses, it inhibits all PDE IV isoenzymes to an equal degree103. Originally designed to treat 
depression, rolipram has also been used to treat asthma, arthritis, multiple sclerosis and 
Alzheimer’s Disease104–107. It is used in clinical trials at an oral dose of 1 mg, at which the peak 
plasma concentration reached is 16 ng/ml. SCH 351591 and SCH 534385 are two PDE IV 
inhibitors that induced vascular injury primarily in rats in the mesentery arteries but also in 
the pancreas, kidney, liver and stomach87. Vascular lesions occurred as early as one hour but 
were not detected after nine days. The pathology of the lesions consisted of haemorrhage 
and necrosis, fibrin deposition, and perivascular inflammation of various blood vessels. 
Activation of mast cells, EC and macrophages was also common. SCH 351591 showed toxicity 
also in monkeys, where perivascular haemorrhage of the stomach and heart were common 
features88. In addition, inflammation of small to medium-sized arteries in various organs 
Figure 1.8 Mechanism of action of minoxidil. Minoxidil acts by opening the ATP-sensitive K+ 
channels on SMC, increasing the efflux of K+, which causes membrane hyperpolarisation, a 
reduction in Ca2+ entry and intracellular Ca2+, resulting in relaxation of SMC and vasodilation. 
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including the heart, stomach, pancreas and kidneys was observed in this study. SCH 
compounds have not been used in this thesis but they are worth investigation in the future. 
 
 
 
Other PDE IV inhibitors that induced arterial lesions in rats are CI-104438,108, and SCH 351591 
and SCH 53438587, and are summarised in Table 1.2. The effects of SK&F 9565438, a PDE III 
inhibitor, are also listed in Table 1.2.  
Figure 1.9 Mechanism of action of rolipram. Rolipram acts by inhibiting PDE IV, the enzyme 
responsible for the hydrolysis of cAMP. This results in an increase of cAMP and consequent 
vasodilation. 
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1.5 Mechanisms of DIVI 
 
The mechanisms that underlie DIVI remain to be established, although three hypotheses have 
been proposed: (1) drugs alter hemodynamics which then has a detrimental effect on the 
endothelium; (2) direct drug toxicity on vascular cells (EC, SMC) or circulating blood cells; (3) 
inflammation. Most likely, it is a combination of these mechanisms inducing DIVI. 
 
1.5.1 Mechanism 1. Hemodynamic alterations 
 
The vasoactive pharmacology of compounds reported to cause DIVI has been suggested to be 
the reason of their arterial toxicity. PDE III inhibitors, minoxidil, dopamine  and DA1 agonists, 
potent vasodilators that induce systemic changes in mean arterial blood pressure (see Table 
1.2), have been all shown to produce arterial lesions56,76,109. Among the DA1 agonists, 
fenoldopam has been associated with marked vasodilation and arterial lesions in the rat, dog, 
and monkeys40,43,110. Fenoldopam is also responsible for acute lesions in large calibre (100-
800 µm) splanchnic and renal arteries of rats76. However, when administered with DA1 
receptor antagonists, or with the potent vasoconstrictor methoxamine, the lesions were 
prevented40,71. In a similar way, arginine vasopressin, a vasoconstrictor, prevented the 
vasodilator PDE III inhibitor SK&F 95654 from inducing mesenteric lesions76. This indicates 
that vasodilation may be a causal factor in the development of DIVI.  
 
Nonetheless, recent work with ET receptor antagonists, which did not induce these systemic 
changes and still caused DIVI, suggests that reduced mean arterial pressure and increased 
heart rate are not prerequisites for development of coronary artery injury in dogs62,73,74. For 
example, SB 209670, an ET receptor antagonist, caused a 6-fold increase in coronary blood 
flow and arterial lesions in dogs, but did not significantly increase the heart rate or decrease 
the mean arterial pressure62. It was thus suggested that DIVI may be induced by a local 
increase in blood flow in specific tissues rather than a systemic change in blood pressure. 
Furthermore, minoxidil not only caused systemic hemodynamic changes but also induced a 
6-10 fold increase in regional cardiac blood flow and coronary arterial lesions in dogs52,111, 
also suggesting that it may be local haemodynamic change that is important, not systemic 
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change. Minoxidil, SK&F 95654 and fenoldopam have been reported to increase mesenteric 
blood flow in rats76 and an increase in coronary blood flow and coronary lesions in dogs have 
been observed with compounds from different classes60,62,112. 
These data indicate that arterial lesions develop in coronary arteries in dogs and mesentery 
arteries in rats potentially due to sustained vasodilation in particular vascular beds (the most 
responsive to the pharmacological action of the drug) and the consequent increase in blood 
flow.  
 
Altered shear stress (the frictional force generated by blood flow on EC) in regions such as 
branching points where shear stress is very high113, can result in leukocyte adhesion, inter-
endothelial breaks, gradual breakdown of vessel wall integrity, breaks in the internal elastic 
lamina, and haemorrhage43,76. Moreover, it has been hypothesised that vasodilation induced 
by certain drugs causes normal laminar flow to change into turbulent flow that mimics shear 
stress alterations thereby producing a cascade of events that eventually culminates in 
haemorrhage and necrosis100. Monitoring regional blood flow, even though it is correlated 
with vascular injury in dogs and rats, is not practical during clinical trials, as the procedure is 
tedious, low throughput and requires specialised equipment and skilled technicians. 
Furthermore, it is not clear which vascular beds should be monitored in terms of DIVI 
assessment. 
 
However, an in vitro study with the PDE IV inhibitor CI-1044 found that one of the features of 
DIVI, extravasation of RBC, occurred without changes in blood flow, which implies that for 
some drugs it may not be a local increase in blood flow that causes DIVI but rather a direct 
mechanism on vascular and circulating blood cells114, described in the sections below. 
 
1.5.2 Mechanism 2. Direct pharmacological or chemical toxicity on vascular and circulating 
blood cells 
 
Vascular toxicity results from the pharmacological interaction with a target that initiates a 
cascade of events leading to vascular damage. Drugs involved in inducing direct toxicity are 
classes of cancer drugs and some immunomodulators115–118. Damage to EC by cancer drugs is 
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related to their pharmacological activity, but hemodynamic factors may also be 
involved119,120. It is also possible that they release secondary signals such as NO. It is 
impossible to differentiate between direct cell toxicity and flow being the major cause of DIVI, 
certainly these drugs may act as modulators of both mechanisms in vivo. 
 
1.5.2.1 NO as a cytotoxic secondary signal 
 
Nitric oxide (NO) is a short-lived second messenger responsible for maintaining vascular tone 
by inducing relaxation of SMC121. However, significantly elevated levels of NO can induce 
increase levels of reactive oxygen/nitrogen species (ROS/RNS) (Figure 1.10). ROS induces 
oxygenation of lipids, proteins and DNA, which cause cell damage, necrosis and apoptosis122 
and RNS induce nitrosylation reactions that alters the structure and function of proteins. 
These effects result in EC apoptosis, SMC proliferation and fibrosis. Serum nitrite is a stable 
breakdown product of NO and it has been reported to be elevated in DIVI, indicating a 
potential correlation between NO and DIVI development108,123,124. Indeed, a NO donor 
increased the induction of DIVI, whilst a nitric oxide synthase (NOS) inhibitor reduced DIVI. 
Fenoldopam, a dopaminergic-1 agonist, caused NO-mediated mesentery artery injuries in 
rats100. It has been suggested that DIVI-related drugs act through this common mechanism 
involving RNS125. 
 
NO is made by 3 isoforms of NOS: inducible NOS (iNOS), endothelial cell-specific NOS (eNOS), 
and neuronal NOS (nNOS)126. eNOS is constitutively expressed, and for this reason the 
regulation of its activity is essential for normal function. Alteration in eNOS signalling has also 
received attention as a pathogenic factor of DIVI. Studies showing increased expression of 
nitrotyrosine, an indirect indicator of NO in vivo, and iNOS (source of NO) on EC and SMC 
suggest that NO produced by activated SMC and EC play an important role in injuries induced 
by vasodilatory compounds124,127,128. There is also some evidence of altered eNOS signalling 
with vasoconstrictors125. Furthermore, macrophages produce reactive oxygen intermediates, 
which combined with nitrogen intermediates, can cause protein nitration of EC, i.e. the 
introduction of a nitro group (-NO2) into proteins, which can induce post-translational 
modifications and affect their function129.
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Figure 1.10 Simplified schematic of the formation of free radicals from nitric oxide (NO). Physiologically, NO is produced by eNOS from 
L-Arginine (L-Arg) and contributes to relaxation of SMC (blue pathway). When there is an excess of NO in pathological conditions, NO can 
react with ROS and RNS through superoxide dismutase (SOD) causing nitration of proteins, lipids and nucleic acids which compromises cell 
function (red pathway).  
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1.5.3 Mechanism 3. Vascular injury secondary to inflammation 
 
DIVI has been proposed to occur as the result of inflammation and immune complexes 
deposition130,131. In this mechanism, some components of the innate immune system, such as 
granulocytes, mast cells, and/or monocytes, are activated by the drug and the damage is due 
to the release of mediators by these cells. The activation of T cells has been shown to result 
in expression of Fas ligand, which in turns causes EC apoptosis129,132. Furthermore, 
macrophages produce reactive oxygen intermediates, which combined with nitrogen 
intermediates, cause protein nitration in EC129. This hypothesis is supported by the 
observation that pre-treatment with the immunosuppressive drug dexamethasone blocks the 
development of lesions seen after treatment with CI-1018, a PDE IV inhibitor127. 
 
In the proceeding paragraphs the key cellular subtypes implicated in mediating the 
mechanisms of DIVI (EC, SMC, and blood cells) are explored, together with biomarkers that 
have been investigated with DIVI-related drugs in each of those cell types.  
 
1.6 Vascular and circulating blood cells that may be affected in DIVI 
 
1.6.1 Endothelial cell barrier 
 
At the interface between blood and tissues, the endothelium forms a selective barrier that 
allows selective exchange of molecules133. The total area of this surface has been estimated 
to be around 350 m2 in humans134. EC are linked to each other by different types of adhesive 
structures or cell-to-cell junctions, complex structures constituted by transmembrane 
adhesive molecules linked to a network of cytoplasmic/cytoskeletal proteins. On the basis of 
morphological and functional characterisation, three types of junctions have been defined: 
tight, adherens and gap junctions135,136. 
 
Tight junctions seal the endothelium and are formed by closely opposed neighbouring plasma 
membranes, which appear to be partially fused. The principal transmembrane constituents 
of tight junctions are proteins named occludins, which are associated to several cytosolic 
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proteins, even though the detailed structure of this complex is still unclear137,138. Junctional 
adhesion molecules are also part of tight junctions139. Adherens junctions are formed by 
cadherins, and vascular endothelial-cadherin (VE-cadherin) is localised at the endothelial cell 
surface. Cadherins are cell adhesion molecules, which are anchored with their cytoplasmic 
tail to several intracellular cytoplasmic proteins, named catenins, that are connected to the 
actin-based microfilament system140. 
 
Furthermore, adhesive proteins such as platelet endothelial cell adhesion molecule (PECAM-
1), intercellular adhesion molecule 2 (ICAM-2), CD34, are involved in the control of vascular 
permeability. PECAM-1 is described in 1.6.1.2. Endothelial permeability changes are 
associated with redistribution of surface cadherins and occludins, stabilisation of focal 
adhesion bonds and progressive activation of matrix metalloproteinases141. Stimuli such as 
histamine and thrombin promote a rapid and short-lived increase in vascular permeability, 
and other cytokines and vascular endothelial growth factor (VEGF) induce a sustained 
response. Most of these agonists are released in acute or chronic inflammatory situations.  
 
1.6.1.1 VE-cadherin in controlling endothelial permeability  
 
VE-cadherin is specific to EC139 and is linked through its cytoplasmic tail to the adherens 
junction proteins p120, β-catenin and plakoglobin142. β-catenin and plakoglobin bind to α-
catenin, which interacts with several actin-binding proteins, such as α-actinin and zonula 
occludens-1 (ZO-1)143, to support the interaction of the VE-cadherin-catenin complex with the 
actin cytoskeleton, controlling junctional permeability and junction stabilisation142,143 (Figure 
1.11). The importance of VE-cadherin in maintaining vascular integrity is reflected in that in 
the adult mouse, administration of anti-VE-cadherin antibodies resulted in a dramatic 
increase in permeability, vascular fragility and haemorrhages144. This effect lasted for several 
hours as the antibodies remained bound to VE-cadherin subsequently blocking junction 
reorganisation. Other stimuli including histamine or low concentrations of VEGF, are naturally 
occurring molecules which also produced breakage of VE-cadherin homotypic interactions 
leading to loss of vascular integrity.   
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VE-cadherin activity is regulated by phosphatases and kinases, which modify protein function, 
signalling, and junctional permeability145,146. The most prominent tyrosine kinase is Src, which 
phosphorylates VE-cadherin at tyrosine 658 in response to histamine, TNF-α, platelet-
activating factor (PAF), VEGF and shear stress147–150, leading to VE-cadherin internalisation 
and impaired barrier function145,151,152 (Figure 1.11). VEGF-induced phosphorylation of VE-
cadherin is inhibited in Src-deficient mice or in wild-type mice treated with Src inhibitors153. 
Conversely, dephosphorylation of VE-cadherin by protein-tyrosine-phosphatases increases 
junctional strength145,146. 
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Figure 1.11 Schematic of VE-cadherin function at the endothelial junctions. VE-cadherin is a dimeric protein. Proteins that are 
well known to interact with VE-cadherin include the catenin proteins p120, β-catenin (βcat) and plakoglobin (plako). β-catenin 
and plakoglobin associate directly with VE-cadherin and α-catenin (αcat) and contribute to the interaction of VE-cadherin with 
the actin cytoskeleton142. In response to stimuli such as histamine or thrombin, VE-cadherin is phosphorylated and internalised 
inducing permeability. 
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Thrombin activates its receptor, protease-activated receptor-1 (PAR-1), through cleavage of 
the N-terminal domain to reveal a tethered ligand in the new N-terminus154. This initiates 
activation of heterotrimeric G-proteins, which induce a decrease in cAMP levels in the cell, an 
increase in intracellular Ca2+ and diacylglycerol (DAG) concentration, and activation of the 
small G-protein Ras homologue (RhoA)154. This triggers activation of myosin light chain kinase 
(MLCK) and subsequent phosphorylation of myosin light chains (MLC), which causes 
actomyosin contraction and rearrangement of the cytoskeleton regulated by 
Ca2+/calmodulin-dependent protein kinase, tyrosine protein kinases and protein kinase C 
(PKC).  
 
There are three proposed mechanisms for increased EC permeability: (1) Activation of the 
serine/threonine kinase PKC-α induces VE-cadherin complex disassembly by phosphorylation 
of p120 and the subsequent internalisation of VE-cadherin. In studies in mouse lung vessels, 
expression of the p120-deficient mutant prevented the increase in vascular permeability 
induced by thrombin155. Blocking of PKC-α-mediated p120 phosphorylation has been 
suggested as a novel anti-inflammatory strategy to prevent disruption of vascular endothelial 
barrier function. (2) In VEGF-stimulated EC, Src mediates Rac1 activation, leading to VE-
cadherin phosphorylation via the serine/threonine kinase p21 activated kinase (PAK), 
increasing endothelial permeability156. (3) VE-cadherin is finally sensitive to enzymatic lysis, 
which causes permeability. It has been reported that exposure to metalloproteases, elastase, 
cathepsin G or trypsin can induce the digestion of VE-cadherin extracellular domain in 
cultured cells, disrupting intercellular junctions157.  
 
Several studies have reported the effects of molecules that increase vascular 
permeability136,150,153,158,159. Some agents such as histamine and thrombin act very rapidly and 
the effect is reversible once they are removed. Other agents such as inflammatory cytokines 
require several hours to increase permeability, but the effect is sustained for much longer, up 
to 48 hours. These observations suggest that the mechanisms regulating vascular 
permeability differ greatly. However, the common mechanism is that which affects the 
organisation of adherens junctions that can be accompanied by EC retraction and by opening 
of intercellular gaps.  
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When the endothelial monolayer is compromised, following vascular damage, the EC retract 
and the subsequent increase in permeability can be accompanied by disruption of the vessel, 
together with haemorrhage, adhesion of leukocytes and the formation of thrombi. This effect 
has been shown to be irreversible. 
 
1.6.1.2 PECAM-1 as a regulator of intercellular adhesion  
 
EC express other adhesive proteins, which are not confined to the adherens or tight junctions. 
Among these, PECAM-1, also known as CD31, is a transmembrane immunoglobulin present 
on EC but that is also expressed in leukocytes and platelets139. Homophilic PECAM-1/PECAM-
1 interactions are responsible for helping to maintain the integrity of the EC barrier, whereas 
heterophilic interactions allow PECAM-1 to interact with glycosaminoglycans (components of 
the extracellular matrix involved in a variety of biological functions), lymphocytes and 
neutrophils160. PECAM-1 has been shown to be involved in the restoration of the EC barrier 
following barrier disruption with histamine161, and also during lipopolysaccharides (LPS)-
induced endotoxemia, a condition where blood vessels of PECAM-1-deficient mice show 
increased permeability162. 
 
Recent mechanistic studies employing Electric Cell-substrate Impedance Sensing technology 
found that, compared with PECAM-1-deficient EC, PECAM-1-expressing EC show increased 
barrier function at rest, as well as more rapid restoration of barrier integrity following 
thrombin-induced perturbation of the EC monolayer integrity163. This effect was found to be 
dependent on the homophilic PECAM-1 interaction, as a homophilic mutant form of PECAM-
1 that could not localize to cell-cell borders was unable to support efficient barrier function. 
PECAM-1 has been demonstrated to be also a mechano-responsive molecule that enables EC 
to respond to shear stress, which modulates inflammatory signalling pathways, cytoskeletal 
structure, and cell-matrix interactions164. PECAM-1 is also involved in the trans-endothelial 
migration of leukocytes during their extravasation to sites of inflammation (refer to section 
1.6.5.3.1). Studies blocking PECAM-1 have shown that PECAM-1 plays a key role in 
transmigration of leukocytes in vitro165,166 and in animal models of inflammation167–169.  
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1.6.2 Endothelial activation  
 
It has been demonstrated that activation of EC is an early critical event in DIVI170. Subsequent 
events include apoptosis, dysfunction, and necrosis of EC, as well as reversible or irreversible 
injury to other vascular smooth muscle cells171. 
 
EC undergo changes that allow them to participate in the inflammatory response; this is 
knows as EC activation. EC activation may be divided into two phases, referred to either as an 
early event called ‘EC stimulation’ and a later event named ‘EC activation’, or referred to as 
‘Type I EC activation’ and ‘Type II EC activation’, respectively172–174. Both types of activation 
are characterised by four components: (1) an increase in local blood flow; (2) a localised 
leakage of plasma-protein-rich fluid (exudate) into the tissue; (3) localised recruitment of 
circulating leukocytes; and (4) a change in EC phenotype from antithrombotic to 
prothrombotic.  
 
1.6.2.1 Type I activation 
 
Type I EC activation happens immediately following stimulation with agents such as thrombin, 
TNF-α, interleukin-1 (IL-1), histamine, LPS and drugs (bleomycin, cisplatin, PDE inhibitors) and 
does not involve de novo protein synthesis or gene transcription171. In general, Type I 
activation is mediated by ligands that bind to the extracellular domains of GPCRs, such as 
histamine H1 receptors173. 
 
Binding of these ligands to EC triggers a transient intracellular elevation of Ca2+ from 
endoplasmic reticulum stores (Figure 1.12). The rise in cytosolic Ca2+ activates phospholipase 
A2 (PLA2) to liberate arachidonic acid, which is converted by cyclooxygenase-1 (COX-1) and 
prostacyclin synthase into prostaglandin I2 (PGI2), a potent vasodilator that relaxes SMC. 
Elevated levels of free Ca2+ also binds to calmodulin and the Ca2+-calmodulin complex 
activates nitric oxide synthase 3 (NOS3), producing NO from L-Arginine, which synergises with 
PGI2 to relax SMC175. Production of these vasodilators by EC increases blood flow and 
leukocyte delivery to the tissues. At the same time, the Ca2+-calmodulin complex also 
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activates the enzyme MLCK, which in turns phosphorylates MLC176. Phosphorylated MLC 
contracts actin filaments, which attach to the proteins forming the tight junction and 
adherens junction complexes, resulting in opening of the junctions. Loss of EC contact leads 
to haemorrhage, edema, and increased vascular permeability172. Phosphorylated MLC also 
initiates the exocytosis of secretory vesicles Weibel-Palade Bodies (WPB), bringing P-selectin 
(normally contained in the WPB) to the cell surface177,178. The display of P-selectin on EC 
surface provides a signal that causes the tethering of circulating neutrophils, which initiates 
neutrophil extravasation179 (refer to section 1.6.5.3.1). 
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Figure 1.12 Endothelial Type I activation. Binding of stimulators such as histamine to EC triggers a transient intracellular elevation 
of Ca2+ from endoplasmic reticulum stores, which (1) activates the conversion of arachidonic acid to PGI2; (2) forms a complex 
with calmodulin, which stimulates the production of NO; (3) calmodulin also causes the phosphorylation of MLC resulting in 
contraction of the actin filaments and EC permeability (4); (5) phosphorylation of MLC also leads to exocytosis of WPB bringing 
P-selectin to the surface, a signal for neutrophil extravasation.   
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Release of von Willebrand factor (VWF) also occurs in Type I activation and its release from 
EC will be described in detail in section 1.6.2.4. In addition, EC show prothrombotic effects, 
which include loss of the surface anticoagulant molecules thrombomodulin and heparan 
sulphate; reduced fibrinolytic potential due to enhanced plasminogen activator inhibitor type 
1 (PAI-1) release; production of platelet activating factor; and expression of tissue factor180. 
 
1.6.2.2 Type II activation 
 
Signals by heterotrimeric G protein-coupled receptors (GPCRs) last for between 10-20 
minutes and the receptor is desensitised preventing restimulation181. This limits the degree 
of neutrophil extravasation caused by Type I activation alone. A more sustained EC activation 
is provided by Type II activation, a delayed response that requires time for the stimulating 
agent to cause the activation of gene transcription and the de novo synthesis of 
proteins173,174. The genes involved encode adhesion molecules, chemokines, cytokines, and 
procoagulant factors172,182.  
 
The principal mediators of this response are TNF-α and IL-1 derived from activated leukocytes 
and stromal cells183. TNF-α and IL-1 bind to TNF-α receptor 1 (TNFR1) and type 1 IL-1 receptor 
(IL-1R1) respectively, and this binding promotes the formation of signalling complexes within 
the cell180 (Figure 1.13). These complexes initiate various kinase cascades that lead to 
activation of the transcription factor nuclear factor-κβ (NF-κβ) and activating protein 1 
(AP1)184. Pro-inflammatory responses arise from new gene transcription mediated by NF-κβ 
and AP1. Since these responses require gene transcription and translation of new proteins, 
the responses of Type II activation require hours to be initiated compared to minutes in Type 
I activation. However, similarly to Type I activation, in Type II there is increased blood flow 
due to vasodilation, increased vascular leakage of plasma proteins and increased leukocyte 
recruitment. Furthermore, the rise in cytosolic Ca2+ (as in Type I) leads to activation of PLA2 
which liberates arachidonic acid, a substrate for constitutively activate COX-2. COX-2 
produces PGI2 to relax SMC but at a much higher rate compared to COX-1. Vascular leakage 
is triggered by reorganisation of the actin cytoskeleton in EC, which leads to opening of gaps 
between adjacent cells185,186.  
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In type II activation, leukocyte recruitment is much more effective compared to Type I. 
Neutrophils are recruited by the synthesis and display of chemokines, such as IL-8 and 
leukocyte adhesion molecules like E-selectin187. Other proteins expressed on activated EC 
include intercellular adhesion molecule 1 (ICAM-1) and vascular cell-adhesion molecule 1 
(VCAM-1), which allow leukocytes to adhere to the endothelium and then move into the 
tissues188. The endothelium also secretes NO and VWF182, the latter explained in detail in 
section 1.6.2.4.
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Figure 1.13 Endothelial Type II activation. Inflammatory cytokines such as TNF-α and IL-1 bind to TNF-α receptor 1 (TNFR1) and type 
1 IL-1 receptor (IL-1R1) respectively, and this binding promotes the activation of NF-κB and AP1. This initiates the transcription of genes 
in the nucleus leading to expression of pro-inflammatory proteins, such as E-selectin, ICAM1, VCAM1, COX2 and chemokines. 
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Endothelial cell activation may precede DIVI in vivo171. Endothelial cell activation is a 
reversible alteration resulting in morphological rearrangement and induction of new 
functions, but without loss of monolayer integrity171.The phenotype of activated EC may 
return to the quiescent, non-activated phenotype189 however, the EC activation process, if 
uncontrolled, can progress to EC apoptosis, which represents irreversible endothelial injury, 
endothelial fragmentation, and EC separation from the intima190. 
 
1.6.2.3 Endothelial cell death 
 
The main examples of cell death are apoptosis, autophagy and necrosis. Apoptosis is defined 
by characteristic morphologic features including condensation of the cytoplasm and nucleus 
with cell shrinkage191, and the re-organisation of cellular material into plasma membrane 
derived blebs. During apoptosis the cell membrane remains intact, preventing the release of 
cellular contents, however there is exposure of several surface molecules that signal to 
neighbouring or phagocytic cells for initiation of engulfment192. Therefore, during apoptosis 
there is limited inflammation, in contract to necrosis in which the cell swells and the 
membrane is disrupted leading to release of constituents, triggering an inflammatory 
response.  
 
Adherens junction proteins are degraded with disruption of barrier function in vitro193. In vivo, 
this could trigger vascular leak and inflammation in adjacent tissue by extravasated plasma 
constituents such as complement and coagulation components. Since EC are exposed to 
flowing blood and shear stress, apoptotic EC could detach prior to engulfment. Loss of even 
a small number of EC by this process could induce vascular leak and expose a thrombogenic 
subendothelial matrix. Apoptotic EC display an ‘eat me’ signal with phosphatidylserine (PS) 
exposure, they become pro-adhesive for platelets and leukocytes and procoagulant, and 
promote coagulation in situ before engulfment or detachment, or in the circulation once 
detached194–196. Some proapoptotic stimuli are: TNF-α, Fas/FasL, LPS and oxidants such as 
oxidised low-density lipoprotein (oxLDL)197.  
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Biomarkers of EC activation and EC death have been explored in DIVI and are summarised in 
Table 1.3. Among these, VWF is a biomarker that has been extensively investigated in DIVI 
and will be described in detail in section 1.6.2.4. 
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Biomarker Function Response in DIVI Drug 
reported 
with  
Species Administration 
route 
Reference 
VWF Platelet adhesion and 
aggregation in hemostasis and 
carrier of FVIII 
Increase in plasma levels at 2 
and 6 hours post dose and 
return to baseline after 24 
hours 
Fenoldopam, 
minoxidil 
Rat Subcutaneous 
injection 
36,198–200 
VWFpp Formed in the Trans-Golgi 
after cleavage of pre-pro VWF, 
regulates the hemostatic 
potential of VWF 
Increase in plasma levels at 3 
hours post dose and sustained 
for 24 hours only with 
endotoxin 
Endotoxin, 
arginine 
vasopressine 
Human, 
dog 
Intravenous 
injection 
201 
Connexin 
43 
Maintains integrity of gap 
junctions 
Decrease in immunoreactivity Fenoldopam Rat Continuous 
infusion 
100 
Claudin Maintains integrity of tight 
junctions 
Decrease in immunoreactivity Fenoldopam Rat Continuous 
infusion 
100 
ZO-1 Maintains integrity of tight 
junctions 
Decrease in immunoreactivity Fenoldopam Rat Continuous 
infusion 
100 
Caveolin-1 Major structural protein of 
caveolae; modulates the 
function of signal transduction 
in EC and SMC 
Decrease (in mild lesions) or 
loss (severe lesions) 
ET receptor 
antagonist, 
minoxidil, 
fenoldopam 
Dog, 
rat 
Intravenous 
injection 
100 
E-selectin Cell adhesion molecule 
expressed on EC 
Marked decrease in serum at 
24 hours 
CI-1044 Rat Oral gavage 202 
NO2- Inflammation Marked increase in serum at 
24 hours 
CI-1044, SCH 
351591 and 
SCH 534385 
Rat Oral gavage 202 
Table 1.3 EC biomarkers reported in DIVI.
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1.6.2.4 VWF: a potential DIVI biomarker  
 
Although the pathogenesis of DIVI remains unclear, it has been predicted that an early event 
that causes the disruption of the integrity of the blood vessel structure is likely to occur34. EC 
activation is an early step in the development of DIVI, and, as discussed, EC when activated 
release a range of molecules, among which there is VWF. VWF and VWF pro-peptide (VWFpp) 
have been suggested as the most promising potential biomarker for DIVI198,201. It has been 
extensively shown that plasma VWF is increased significantly over time during DIVI201. For 
example, dogs treated with a K+ channel opener VWF plasma levels were observed to increase 
for 3 hours post-dosing203, primarily from EC, and thus elevation in plasma is suggestive of EC 
compromise.  
 
VWF secretion has been documented in dogs and rats with various drugs responsible for DIVI, 
such as fenoldopam, dopamine, vasopressin, the K+ channel opener ZD6169, and 
endotoxin198,201,204,205. Moreover, it has also been suggested as a useful diagnostic indicator 
of plasma penetration into damaged arteries caused by the K+ channel opener, ZD6169 and  
the ET receptor antagonist ZD1611199. 
 
VWF is a multimeric glycoprotein present in blood plasma, the subendothelial matrix, storage 
granules in EC (WPB) and α-granules in platelets206. It has been reported that EC injury leads 
to increased secretion of VWF, rendering soluble VWF a marker for EC activation and/or 
damage. For example, elevated plasma levels of VWF have been reported in patients with 
systemic inflammation207 and also in patients with type 2 diabetes and dyslipidemia208, 
suggestive of EC injury.  
 
The role of VWF is dual: (1) contributing to the haemostatic process by mediating platelet 
adhesion and aggregation at sites of vascular injury and (2) carrying coagulation factor VIII 
(FVIII) in the circulation in a tight complex206. FVIII acts as a co-factor to accelerate the 
activation of factor X in the coagulation cascade, which results in the formation of a fibrin 
clot209. Individuals lacking VWF show a severe haemorrhagic phenotype, originating from 
defective formation of platelet-rich thrombi and a secondary deficiency of FVIII impairing the 
generation of a fibrin network.  
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1.6.2.4.1 Synthesis and storage 
 
VWF is synthesised by EC and megakaryocytes as a single pre-pro-polypeptide (a protein 
precursor that will undergo post-translational modifications in order to become active) of 
2813 amino acids, and is stored in the cytoplasmic WPB of EC together with P-selectin, and in 
α-granules in platelets189. The pre-pro VWF undergoes intracellular modifications including 
signal peptide cleavage, C-terminal dimerization, glycosylation, sulfation, and aminoterminal 
multimerisation. Proteolysis occurs in the trans-Golgi where the VWFpp is cleaved but 
remains stored together with mature VWF in ɑ-granules in megakaryocytes and WPB in EC. 
After secretion into plasma, VWFpp dissociates from VWF (Figure 1.14). 
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Figure 1.14 VWF synthesis, storage and release. VWF is synthesised as pre-pro-VWF and directed into the endoplasmic reticulum where the 
pro-VWF is formed by cleavage. Other modifications occur in the Golgi apparatus. The mature VWF multimers, which include VWF and VWFpp, 
are trafficked to EC, from where VWF is directly released or packaged into WPB, and α-granules in platelets from where release occurs. 
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Post synthesis, VWF is transported to storage organelles in α-granules in 
megakaryocytes/platelets and in the WPB of EC. It is unknown whether the process of WPB 
formation begins in the Golgi apparatus or the Trans-Golgi network. Organelle formation 
requires VWF multimers to be packaged into a helicoidal structure, where VWF is compacted 
by 100-fold. The tubular structure of WPB reflects how VWF is folded in these organelles. The 
VWF cargo originating from different ministacks is copackaged together into organelles that 
produce WPB of sizes varying from 0.5 to 5 µm. The VWF tubules induce membrane 
protrusions from the Trans-Golgi network, leading to vesicles budding off and formation of 
immature WPB. At the molecular level, a clathrin coat appears necessary for VWF packaging 
into nascent organelles, probably to provide a scaffold and form the typical rod-shaped 
structure of the WPB206.  
 
The mature VWF released into circulation has all the adhesive sites required for its 
haemostatic function. These are: D’-D3 domain that binds factor VIII, A1 domain that binds 
platelet glycoprotein (GP)Ib receptor, A2 domain that serves a site for ADAMTS-13-mediated 
cleavage of VWF, A3 domain that binds exposed collagen, and C1 domain that binds platelet 
GPIIb/IIIa210–213 (Figure 1.15). 
 
 
Figure 1.15 Schematic of VWF domains. D’ and D3 are implicated in the binding of 
coagulation factor VIII, A1 and C1 of platelets through GPIb and GPIIb/IIIa, respectively, and 
A3 of exposed collagen. In addition, A2 domain is the site for cleavage of VWF by ADAMST-
13. 
 
1.6.2.4.2 Release 
 
Whereas α-granules release VWF predominantly upon platelet activation, release of VWF 
from EC occurs through one of the following mechanism: (1) regulated secretion from WPB, 
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in response to a specific agonist upon vascular injury; (2) basal secretion from WPB, 
independent from an agonist; (3) constitutive, independent from an agonist from non-WPB 
compartments. When present in the endothelial cell cytoplasm, WPB move around  
eventually locating single WPB to the cellular periphery, allowing them to fuse with the 
plasma membrane and release their contents into the extracellular space (blood or 
subendothelium)214. Exocytosis of VWF results in a rapid unfolding of VWF tubules into 
ultralong strings (up to 100 µm) docking on the EC, allowing platelets to adhere215.  
 
Following secretion, VWFpp dissociates from VWF multimers and circulates independently as 
a non-covalent homodimer with a short half-life of around 2 hours. By contrast, VWF 
multimers are cleared more slowly (see below), with a half-life of around 12 hours. It has been 
reported that VWFpp regulates the hemostatic potential of VWF by reducing binding of VWF 
to platelets216. 
 
Regulated VWF release from EC by thrombin 
 
Following EC injury, EC and recruited platelets release the stored VWF217. The exact 
mechanism by which thrombin-induced VWF is released is not clear, although it appears to 
depend on the proteolytic activity of thrombin218. In mice with EC specific knockout of G 
protein subunits (Gα12 and Gα11), thrombin-induced release of VWF was reduced whereas 
basal secretion of VWF was decreased in Gα12 knockout mice, suggesting that VWF secretion 
is G protein-dependent219. An in vitro study showed the difference in the structure of VWF 
released after stimulation with thrombin compared to VWF secreted constitutively, which 
contained predominantly dimers with a significant proportion of precursor subunits220.  
 
1.6.2.4.3 Interaction of VWF with other cells 
 
Released VWF binds to exposed collagen through its A1 and A3 domains, resulting in VWF 
immobilisation at the injury site. At this stage, VWF is subjected to shear stress in the 
circulation and undergoes conformational change exposing GPIb-binding site within its A1 
domain resulting in platelet adhesion via their GPIb site221,222.  
 53 
 
Adhered and activated platelets roll on the endothelium causing a GPIIb/IIIa conformational 
change and binding of platelet GPIIb/IIIa to VWF via its C1 domain, a process that is 
irreversible and culminates in the formation of a platelet plug223,224. VWF also binds and 
stabilises FVIII through D’-D3 domains212, activated FVIII subsequently activates factor X 
through formation of a complex with FIX and calcium225,226. The activation of the coagulation 
cascade leads to the formation of a fibrin clot (Figure 1.16). 
 
In summary, VWF is important in platelet adhesion (through GPIb binding), platelet 
aggregation (through GPIIb/IIIa binding) and in coagulation by prolonging the half-life of FVIII. 
Since VWF is also stored in EC, its increase in plasma levels is indicative of EC compromise and 
thus can be used as a useful biomarker in DIVI.  
 
Although micro-thrombi or thrombi have not been observed as a phenotype in DIVI, this is 
likely due to post mortem analysis where these thrombi will be removed prior to analysis. 
However, the result of increased VWF release coupled with EC damage would be very likely 
to result in platelet activation and micro-thrombosis171. 
 
VWF has been also found in SMC in disease states. For example, VWF has been reported to 
breach the endothelium in cerebral small vessel disease227. In a co-culture study using Notch 
ligand expressing rat SMC to stimulate Notch in astrocytes (A7R5), it was found that VWF 
strongly inhibits Notch signalling and the activation of mature smooth muscle gene 
promoters. Similar effects were seen in primary human cerebral vascular SMC. Moreover, 
expression of the intracellular domain of Notch3 allowed cells to bypass the inhibitory effect 
of VWF. It has also been observed that VWF forms molecular complexes with all four 
mammalian Notch ectodomains, indicating a new function of VWF as an extracellular inhibitor 
of Notch signalling. These experiments demonstrate a novel role of VWF in the promotion of 
vascular disease through a non-haemostatic mechanism.  
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Figure 1.16 Function of VWF. At the injury site, activated EC and recruited platelets release stored VWF which bind to collagen through A3 
domain and gets immobilised. Subjected to shear stress, VWF undergoes a conformational change exposing GPIb binding site within A1 domain. 
Circulating platelets bind to exposed GPIb binding site on immobilised VWF, leading to platelet adhesion. Adhered platelets then roll on EC until 
GPIIb/IIIa-mediated binding occurs resulting in platelet aggregation and the formation of a platelet plug. VWF also binds and stabilises FVIII. Once 
FVIII is activated, it activates FX by forming a complex with FIX and calcium. Activation of the coagulation cascade results in the formation of a 
fibrin clot. 
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1.6.2.4.4 Clearance 
 
Following release in the circulation and the interaction with platelets, VWF is cleared by 
ADAMST-13, a metalloprotease that cleaves VWF decreasing its activity228. VWF circulatory 
lifespan is limited and varies between 4 to 26 hours a variation that is most likely due to 
different glycosylation patterns. The majority of VWF is targeted to the liver, indicating that 
VWF is cleared via an active regulatory mechanism rather than through passive elimination. 
Immunohistochemical analyses of liver and spleen showed that VWF principally colocalises 
with macrophages229. This was confirmed in other studies whereby the chemical depletion of 
macrophages led to an increase in VWF survival. In addition, experiments with human 
macrophages confirmed that VWF is bound and endocytosed by macrophages. However, this 
does not exclude the participation of other non-macrophage cells in this process. By clearing 
cell debris, resolving inflammation and promoting fibrosis, macrophages have a central role 
in the response to injury230. However, they have also been linked to chronic inflammation in 
situations of continuous injury or failed resolution, in which their activity became detrimental. 
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1.6.3 Smooth muscle cells 
 
SMC provide the main support for the structure of the vessel wall and they regulate vascular 
tone through contraction231. Compared to other cell types, SMC retain significantly more 
plasticity to regulate functions such as contraction, proliferation and extracellular matrix 
synthesis232. SMC plasticity depends on variations in environmental cues and extracellular 
signals sensed by the cell. SMC can switch between two phenotypes: (1) quiescent SMC are 
differentiated, and express a range of upregulated markers such as α-smooth muscle actin (α-
SMA), smooth muscle myosin heavy chain, and calponin, and (2) a synthetic or proliferating 
phenotype, characterised by decreased contractile marker expression, and increased 
proliferation, migration and extracellular matrix synthesis233–235. Mature SMC are defined as 
differentiated or contractile under normal physiological conditions. SMC switch to a 
proliferative state under pathological conditions, such as atherosclerosis236 in response to 
environmental stimuli, such as growth factors, mitogens, inflammatory mediators, where 
SMC lose the ability to contract, but migrate, proliferate and accumulate in the intima237.  
 
The mechanisms involved in SMC differentiation are still not entirely known. SMC can arise 
from multipotent progenitors and can further mature into different SMC subtypes238. This 
process depends on several stimuli, including cytokines or growth factors, the extracellular 
matrix, microRNAs, chromosome structural modifiers and mechanical forces239. 
 
The main signals involved in SMC differentiation are (1) transforming growth factor (TGF)-β, 
(2) Notch signalling, and (3) platelet-derived growth factor (PDGF). TGF-β signalling plays a 
pivotal role in SMC differentiation during vascular development as well as phenotypic 
switching in disease states240. TGF-β has been shown to be involved in the development of 
many CV diseases including atherosclerosis, congenital heart diseases, aortic aneurysm, 
hypertension and hereditary haemorrhagic telangiectasia241–243. Overexpression of TGF-β 
increases the neointimal formation and SMC proliferation and differentiation in a model 
where rabbits were induced arterial injury with a balloon catheter244,245. Its role in DIVI has 
never been fully explored, but it is likely that TGF-β is involved in the progression of the 
lesions. Given the plasticity of SMC and their ability to switch between phenotypes, it would 
be interesting to understand if this mechanism is also implicated in the resolution of the 
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lesions in DIVI. In atherosclerosis, SMC play a maladaptive role in lesion development and the 
progression of the disease; in apolipoprotein E (a protein involved in the metabolism of fats) 
deficient mice, it was found that high expression of TGF-β contributes to the stability of the 
lesion246,247.  
 
Similarly to TGF-β, Notch signalling induces SMC differentiation248. Several studies have 
shown that Notch induces SMC specific marker expression including α-SMA, SM22α, calponin 
and smooth muscle myosin heavy chain (SMMHC) in a number of cell lines248–250. Although 
there are four types of Notch receptor, only Notch1 and Notch3 are expressed in SMC and 
Notch3 in particular is involved in SMC differentiation. It has been described that the 
expression of late stage SMC marker smoothelin B is significantly inhibited in Notch 3 mutant 
arteries, suggesting a pivotal role in the maturation of SMC251 .  
 
PDGF has the ability to induce phenotypic switching from contractile to proliferative state in 
SMC252. Using human aortic SMC, it has been demonstrated that prolonged PDGF treatment 
leads to sustained increases in the phosphorylation of protein kinases such as Akt, 
p70S6kinase, and ERK1/2, which mediate SMC proliferation253. An increase in the expression 
of PDGF and its receptor has been shown in a model of angioplasty using human coronary 
arteries, which could suggest that PDGF released from SMC is involved in repair processes 
after injury254.  
 
Finally, shear stress has also been found to affect SMC differentiation. In vitro studies of the 
effects of shear stress on vascular cells have focused primarily on EC because under normal 
physiological conditions they are directly exposed to blood flow255–257. However, it is 
becoming increasingly clear that shear stress and NO also affect SMC function. SMC produce 
both NO258 and iNOS259 in response to elevated shear stress levels, and it has been reported 
that shear stress inhibits SMC migration via NO-mediated downregulation of matrix 
metalloproteinase-2 (MMP-2) activity. This was demonstrated in a study with rat aortic SMC 
that were seeded onto Matrigel-coated cell culture inserts, and their migratory activity 
quantified when exposed to shear stress in a rotating disk apparatus260. 
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1.6.3.1 SMC activation  
  
SMC activation upon injury produces cytokines, including PDGF, TGF-β, macrophage 
inhibitory factor, interferon (IFN)-γ, and monocyte chemoattractant protein (MCP-1), that 
attract and activate leukocytes, induce proliferation of SMC, promote EC dysfunction, and 
stimulate production of extracellular matrix components261. Most importantly, SMC undergo 
phenotypic changes in diseases states that will be described in detail in chapter 6. 
 
1.6.3.2 SMC death 
 
1.6.3.2.1 Apoptosis 
 
SMC apoptosis is induced by pro-inflammatory cytokines, oxidised low-density lipoprotein 
(oxLDL), high levels of NO and mechanical injury. Pro-inflammatory cytokines such as TNF-α 
and IFN-γ produced by macrophages and T-cells, respectively, sensitise SMC to death receptor 
Fas (CD95) mediated apoptosis by causing Fas trafficking to the cell surface262,263.  
 
1.6.3.2.2 Necrosis  
 
As with EC, necrosis is characterised by an increase in cell volume and swelling of organelles 
followed by breakage of the plasma membrane and release of intracellular contents which 
initiates inflammation. Although originally necrosis was considered a non-programmed form 
of death, there is new evidence suggesting that necrosis is regulated via different pathways 
that result in the formation of a necrosome, a complex consisting of Fas-associated protein 
among others that stimulates an inflammatory response263.  
 
Markers of SMC function and death have been explored in DIVI and are summarised in Table 
1.4. As already mentioned, α-SMA and calponin are specific markers of mature and 
differentiated SMC and they have been shown to be reduced in DIVI203. 
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In addition, caveolin-1 has been found to decrease or be lost in SMC (and in EC, refer to Table 
1.4). In addition to the ones listed, TGF-β, Notch3, PDGF and NO are also markers that may 
be interesting in identifying biomarker for DIVI. 
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Biomarker Function Response in DIVI Drug reported with  Species Administration 
route 
Reference 
Activated 
caspase-3 
Involved in the 
execution phase 
of apoptosis 
Increased activation Fenoldopam Rat Continuous 
infusion 
127 
α-SMA Involved in cell 
motility, 
structure and 
integrity 
Decreased 
immunoreactivity 
Fenoldopam Rat Continuous 
infusion 
202 
Caveolin-1 Major structural 
protein of 
caveolae; 
modulates the 
function of 
signal 
transduction in 
EC and SMC 
Decrease (in mild lesions) or 
loss (in severe lesions) 
ET receptor antagonist, 
minoxidil, fenoldopam 
Dog, rat Continuous 
infusion 
35,100,203 
Calponin Regulates the 
actin/myosin 
interaction 
Mild increase at 8 hours 
post dose followed by 
robust decrease at 24 hours 
CI-1044  Rat Oral gavage 2 
Table 1.4 SMC biomarkers reported in DIVI.
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1.6.4 Endothelial-smooth muscle cell interactions  
 
As previously mentioned, blood vessels are characterised by three layers: (1) the intima, a 
single concentric layer of EC that forms the inner tube of the vessel; (2) the media, 
surrounding the intima, composed of SMC (or SMC-related pericytes); (3) the adventitia, a 
mixture of extracellular matrix (ECM), fibroblasts, and nerve cells264 (Figure 1.2).  
Despite vascular bed-specific differences, EC and SMC share similar functions in all blood 
vessels. The largest arteries, such as the aorta, consist of multiple layers of SMC intertwined 
with a matrix made of elastin and collagen to sustain systemic pressure under pulsatile flow. 
In contrast, veins operate under low pressure and facilitate the return of blood from the 
organs to be reoxygenated. Veins are characterised by fewer layers of smooth muscle and a 
less complex ECM component. The smallest vessels, the capillaries, have limited smooth 
muscle (or pericyte) coverage to allow for maximum diffusion, with EC that are highly 
permeable to permit gas exchange and nutrient delivery to cells via tiny pores or 
fenestrations264. 
 
Communication between EC and SMC begins early on in embryogenesis when the blood 
vessels begin to form265,266. Mechanistically, the signalling strategies can occur through a 
soluble or secreted molecule, or they can require direct physical contact between the EC and 
SMC.  
 
1.6.4.1 Diffusible signalling 
 
The ratio between PDGF and VEGF plays a pivotal role in the fine balance required for blood 
vessel growth and maturation267,268. It has been shown that inhibition of VEGF signalling in 
the endothelium and PDGF signalling in mural cells using different kinase inhibitors increased 
the antitumor effects of pericytes that are potential antiangiogenic targets in tumour therapy, 
as compared to VEGF inhibition alone269. 
 
Another important signalling pathway involved in EC-SMC communication is the 
Angiopoietin-1-Tie-2 pathway270. Angiopoietin-1 (Ang-1) is a growth factor largely secreted by 
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SMC and ligand for endothelium-specific receptor tyrosine kinase Tie-2. It has also been 
suggested that Ang-1/Tie-2 is critical for maintaining the physical interaction of EC and SMC 
and in preventing cell death271–273. It was demonstrated using endothelial Abelson (Abl) kinase 
knockout mice that loss of Abl kinase (involved in different cellular processes including 
proliferation, survival, adhesion and migration) leads to a decreased Tie-2 expression, 
diminished Tie2 receptor signalling and loss of Ang-1-mediated survival. Loss of Abl resulted 
in lethality at late embryonic and perinatal stages of development, with focal regions of 
vascular loss and tissue necrosis/apoptosis271. It was also found that Abl kinases are activated 
by Ang-1/Tie-2 signalling. 
 
Another receptor-ligand combination implicated in EC-SMC communication is the 
sphingosine-1-phosphate (S1P) pathway274,275. S1P is a sphingolipid metabolite that signals 
through a family of G-protein-coupled receptors. It has been shown that deletion of the S1P1 
receptor on EC results in significant defects in smooth muscle coverage, suggesting the 
importance in smooth muscle recruitment by EC. The role of NO in EC-SMC signalling is also 
important in promoting SMC relaxation, as well as the previously mentioned PGI2, a potent 
vasodilator produced by EC that relaxes SMC. 
 
1.6.4.2 Contact-dependent signalling  
 
Physical communication relies on membrane-bound proteins ‘hooking up’ on adjacent cells. 
Studies revealed that EC-SMC interactions in adult vessels are controlled by Notch signalling, 
as Notch3 was found to regulate vascular tone in small arteries. In addition, deletion of Notch 
ligand Jagged 1 in EC leads to vascular defects associated with SMC differentiation, whereas 
EC appeared normal. Some studies showed that EC-expressed Jagged 1 can induce the 
expression of Notch3 in co-cultured SMC, and this induction is critical for smooth muscle 
differentiation276.  
 
In mature blood vessels, the basement membrane and the internal elastic lamina are 
considered significant barriers to physical interactions of EC-SMC. Despite this, 
myoendothelial communication exists via myoendothelial junctions that link the plasma 
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membranes of juxtaposed EC and SMC277,278.  In 1973, it was demonstrated for the first time 
that cellular extensions from two different cells could form heterocellular gap junctions, as 
revealed by freeze-fracture transmission electron microscopy (TEM) images279. In 2000, 
three-dimensional reconstructions of the myoendothelial junctions from sequential TEM 
sections confirmed that very small gap junctions could exist between EC and SMC280. These 
and other EC-SMC interactions are dysregulated during vascular injury and thus are likely to 
be disrupted in DIVI. It has been suggested that alterations in direct EC-SMC cross-talk 
(involving physical contact through cell surface proteins such as connexins, Eph/ephrins, and 
Jagged/Notch3) and indirect cross-talk (involving cell-secreted factors and the extracellular 
matrix) promotes atherogenesis281.  
 
1.6.5 Circulating blood cells  
 
Haemorrhage including extravasation of RBC into the tunica media of blood vessels is a 
feature of DIVI, where RBC are lost through inter-endothelial gaps76. The crosstalk of RBC with 
leukocytes may be an important player in the pathogenesis of DIVI. There is evidence that 
oxidised RBC contribute to the perpetuation of inflammation in the pathogenesis of CV 
disorders282,283.  
 
1.6.5.1 RBC activation 
 
Under physiological conditions, RBC act as circulating scavengers of ROS and RNS generated 
in the vasculature through their antioxidant machinery such as reduced glutathione, 
thioredoxin, ascorbic acid, and vitamin E284. When RBC cross a tissue characterised by an 
intense production of pro-oxidant reactive species, the RBC are unable to counteract the new 
pro-oxidant status of the microenvironment and become themselves a source of ROS. 
Oxidative stress can cause several RBC changes, such as cytoskeleton rearrangement and 
oxidation. These RBC become more rigid and therefore undergo lysis more easily releasing 
cytotoxic species in the vasculature. Oxidized RBC release Hb, heme-Fe, and iron285, which are 
powerful oxidants able to activate an inflammatory response286–288. 
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RBC extravasation has been investigated in DIVI in a microfluidic system with the PDE IV 
inhibitor CI-1044, a drug known to cause DIVI in rats and it was shown that the drug caused 
extravasation of RBC in the smooth muscle layer after 8 hours infusion114. However, the 
extravasation phenomenon in DIVI has only been evaluated qualitatively as present or absent 
in the device and further assessment of the underlying mechanisms remain to be conducted.  
It is possible that RBC contribute to the progression of the lesions through free radical 
formation.  
 
1.6.5.2 Platelet activation 
 
Platelets play a key role in haemostasis. In section 1.6.2.4 the interaction of VWF with 
platelets has been described. Platelet activation is stimulated by bound platelet secretion 
products and local pro-thrombotic factors such as tissue factor289.  
 
Platelet activation requires activation of the GPIIb/IIIa receptor (also known as integrin αIIbβ3), 
which results in the cross-linking of fibrinogen or VWF between receptors, leading to platelet 
aggregation290,291. This induces the recruitment of additional platelets to the site of injury, 
allowing the thrombus formation. The function of the integrin αIIbβ3 depends on its capacity 
to transit from a low to a high affinity state for its ligands, fibrinogen and VWF, resulting in 
aggregation and thrombus stabilisation.  
 
When activated, platelets also express large amounts of P-selectin, which is mobilised from 
α-granules to the surface292–294. P-selectin interacts with its ligand P-selectin glycoprotein 
ligand-1 (PSGL-1) on leukocytes, resulting in the formation of platelet-leukocyte aggregates. 
 
Moreover, ADP released from damaged EC and activated platelets stimulates platelet P2Y1 
and P2Y12 GPCRs, which causes further platelet activation and release of ADP. Thromboxane 
A2 produced and released by stimulated platelets also activates further platelets, promoting 
plug formation. 
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1.6.5.3 Leukocyte activation 
 
Activation of leukocytes and their migration towards an extravascular site of damage involves 
a series of highly organised events collectively termed the ‘multi-step leukocyte adhesion 
cascade’295 and is depicted in Figure 1.17. 
 
1.6.5.3.1 The leukocyte adhesion cascade 
 
The first stage in the leukocyte cascade is the contact between the endothelium and 
leukocytes, termed tethering or capture, where upon tissue damage the selectin molecules, 
L-selectin (expressed by most leukocytes), P-selectin and E-selectin (expressed by inflamed 
EC, P-selectin also by activated platelets), mediate tethering of the leukocytes296. PSGL-1, 
expressed on almost all leukocytes and by certain EC297, has a dominant role as a ligand for 
all selectins298 and it is functional only when glycosylated correctly299.  
 
Besides PSGL-1, E-selectin also binds to glycosylated CD44 and E-selectin ligand 1 (ESL-1)300. 
The binding of PSGL-1 to L-selectin allows leukocyte–leukocyte interactions, by which 
adherent leukocytes and leukocyte-derived fragments facilitate secondary leukocyte 
capture301,302. 
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Figure 1.17 The leukocyte adhesion cascade. The recruitment of leukocytes to sites of inflammation requires interaction between EC and the 
leukocytes. Leukocytes are captured from blood flow and interact with EC through interaction of selectins (on EC) and PSGL-1 (on leukocytes). 
Leukocyte rolling also entails interaction with selectins. Activation of integrins result in the arrest of the leukocytes and subsequent 
transmigration that can occur through a paracellular (between EC junctions) or transcellular route (through the EC body). The pivotal role of 
VCAM-1 and ICAM-1 expression on EC is also highlighted. 
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Leukocyte rolling provides sustained contact between the leukocytes and the endothelium. 
Rolling is mediated by L-selectin, P-selectin and E-selectin, and their interaction with PSGL-1.  
The pivotal role of these selectins in rolling has been demonstrated using a triple L-,E-,P-
selectin knock-out mouse that exhibited a dramatic decrease in rolling303,304. Integrins, 
heterodimers composed of an α and β subunit, which are both type I transmembrane 
proteins, mediate leukocyte arrest and firm adhesion to the endothelium305. Integrins are 
‘activatable’ receptors, because intracellular signalling through cell-surface molecules, such 
as GPCRs is required to increase their ligand-binding capability. The most important integrins 
for leukocyte adhesion to the endothelium are: (1) lymphocytes function-associated antigen-
1 (LFA-1), also known as αLβ2-integrin and expressed on all leukocytes; (2) very late antigen-4 
(VLA-4), known as α4β1-integrin and expressed on monocytes, eosinophils and neutrophils in 
certain situations; and (3) macrophage-1 antigen (MAC-1), also known as αMβ2-integrin or 
CD11b-CD18 and expressed on neutrophils and monocytes306,307.  
 
One of the key events in the cascade is expression of immunoglobulin superfamily members 
vascular cell adhesion molecule-1 (VCAM-1) and intracellular cell adhesion molecule-1 (ICAM-
1) on EC. In the active conformation, integrins bind with high affinity to VCAM-1 and ICAM-1, 
allowing the leukocytes to firmly adhere to the endothelium. LFA-1 binds to ICAM-1, whereas 
VLA-4 binds to VCAM-1. Measuring VCAM-1 and ICAM-1 expression on EC allows assessment 
of leukocyte interaction with the endothelium and their transmigration (see below) during 
inflammation.  
 
Leukocytes also bind to E-selectin, P-selectin or L-selectin activates integrins308. In addition, 
in vitro and in vivo studies have demonstrated that leukocyte arrest during rolling is triggered 
by chemokines or other chemoattractants309,310. During inflammation, EC are activated by 
inflammatory cytokines to express adhesion molecules and produce chemokines and lipid 
chemoattractants presented on their surface. Other chemoattractants, such as chemokine 
ligand 5 (C-C motif) (CCL5), chemokine ligand 4 (C-X-C motif) (CXCL4) and chemokine ligand 5 
(C-X-C motif) (CXCL5) can be generated by proteolytic cleavage in activated mast cells and 
platelets and delivered to EC through circulating microparticles or exocytosis of intracellular 
granules. These molecules also trigger the arrest of rolling leukocytes311,312.  
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Following firm adhesion to the endothelium, leukocytes can move away from their initial site 
of arrest, and extend membrane protrusions into the EC body or at the junctions between 
EC313. This phenomenon promotes myosin contractility within EC and induces the formation 
of gaps between EC. It has been shown that binding of MAC-1 to ICAM-1 is critical in this 
process, as neutrophils lacking MAC-1 emigrated without crawling in a murine study314. At a 
molecular level, binding of ICAM-1 is associated with increased intracellular Ca2+ and 
activation of p38 MAPK and Rho GTPase295. 
 
Transmigration of leukocytes through the endothelium can occur in two different ways: (1) 
paracellular, between adjacent EC; and (2) transcellular, through the body of a single EC. Some 
endothelial junctional molecules, such as immunoglobulin superfamily members PECAM-1, 
ICAM-1, ICAM-2, junctional adhesion molecules JAM-A, JAM-B, JAM-C, as well as the non-
immunoglobulin molecule CD99, actively mediate leukocyte transendothelial migration315,316. 
Whereas ICAM-1 and ICAM-2 interact with LFA-1 integrin, PECAM-1 and CD99 exert 
homophilic interactions, and the JAMs support both homophilic and integrin interactions. 
Different molecules mediate transmigration in either a stimulus-specific or leukocyte-specific 
manner. For example, PECAM-1, ICAM-2 and JAM-A mediate leukocyte transmigration in 
response to interleukin-1β (IL-1β) but not TNF-α317. Leukocyte transmigration can be 
modulated by translocation of PECAM-1 to EC junctions from a cell-surface-connected 
vesicular compartment and the loosening of adhesive contacts between VE-cadherin on 
neighbouring cells318. Leukocyte migration through the transcellular route occurs in the blood 
brain barrier and in various inflammatory scenarios319,320 and in vitro models321,322. The same 
molecules that mediate migration through endothelial-cell junctions may also be involved in 
transcellular migration320. ICAM-1 binding results in the translocation of ICAM-1 to F-actin- 
and caveolae-rich regions321,323. ICAM-1-containing caveolae link together forming vesiculo-
vacuolar organelles that produce an intracellular channel through which a leukocyte can 
migrate. Following penetration of the EC barrier, leukocytes then need to migrate through 
the endothelial basement membrane and the pericyte sheath, which occurs through gaps 
between adjacent pericytes and regions of low protein deposition within the extracellular 
matrix. This response can be facilitated by α6β1-integrin and proteases, such as matrix 
metalloproteinases and neutrophil elastase324. 
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Biomarkers of circulating blood cells described in the above sections have been investigated 
in DIVI and are summarised in Table 1.5.
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Biomarker Function Response in DIVI Drug reported with  Species Administration 
route 
Reference 
Chemokine 
ligand-1 
Recruitment of 
neutrophils 
Serum levels markedly 
increased at 4 hours 
CI-1044, SCH 351591 
and SCH 534385 
Rat Oral gavage 202 
Lipocalin-2 Produced by 
activated 
neutrophils 
Serum levels markedly 
increased at 8 hours 
CI-1044 Rat Oral gavage 202 
TIMP-1 Modulator of 
lipocalin-2 and 
matrix 
metalloprotease 
Serum levels markedly 
increased at 8 hours 
CI-1044, SCH 351591 
and SCH 534385 
Rat Oral gavage 123,325 
Interleukin-1β Mediator of the 
inflammatory 
response 
 CI-1044 Rat Oral gavage 202,325 
Interleukin-6 Mediator of the 
inflammatory 
response 
Serum levels markedly 
increased at 24 hours 
CI-1044, SCH 351591 
and SCH 534385 
Rat Oral gavage 123,202,325 
Macrophage 
inflammatory 
protein 3a 
Chemotactic for 
lymphocytes 
and weak 
attractant for 
neutrophils 
Serum levels markedly 
increased at 24 hours 
CI-1044 Rat Oral gavage 202 
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TNF-α Mediator of the 
inflammatory 
response 
No change SCH 351591 and SCH 
534385 
Rat Oral gavage 202 
α1-acid 
glycoprotein 
Mediator of the 
inflammatory 
response 
Serum levels markedly 
increased at 8 hours 
SCH 351591 and SCH 
534385 
Rat Oral gavage 123,202 
Thrombomodulin Stimulator of 
blood vessel 
formation 
Serum levels decreased CI-1044, SCH 351591 
and SCH 534385 
Rat Oral gavage 123 
VEGF Binds free 
plasma 
hemoglobin 
Serum levels markedly 
increased at 8 hours 
SCH 351591 and SCH 
534385 
Rat Oral gavage 123,202 
Haptoglobin Levels rise in 
response to 
inflammation 
Serum levels markedly 
increased at 8 hours 
SCH 351591 and SCH 
534385 
Rat Oral gavage 123,325 
C-reactive 
protein 
Levels rise in 
response to 
inflammation 
Serum levels markedly 
increased at 8 hours 
SCH 351591 and SCH 
534385 
Rat Oral gavage 123,325 
Table 1.5 Biomarkers of circulating blood cells investigated in DIVI. 
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1.6.6 Cross-talk of cells during inflammation, a typical feature of DIVI 
 
Figure 1.18 summarises the cross-talk between vascular and circulating blood cells. These 
phenomena collectively occur in DIVI and the related biomarkers investigated have been 
listed in Tables 1.3, 1.4 and 1.5. 
An element that should have more attention in DIVI is the role of extracellular vesicles. For 
example, it has been demonstrated that extracellular vesicles are elevated in pigs after a 
single administration of roflumilast, a PDE IV inhibitor. This could provide to be a novel marker 
that can be easily detected in peripheral blood.
 73 
 
Figure 1.18 Proposed schematic model showing the cross-talk between the cell types involved in DIVI. At the site of the injury, leukocytes 
adhere to the inter-endothelial gaps, RBC extravasate into the tunica media and occupy cavitations left from necrotic SMC. Cell debris from dead 
SMC promotes inflammation with recruitment of leukocytes. RBC may acquire an oxidised phenotype sustaining the inflammatory process. 
Activated platelets congregate at the lesion, contributing to thrombus formation together with VWF released from activated EC. Platelets also 
form aggregates with leukocytes, upregulating release of pro-inflammatory cytokines. Author’s own drawing.
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1.7 The importance of flow in blood vessel function 
 
EC in the normal circulation are exposed to two types of forces induced by blood flow: (1) 
shear stress, the frictional force per unit area parallel to the wall deriving from flowing blood, 
and (2) circumferential or hoop stress, deriving from blood pressure that drives blood flow, 
which acts on both EC and SMC326. The ability of EC and SMC to respond to shear stress 
exerted by blood flow is fundamental for the development and function of the vascular 
system. EC in arteries respond to increased blood flow by causing relaxation of the 
surrounding SMC and they do so by producing vasodilator substances such as NO, and 
prostacyclin326. By contrast, decreased flow causes vessel narrowing that is also mediated by 
signals from EC327. Under pathological conditions, low flow can lead to apoptosis of EC328. 
VEGF inhibition in mouse tracheas was shown to induce apoptosis of EC marked by activated 
caspase-3 in capillaries without blood flow. 
The changes in EC functions were demonstrated using a model of local stenosis obtained by 
narrowing large arteries such as abdominal aorta or carotid artery in rats, dogs, and rabbits. 
It was observed that expression of endothelial genes (see below) greatly differed in areas with 
laminar as opposed to disturbed flow. In areas of laminar flow, expression of transcription 
factor Kruppel-like factor-2 (KLF-2), which is responsible for maintaining EC survival, was 
increased. VE-cadherin expression, which promotes the integrity of the EC junctions, was also 
upregulated. By contrast, in the post-stenotic region, expression of KLF-2 and VE-cadherin 
was reduced, and SMAD1/5, a marker of proliferation, was increased329,330. These changes in 
EC functions demonstrate the importance of shear stress in the study of DIVI.  
 
1.7.1 Piezo-1 channel controls blood flow on EC 
 
EC express specific mechanotransducers that convert physical stresses into biochemical 
signals. Several mechanotransducers have been proposed to function in sensing flow, 
including ion channels, integrins, receptor tyrosine kinases, the apical glycocalyx, primary 
cilia, heterotrimeric G proteins, PECAM-1 and VE-cadherin331,332. 
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Piezo-1 and Piezo-2 are mechanically activated cation channels that form homomultimeric 
complexes that mediate mechanically induced currents333,334. Piezo-2 is the main sensor of 
mechanical stimuli in mammalian Merkel cells (located in the basal epidermal layer of the 
skin)335, whereas Piezo-1 has been shown to mediate mechanically activated cation currents 
in various other cell types, including EC336,337. It has been demonstrated that deficiency of 
Piezo-1 leads to disruption of vascular development in the mouse embryo and yolk sac 
demonstrated with hematoxylin and eosin (H&E) staining and PECAM-1 immunostaining to 
observe vessel morphology. These vascular defects resulted in embryonic lethality. In the 
same study, it was also demonstrated that Piezo-1 can be activated by shear stress and that 
loss of Piezo-1 affects the ability of HUVEC to alter their alignment when subjected to shear 
stress336. 
 
Furthermore, it has been shown using Piezo-1 deficient mice, that Piezo-1 mediates flow-
induced ATP release and subsequent activation of Gq /G11–coupled purinergic P2Y2 receptors 
that are involved in NO formation and thus regulation of vascular tone and blood pressure338. 
Activation of Gq /G11–coupled purinergic P2Y2 receptors promotes the phosphorylation and 
activation of Akt, which in turns phosphorylates and activates eNOS, responsible for the 
production of NO from L-Arginine339. Piezo-1 deficient mice lost the ability to induce NO 
formation and vasodilation in response to flow and developed hypertension. 
 
1.7.2 Yoda-1 activates EC Piezo-1 channels mimicking shear stress 
 
In addition to flow, Piezo-1 channels can also be activated by the synthetic small molecule 
Yoda-1. Yoda-1 stabilizes the open conformation of the Piezo-1 channel, reducing the 
mechanical threshold for activation in the absence of flow. Interestingly, Yoda-1 does not 
activate Piezo-2, despite the high sequence similarity between these two homologs. 
 
In vitro, administration of Yoda-1 mimicked the effect of shear stress and induced activation 
of eNOS and vasodilation of isolated arteries338. Moreover, Yoda-1 in static HUVEC cultures 
mimicked the effect of laminar shear stress by promoting phosphorylation of Akt and eNOS, 
the well-established effects of shear stress on expression of ICAM-1 and VCAM-1340. It was 
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also shown that Yoda-1 inhibited the ability of TNF-α to increase ICAM-1 and VCAM-1 
expression in HUVEC.   
Given the similarities between the effects of flow and Yoda-1 on Piezo-1 channels, Yoda-1 
may represent a useful tool in constructing an in vitro human model without the use of 
complicated systems involving flow.  
 
1.8 An in vitro model of DIVI 
 
An in vitro model would be a very useful tool for the study of DIVI among other vascular 
disorders. Specifically, a model that allows study of EC and SMC injury and subsequent 
inflammation would help understand the human relevance of DIVI that is currently unclear. 
As mentioned earlier, drugs that cause DIVI in preclinical species are often stopped from 
further development or the drug development is delayed to allow further safety evaluation. 
An in vitro model to understand the mechanisms of DIVI would be the first step to allow 
screening of compounds for DIVI risk in drug development making the entire process more 
time- and cost-efficient. 
 
Currently, there is a lack of in vitro human systems to study DIVI and only two models of DIVI 
are available. The limitations with these models are that they are quite complicated to build 
and to standardise across different laboratories. An overview of these systems is given in the 
below sections. 
 
1.8.1 Existent in vitro models to study DIVI 
 
Efforts have been made to identify biomarkers of DIVI and in developing in vitro models. The 
most successful models focus on the study of EC-SMC interaction and flow in order to 
recapitulate the in vivo physiology of blood vessels.  
 
An in vitro model of DIVI has been developed by the American company HemoShear, whereby 
a co-culture platform of rat primary EC and SMC separated by a synthetic internal elastic 
lamina allowed exposure of the endothelium to in vivo-derived hemodynamics79. In this 
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system it was observed that fenoldopam enhanced permeability and expression of 
inflammatory, cell death and oxidative stress genes. 
 
A second model for the study of DIVI is a microfluidic vascular device, whereby primary rat 
aortic EC and SMC are co-cultured across a porous membrane that mimics the internal elastic 
lamina, and the cells are exposed to arterial flow rates within the endothelial chamber114. This 
model also allows for study of extravasation of RBC into the smooth muscle layer, a 
phenomenon common in DIVI. A previously identified compound that causes DIVI, the PDE IV 
inhibitor CI-1044 (Table 1.5), has been tested in this device and it has been found to induce 
significant extravasation of RBC (which has been qualitatively assessed in this study, as 
present or absent in the device). Extravasation may have been due to the deleterious effects 
of the drug on the EC junctions, or perhaps via vascular oxidant stress and inflammation114. 
Importantly, blood flow does not change in this model, suggesting that DIVI phenotype can 
occur without a local increase in blood flow. Therefore, complex co-culture models can give 
insights into mechanisms that cannot be seen in vivo. However, although this model allows 
recapitulation of many of the mechanisms implicated in DIVI, it has some limitations. For 
example, flow in the device is laminar and non-pulsatile as it is in vivo. In addition, the SMC in 
the device do not undergo mechanical stresses as they do in resistance vessels and likely do 
not have a contractile phenotype. This phenotype could be induced in vitro by reducing the 
growth factors and serum in the cell medium, which causes the cells to differentiate.  
 
Currently, there is nothing available beyond these in vitro models. Furthermore, these 
systems are complex and neither time- nor cost-efficient. In order to have utility as an in vitro 
screening test of candidate drugs with DIVI risk, the model should be easy to build, 
reproducible, high-throughput and predictive. However, it may be unrealistic to expect that 
one model may be able to capture the mechanism by which all the drugs contribute to DIVI. 
The aim of this PhD is to rather study a toxicological event in human cells, and specifically 
define a toxicological limit around which the therapeutic index (IT) of a drug can be set, so 
that in the future the number of DIVIs seen in the clinic would be reduced. Although the on-
target effect of each drug has been presented in this Introduction, it is more likely that an off-
target action is implicated in DIVI. No studies so far have been directed at understanding the 
off-target effect of DIVI-related drugs.   
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In summary, the mechanisms driving DIVI are poorly understood. Vasodilatation and changes 
in blood flow are critical events in the pathogenesis of injuries, but a clear understanding of 
the onset and progression of the lesions is lacking. Finally, the clinical relevance of DIVI 
remains uncertain, as there are no reports of DIVI in humans treated with the same drugs that 
caused DIVI in preclinical species. However, in the absence of methodologies to effectively 
assess the drug-induced vascular lesions in humans, the occurrence of DIVI during preclinical 
assays can hinder the development of potentially novel medicines. Therefore, a model to 
accurately translate from preclinical observation to clinical setting is needed. This would be 
beneficial to cut time and costs of drug development and to reduce morbidity and mortality 
associated with ADRs.  
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1.9 Aims and objectives 
 
Reports suggest that the research and development (R&D) process of a new drug takes on 
average 15 years and costs over 1 billion dollars, with only 0.01 % of compounds making it to 
market1,2. This is, in part, due to toxicity, which accounts for 22 % of drugs that enter the 
clinical phase, with an even larger proportion of drugs being halted during preclinical 
development. Despite years of effort to improve R&D efficiency and performance, bringing a 
new drug to market still remains a very expensive and time-consuming process. A major issue 
is the ability to predict and translate drug toxicity from the pre-clinical animal studies to 
clinical trials. 
 
The aim of this thesis was to help define a toxicological limit around which the therapeutic 
index (TI) of a drug can be set, in order to reduce in the future the number of DIVIs seen in 
the clinic. Throughout this PhD this is achieved by determining the dose window for DIVI. 
 
The drugs chosen in this thesis (refer to Introduction, section 1.4.1, for selection criteria) have 
all been shown to produce DIVI at the non-clinical stage.  
 
This thesis, in collaboration with the Cardiovascular Safety Group, Drug Safety and 
Metabolism at AstraZeneca, had two specific objectives:  
 
1) Reproduce DIVI in an ex vivo model using the selected drugs in relevant animal tissue 
(refer to Introduction, section 1.4.1).  
 
2) Identify whether the selected drugs could induce vascular injury either directly on 
human vascular cells or indirectly through interaction with human blood cell, using 
conditions that would mimic the in vivo physiology.  
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2. Materials and Methods
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2.1 Materials 
 
A list of reagents and chemicals used within this thesis is presented in Table 2.1. Table 2.2 
illustrates cells, media and reagents used in cell culture, and Table 2.3 shows a list of primary, 
secondary antibodies and isotype controls. Finally, in Table 2.4 a list of reagents used for 
protein biochemistry is presented.  
 82 
 
Reagent Manufacturer Catalog 
number 
Composition/ 
Working concentration 
Application 
Bosentan Cayman 
Chemicals 
11731 1, 10, 100 µM FC, ICH, IF, 
Luminescence 
BQ 123 Sigma Aldrich B150 1 µM FC 
BQ 788 Sigma Aldrich B157 1 µM FC 
BSA Sigma Aldrich A7906 2 % or 10 % w/v ICH, IF 
CellTiter-Glo Promega G7572 n/a Luminescence 
Cell tracker™ 
green 
Life 
Technologies 
C7025 10 µM IF 
Cell tracker™ 
deep red 
Life 
Technologies 
C34565 0.5 µM IF 
DAPI Thermo Fisher D1306 300 nM ICH, IF 
DMSO Sigma Aldrich 276855 Neat FC, ICH, IF, 
Luminescence 
Fenoldopam 
mesylate 
Cayman 
Chemicals 
17629 1, 10, 100 µM FC, ICH, IF, 
Luminescence 
Fix/lyse 
solution 
eBioscience 00-
5333-54 
1x FC 
fMLP Sigma Aldrich F3506 10 µM FC 
Goat serum Sigma Aldrich S-26M 5 % v/v ICH 
ibidi mounting 
medium 
ibidi 50001 Neat IF 
Krebs buffer Made in house n/a 10x stock (used at 1x): 
1.26 M NaCl, 25 mM KCl, 
250 mM NaHCO3, 12 
mM NaH2PO4, 12 mM 
MgCl2, 25 mM CaCl2 
ICH 
Minoxidil 
sulfate salt 
Sigma Aldrich M7920 1, 10, 100 µM FC, ICH, IF, 
Luminescence 
O.C.T. Thermo Fisher 23-730-
571 
Neat ICH 
PBS Sigma Aldrich P4417 1x FC, ICH, IF 
PFA Alfa Aesar J61899 4 % v/v FC, ICH, IF 
PPACK Cayman 
Chemicals 
15160 75 µM FC 
ProLong Gold 
antifade 
mounting 
medium 
Life 
Technologies 
P36930 Neat ICH 
PI Sigma Aldrich P4170 10 µg/ml FC 
Rolipram Sigma Aldrich R6520 1, 10, 100 µM FC, ICH, IF, 
Luminescence 
Saponin Sigma Aldrich 47036 0.15 % v/v Luminescence 
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Shandon 
embedding 
matrix 
Thermo Fisher 1310 Neat ICH 
Sylgard 184 Dowsil 101697 n/a ICH 
Thrombin from 
bovine plasma 
Sigma Aldrich T4648-
1KU 
1 U/ml ICH, IF 
TRAP-6 amide Bachem H-2936 100 µM FC 
Triton X-100 Sigma Aldrich T9284 0.1 % v/v IF 
TNF-α R&D systems 210-TA-
010 
1 - 100 U/ml FC 
Tween 20 Santa Cruz SC-
29113 
0.1 % v/v ICH 
Yoda-1 Sigma Aldrich SML 
1558 
0.05 - 100 µM IF, 
Luminescence 
 
  
Table 2.1 List of reagents and chemicals used in alphabetical order. Abbreviations: FC = Flow 
cytometry, ICH = Immunocytochemistry, IF = Immunofluorescence. 
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Product Manufacturer Catalog 
number 
Composition/ 
Working concentration 
Application 
HCASMC Promocell C-12511 500,000 cryopreserved cells Cell culture 
HCASMC 
media 
Promocell C-22062 n/a Cell culture 
Supplements 
HCASMC 
media 
Promocell C-39267 Fetal calf serum (0.05 ml/ml), 
epidermal growth factor 
(recombinant human, 0.5 
ng/ml), basic fibroblast 
growth factor (recombinant 
human, 2 ng/ml), insulin 
(recombinant human, 5 
µg/ml) 
Cell culture 
HUVEC Promocell C-12203 500,000 cryopreserved cells Cell culture 
HUVEC 
media 
Promocell C-22010 n/a Cell culture 
Supplements 
HUVEC 
media 
Promocell C-39215 Fetal calf serum (0.02 ml/ml), 
endothelial cell growth 
supplement (0.004 ml/ml), 
epidermal growth factor 
(recombinant human, 0.1 
ng/ml), basic fibroblast 
growth factor (recombinant 
human, 1 ng/ml), heparin (90 
µg/ml), hydrocortisone (1 
µg/ml) 
Cell culture 
Cryo-SFM Promocell C-29912 n/a Cell culture 
FBS Gibco 26140079 1x Cell culture 
Gentamycin Sigma Aldrich G1272 35 µg/mg Cell culture 
Medium 
M199 
Sigma Aldrich M2520 1x Cell culture 
Trypsin-
EDTA 0.25 % 
v/v 
Gibco 25200-056 1x Cell culture 
 
 
 
 
 
 
 
 
Table 2.2 List of cells, media and reagents used in cell culture. 
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Antibody Host Manufacturer Catalog 
number 
Dilution Application 
Primary antibodies 
CD31 Mouse Abcam Ab119339 ICH 1 : 
100 
IF 1 : 
500 
ICH, IF 
Human CD11b (APC) Mouse eBioscience  340937 1 : 100 FC 
Human CD14 (PE) Mouse eBioscience  12014942 1 : 100 FC 
Human CD15 (FITC) Mouse eBioscience  562370 1 : 100 FC 
Human CD31 (APC) Mouse eBioscience  17031942 1 : 100 FC 
Human CD41 (PE-Cy7) Mouse eBioscience  303718 1 : 50 FC 
Human ICAM-1 (FITC) Mouse eBioscience  BMS108FI 1 : 100 FC 
Human PAC-1 (FITC) Mouse eBioscience  340507 1 : 20 FC 
Human P-selectin (PE) Mouse eBioscience  304905 1 : 20 FC 
Human VCAM-1 (PE-Cy7) Mouse eBioscience  25106942 1 : 100 FC 
Phospho-Akt Rabbit Cell Signaling 9272 1 : 1000 WB 
Phospho-eNOS Rabbit Cell Signaling 9572 1 : 1000 WB 
β-tubulin Rabbit Cell Signaling 2146 1 : 1000 WB 
VWF Rabbit Abcam Ab6994 ICH 1 : 
200 
IF 1 : 
1000 
ICH, IF 
Secondary antibodies 
F(ab’)2 Goat Anti-Rabbit 
IgG (FITC) 
Goat Invitrogen 11483981 ICH 1 : 
500 
IF 1 : 
1000 
ICH, IF 
Goat Anti-Mouse IgG 
(Alexa Fluor 647) 
Goat Thermo 
Fisher 
A21235 ICH 1 : 
500 
IF 1 : 
1000 
ICH, IF 
Isotype controls 
Mouse IgG1 κ (APC) Mouse eBioscience 17471482 1 : 100 FC 
Mouse IgG1 κ (FITC) Mouse eBioscience 11471442 1 : 100 FC 
Mouse IgG1 κ (PECy7) Mouse eBioscience 25471442 1 : 100 FC 
  
Table 2.3 List of primary and secondary antibodies and isotype controls used within this 
thesis. Abbreviations: FC = Flow cytometry, ICH = Immunocytochemistry, IF = 
Immunofluorescence, WB = Western blot.  
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Product Manufacturer Catalog 
number 
Composition/ 
Working 
concentration 
Application 
Chemiluminescent 
substrate 
Thermo 
Fisher 
34577 n/a WB 
DTT Sigma Aldrich 10197777001 10 mM WB 
PBS-T Made in 
house 
n/a 1x PBS 
0.1 % w/v Tween 20 
WB 
Protease inhibitor 
cocktail 
Sigma Aldrich P8340 1 : 100 WB 
RIPA lysis buffer Made in 
house 
n/a 100 mM tris pH 8; 2 % 
v/v Triton X-100; 0.2 % 
w/v SDS;  
1 % w/v sodium 
deoxycholate; 300 
mM sodium chloride  
WB 
Running buffer Made in 
house 
n/a 10x stock (used at 1x): 
0.1 % sodium dodecyl 
sulfate; 190 mM 
glycin; 25 mM tris-
base 
WB 
Transfer buffer Made in 
house 
n/a 10x stock (used at 1x): 
190 mM glycin; 25 
mM tris-base 
WB 
 
  
Table 2.4 List of reagents used for protein biochemistry. Abbreviation: WB = Western blot. 
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2.2 Methods 
 
2.2.1 Ex vivo studies 
 
Animal handling and experiments conformed to the UK Animal Scientific Procedures Act – 
specifically schedule 1 procedures that cover methods of euthanasia appropriate for different 
species, weights and stage of development, and were planned in order to minimise the usage 
of animals. Animal handling and sacrifice was carried out by AstraZeneca scientists. Han 
Wistar male and female rats 8 weeks old were euthanised using carbon dioxide (CO2) before 
confirmation of death. A total of 4 rats was used for an experimental set.  This is a limited 
number for in vivo studies and more animals should have been included in the study. 
However, previous studies in the field describe similar experiments using a comparable 
number of animals. In addition, considerations related to the Replacement, Refinement and 
Reduction of Animals in Research (3Rs) have been made and the number of rats used kept to 
the minimum.  
 
2.2.1.1 Isolation of the rat superior mesenteric artery, treatment and fixation 
 
Fresh gut tissue from rats was transported to the department of Pharmacology on ice in 
carbogenated Krebs buffer (see Table 2.1 for recipe) and processed immediately. Krebs buffer 
pH was adjusted to 7.2 and the solution autoclaved and stored for a maximum of 24 hours. 
The rat gut was carefully dissected to isolate the superior mesenteric artery (SMA) (see 
chapter 3 for location of the artery). Care was taken to minimise trauma to the artery. The 
dissection was conducted using a dissection microscope with high quality sharp forceps and 
micro scissors. A petri dish coated with Sylgard 184 was used to pin down the tissue to 
facilitate the isolation of the artery. The Krebs solution in the petri dish was replenished when 
needed, to ensure that the tissue remained hydrated and alive. An oxygen cylinder was used 
to oxygenate the Krebs buffer throughout the dissection and also later for the entire 
treatment duration. 
 
Following isolation, the SMA was cut into six equal length segments (approximately 2 mm in 
length).  Each segment was incubated separately with a drug (refer to Introduction, Table 1.1) 
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or the appropriate control and kept at 37 C for 24 hours. Following treatment, segments 
were washed twice in Krebs buffer and fixed overnight using 4 % v/v PFA.  
 
2.2.1.2 Tissue freezing and cryostat sectioning 
 
Aortic tissue segments were frozen promptly as described below to avoid large ice crystal 
formation that can cause morphological distortions that can damage the tissue. Vessel 
segments were adjusted in labelled cryomolds with Shandon embedding matrix to cover the 
tissue ensuring optimal conditions for freezing, by avoiding the formation of crystals in those 
specimens containing high water content. The orientation of the vessel segment was labelled 
on the cryomold to make sure its horizontal or vertical direction during cryo-sectioning was 
known. The cryomolds holding each vessel segment were then immersed in liquid nitrogen 
until completely frozen and then stored at - 80 C until further use. 
 
Before sectioning with the cryostat (Leica CM1900, Leica Biosystems), the frozen blocks were 
allowed to equilibrate in the cryostat chamber (-24 C) for approximately 30 minutes. 
Optimum cutting temperature formulation was used to make the frozen block adhere to the 
sample support and left to freeze. Sections were cut to 10 µM thickness and collected on 
Superfrost Plus glass slides. The anti-roll plate, made of coated glass, was used to prevent 
frozen sections from curling upwards, after sectioning. 
 
2.2.2 Cell culture 
 
All primary cells were cultured at 37 C, 5 % CO2, under humidifying conditions. Appropriate 
sterile tissue culture treated plasticware was used. 
 
Human umbilical vein endothelial cells (HUVEC) and human coronary artery smooth muscle 
cells (HCASMC) were purchased from PromoCell as cryovials containing 500,000 cells and 
seeded at the recommended density of 10,000 cells/cm2 into a T25 flask. HUVEC were from 
pooled donors, and HCASMC were isolated from tissue from a single donor (Table 2.2). It 
would have been ideal to use for the studies endothelial and smooth muscle cell lines 
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originating from arteries usually affected by DIVI. HUVEC are derived from veins from 
immune-naïve foetal tissue and show differences from adult vascular endothelium.  
However, HUVEC were selected as the source of EC since they have been extensively 
characterised in the literature341 and HCASMC were used as the source of arterial vascular 
SMC as they have also been widely described342. Limitations related to the sensitivity to drugs 
and shear stress should be taken into considerations and will be described more in detail in 
the specific chapters sections. 
 
2.2.2.1 Cell passaging, storage and thawing 
 
All cells were cultured in medium supplemented with growth factors and 35 µg/ml antibiotic 
(gentamycin) to prevent infections (Table 2.2). Medium was changed 24 hours after plating 
and subsequently every 2 days, until cell confluency was reached. Cells were passaged when 
they reached 70 - 90 % confluency until passage 6. A schematic of a typical passaging 
timescale is shown in Figure 2.1.  
 
Firstly, the cells were washed with ethylenediaminetetraacetic acid solution (EDTA), a 
chelator used to remove calcium from the media. Cadherin and integrin protein which hold 
cells to each other and their underlying substrate rely on calcium ion binding to maintain their 
globular structure. Cells are detached with addition of pre-warmed trypsin. The cells detach 
once pre-warmed trypsin is added. Trypsin is a serine protease which hydrolyses adhesion 
proteins. Complete cell detachment was verified by light microscopy. Trypsin was neutralised 
with an excess of pre-warmed M199 media containing 20 % filtered fetal bovine serum (FBS) 
and the cells were centrifuged at 1,500 RPM for 4 minutes. After centrifugation, the pellet 
was resuspended in fresh EC or SMC medium (as described above) and the cells were 
reseeded. Upon reaching passage 6, cells were harvested, pelleted and resuspended in 1 ml 
cryopreserving medium aliquots (Cryo-SFM). Cryo-SFM is a protein-free medium containing 
methylcellulose and DMSO to provide preservation of cells. Cells were stored for at least 4 
hours at - 80 C, before being transferred to liquid nitrogen for long-term storage.  
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For thawing, the cryovial was removed from the liquid nitrogen container and immediately 
placed on dry ice for transportation to the correct location. The vial was then immersed into 
a water bath (37 C) for approximately 2 minutes until only a small cell ice pellet could be 
observed; the cells were transferred to a T25 flask containing pre-warmed medium. The 
medium was replaced after 24 hours and the cells grown for 48 hours post thawing before 
conducting an experiment. HUVEC were not used experimentally after passage 8 as it has 
been shown that HUVEC lose their characteristic phenotype and become more fibroblast-like 
in nature343.  
 
 
 
2.2.2.2 Co-culture of HUVEC and HCASMC 
 
HUVEC and HCASMC at passage 6 were grown in T25 flasks separately until confluent. Cell 
trackers were used to visualise the two cell types. SMC were labelled with Cell Tracker Deep 
Red (0.5 μM), while EC were labelled with Cell Tracker Green (10 μM) (Table 2.1). The working 
concentration was selected (according to manufacturer’s guidance) such that normal cellular 
physiology would be maintained whilst producing a signal sufficient enough to observe 
without providing artefacts. Since the red dye produces a higher fluorescent signal compared 
to the green, the selected concentration was lower in these experiments. Cells were washed 
with RPMI and incubated for 20 minutes with the trackers at 37 C. Trackers were washed off 
Figure 2.1 Typical cell passaging timescale from P1 to P4. 
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to remove excess dye and the stained cells resuspended together at the correct density. Cells 
were seeded into ibidi slides and incubated for 24 hours before fixation in 4 % v/v PFA and 
microscopy imaging. 
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2.2.2.3 HUVEC culture under shear stress 
 
HUVEC were seeded into a µ-slide VI0.4 (ibidi) at 6 x 104 cells/channel and left to adhere for 2 
hours prior to the addition of flow through the connection of a perfusion pump set (ibidi, 
10902). The perfusion system is a computer-operated positive air pressure pump (ibidi). 
HUVEC were exposed to a continuous shear rate of 5 dyn/cm2, according to the 
manufacturer’s instructions. HUVEC were maintained at 5 % CO2 and 37 οC while under shear 
stress.  
 
2.2.3 Whole blood experimentation 
 
2.2.3.1 Whole blood collection and treatment  
 
Blood was taken from healthy volunteers who gave full informed consent. Care was taken to 
select donors that were not on medication or pain relief that may interfere with blood cell 
activation. Blood was taken through venipuncture by trained phlebotomists in the Harper lab. 
Blood was collected in Vacuettes containing 75 µM D-Phenylalanyl-propyl-arginyl 
Chloromethyl Ketone (PPACK). PPACK is a synthetic peptide derivative that acts as an 
anticoagulant, irreversibly and specifically inhibiting thrombin-mediated platelet activation 
by binding with high affinity to an allosteric site of thrombin. Unlike more commonly used 
anticoagulants, such as sodium citrate or EDTA, the divalent cation concentration in plasma 
is maintained at normal levels.  
 
Never longer than 5 minutes after being taken, blood was aliquoted into 1.5 ml centrifuge 
tubes and treated with either bosentan, fenoldopam mesylate, minoxidil sulfate salt, and 
rolipram (Table 2.1) at 1 µM, 10 µM, and 100 µM concentrations. 100 µM thrombin receptor-
activating peptide (TRAP)-6 amide and 10 µM N-formyl-Methionyl-Leucyl-Phenylalanine 
(fMLP) were used as a positive control for platelet activation and leukocyte activation, 
respectively.  
 
After a 20, or 60 minute stimulation, conducted at room temperature, 50 µl of blood per 
condition was aliquoted into fresh 1.5 ml centrifuge tubes and stained with the appropriate 
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antibodies for 5 minutes in the dark. Antibodies used in this study were CD41 PE-Cy7, P-
selectin PE, and PAC-1 FITC for platelets; CD14 PE, CD15 FITC, and CD11b APC for leukocytes. 
Isotype controls were used for each antibody. See Table 2.3 for corresponding catalogue 
numbers and dilutions.  
 
Following antibody staining, 350 µl fix-lyse solution diluted to 1x in dH2O was added to cells 
and incubated for 15 minutes at room temperature. Fix-lyse solution contains ammonium 
chloride which lyses red blood cells (RBC) with minimal effect on leukocytes. This lysis of only 
RBC allowed clear visualisation of the other fixed blood components after staining with 
antibodies. Samples were read using a flow cytometer (BD Accuri C6, BD Biosciences).  
 
2.2.4 Flow cytometry  
 
2.2.4.1 Instrument parameters  
 
FITC signal was excited at 488 nm and detected at 530 nm; APC signal was excited at 633 nm 
and detected at 660 nm; PE was excited at 488 and detected at 575 nm; Pe-Cy7 was excited 
at 488 nm and detected at 774 nm. Data were acquired and analysed with the software BD 
Accuri C6. Gating strategies are explained in detail in appropriate results chapters.   
 
2.2.4.2 Investigating inflammation by measuring VCAM-1 and ICAM-1 expression 
 
HUVEC were grown for 24 hours in a 24-well plate. Cells were treated separately with drugs 
or 100 U/ml TNF-α, a known inflammatory stimulus that served as a positive control for 24 
hours. Cells were detached from the wells using accutase, a less stringent protease than 
trypsin that would leave the surface adhesion molecules intact or uncleaved. Cells were 
pelleted using the protocol in section 2.2.2.1. The supernatant was removed, and the cell 
pellets were resuspended in 100 µl of filtered PBS. For each treatment, cells were stained with 
the following antibody cocktails for 5 minutes in the dark: i) ICAM-1 FITC, VCAM-1 PECy7; ii) 
IgG FITC, IgG PECy7; iii) CD31 APC; iv) IgG APC (refer to Table 2.3). Unbound antibody was 
washed off by centrifugation, and the samples read with the flow cytometer BD Accuri C6. A 
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total of five N was conducted. Analysis was conducted using the BD Accuri C6 software (see 
section 2.2.4.5 below). 
 
2.2.4.3 Investigating cell death with propidium iodide in co-culture  
 
HCASMC were tracked with Cell Tracker Deep Red (0.5 μM) as described in section 2.2.2.2, 
then HUVEC and HCASMC were seeded in a 2:1 mixture in 24 well plates, left to grow for 24 
hours and then treated with the drugs at 100 µM for 24 hours or with cisplatin 50 µM used 
as positive control. Single HUVEC and single HCASMC were also seeded in parallel. Following 
treatment, cells were washed with EDTA and incubated with accutase for cell detachment. 
Accutase was neutralised with M199 containing 20 % v/v FBS, cells were harvested, spinned 
down, HUVEC were stained with CD31, and propidium iodide (PI) 10 µg/ml was added to all 
cells. Finally, cells were analysed by flow cytometry. 
 
2.2.4.4 Acquisition of events with flow cytometer 
 
Initially, live cell populations were gated using the forward and side scatter profiles 
(representing the size and granularity of cells, respectively) to exclude dead cells and cellular 
debris. These populations were then further gated using a cell type specific antibody. For each 
experiment, at least 20,000 events were collected in the platelet gate, and 1,000 events were 
collected in the neutrophil- and monocyte-gate. For EC or SMC, at least 10,000 events were 
acquired. For compensation beads, a gate was drawn around the beads and 5,000 events 
were acquired.  
 
2.2.4.5 Analysis from data acquired by flow cytometry 
 
Prior to the analysis each channel was compensated to account for fluorescence bleed-
through. OneComp eBeads (eBioscience) were used for compensation according to the 
manufacturer's instructions. Compensation analysis and analysis of the compensated data 
were carried out using the BD Accuri C6 software, using the median fluorescent intensity (MFI) 
to reflect the abundance of a specific surface protein.   
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2.2.5 Confocal microscopy  
 
2.2.5.1 Equipment and imaging parameters 
 
Images were acquired using the Leica TCS SP5 confocal microscope (Leica Microsystems). 
DAPI (4’, 6-diamidino-2-phenylindole) was excited at ʎ=405 using a UV laser line; AlexaFluor® 
488 nm was excited with an Argon laser at ʎ=488, AlexaFluor® 633 was excited with a helium-
neon laser at ʎ=633. Images were acquired using LAS AF software (Leica Microsystems) with 
a 20x (for the mesenteric artery experiment) or 63x (for cell culture) oil immersion objective 
at 1024 x 1024 pixels with a 16-bit resolution at a frequency of 100 Hz and 3-line average. 
 
2.2.5.2 Vessel fixation and staining procedures 
 
Cryo-sections were outlined with a hydrophobic wax pen to minimize antibody usage. Cryo-
sections were permeabilised with 0.1 % v/v Tween 20, and then incubated for 1 hour in block 
solution (10 % w/v BSA, 5 % v/v goat serum, and 0.1 % v/v Tween 20, in PBS). The sections 
were then incubated with a combination of one of the primary antibodies (Table 2.3) 
overnight at 4 C in block solution (without 0.1 % v/v Tween 20). Sections were washed twice 
in PBS and incubated in blocking solution with fluorescently conjugated secondary antibodies 
and DAPI (Table 2.3) for 1 hour at room temperature. Following two washes, sections were 
mounted using ProLong Gold antifade mounting medium that preserves the fluorescent signal 
and reduces the degree of photo bleaching when imaging. Slides were stored at 4 C prior to 
imaging to ensure the stability of the samples. One picture of a complete vessel cross section 
was analysed for every condition per N, for a total of 4 N performed with different animals on 
separate days.  
 
2.2.5.3 Cell fixation and immunostaining  
 
Cells were seeded at 100,000 cells/well in ibidi slides and left to grow for 24 hours. After 
treatment, cells were washed with PBS and fixed with 4 % v/v PFA for 10 minutes at room 
temperature, permeabilised with 0.1 % v/v Triton X-100 for 5 minutes and then blocked with 
2 % w/v BSA in PBS prior to immunostaining. The antibodies used for staining are shown in 
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Table 2.3. The cells were mounted using ibidi mounting media. Six images were collected per 
treatment per N, for a total of four N. Analysis was conducted in ImageJ. Images in the green 
channel (VWF) were thresholded to remove background noiseand the VWF-positive cells 
were counted. Analysis of VWF and endothelial junctional breakage is described in detail in 
chapter 4.  
 
2.2.6 Investigating cell death using an ATP viability assay  
 
The luminescent cell viability assay was used to determine the number of viable cells in 
culture based on the quantification of the nucleotide adenosine triphosphate (ATP). The 
reaction is catalysed by the enzyme luciferase obtained from the firefly (Photuris 
pennsylvanica). In the presence of ATP, luciferin gets catalysed by the enzyme luciferase to 
the light-emitting product, oxyluciferin (Figure 2.2). Cell injury or cell death results in loss of 
plasma membrane integrity leading to a decrease in cytoplasmic ATP, therefore in this assay 
the luminescence signal is proportional to the number of viable cells present.  
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HUVEC and HCASMC were seeded in an opaque-walled (to prevent luminescence bleed-
through) 96-well plate at a density of 10,000 cells/well and grown for 24 hours. Cells were 
treated with the drugs (refer to Introduction, Table 1.1) or DMSO (to serve as a control) for 
1, 4 and 24 hours at 37 C. 0.15 % w/v of the detergent saponin was used as positive control 
for cell death. The detergent (also present in the assay reagent) induces cell lysis, enabling 
the released ATP to react with the luciferin and emit light. 30 minutes before each time point, 
the plate was left to equilibrate at room temperature, after which CellTiter-Glo® reagent was 
added to the cells to induce cell lysis at a volume equal to the cell culture medium present in 
each well. The content was mixed for 2 minutes on an orbital shaker and the plate was then 
incubated at room temperature for 30 minutes in the dark. During this time, unstable ATP is 
catalysed to ADP. For the Yoda-1 experiment, experimental conditions remained the same 
except that cells were pre-treated with Yoda-1 for 24 hours before drug treatment. 
 
The luminescence was measured and recorded with a microplate reader (CLARIOstar Plus, 
BMG Labtech). Data were expressed as % survival compared to a vehicle treated cells on the 
Figure 2.2 ATP luminescence assay. Mono-oxygenation of luciferin is catalysed by luciferase, 
contained in the reagent, in the presence of Mg2+, O2, and ATP. 
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same plate. In addition, wells containing medium without cells were used to obtain a value 
for background luminescence. A standard curve with 4 concentrations of ATP (1 nM, 10 nM, 
100 nM, 1 M) was also obtained in order to understand the working range of the assay prior 
to the biological experiments. The curve was generated by preparing serial tenfold dilutions 
of ATP in culture medium and following the same protocol explained previously. Experiments 
were conducted in triplicates for each drug condition and a total of 5 experiments was 
performed.  
 
2.2.7 Protein biochemistry 
 
2.2.7.1 Gel electrophoresis   
 
HUVEC lysates were made by scraping cells off their support using a cell scraper. This was 
carried out in ice cold RIPA lysis buffer. Protease inhibitor cocktail mix was added to prevent 
protein degradation (refer to Table 2.4 for recipe and concentrations). To decrease the 
viscosity of the sample and ensure accurate gel loading, the preparation was sonicated for a 
few pulses to shear the DNA. Samples were subsequently placed in a heat block at 95 C for 
5 minutes to complete protein denaturation. Prior to gel loading, lysate concentrations were 
established via Bradford assay. BSA standards from 0 to 1000 μg/ml (the range over which 
the assay is linear) were prepared. Samples were incubated at different concentrations with 
Bradford reagent for 5 minutes at room temperature. Absorbance was measured at 595 nm 
using a microplate reader (CLARIOstar Plus, BMG Labtech).  
 
Once the protein concentration had been established, 4x sample buffer containing 20 μg 
protein was separated by SDS-PAGE on 12 % polyacrylamide gels under reducing conditions 
(10 mM DTT). Electrophoresis was performed at a voltage between 100 - 180 volts and was 
stopped when the dye front reached the base of the gel casing. Pre-stained protein standard 
molecular weight markers (Life Technologies) were used on all gels. 
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2.2.7.2 Western blotting 
 
Proteins were transferred to a PVDF membrane that was previously activated with methanol. 
Membranes were pre-wet in transfer buffer. Wet transfer was carried out in a Biorad transfer 
blot module at 100 volts for 1 hour. Membranes were blocked for 1 hour at room temperature 
with 5 % w/v BSA in PBS-T (Tris-buffered saline containing 0.1 % v/v Tween-20, and 
subsequently incubated with eNOS and Akt antibodies in blocking solution (Table 2.3) at 4 oC 
for overnight incubation. After washing with PBS-T 3 times, membranes were blocked for 1 
hour in 5 % w/v milk block, followed by incubation for 2 hours at room temperature with anti-
rabbit HRP 1 : 5,000 or anti-mouse HRP 1 : 10,000. -tubulin was used as loading control. 
Membranes were washed as described above before imaging. Images were collected through 
high resolution chemiluminescent substrate chemistry and documented on X-ray film.  
 
2.2.7.3 Densitometry analysis 
 
Bands were analysed and quantified using ImageJ. Protein levels were determined based on 
their band intensities and normalised to the respective loading control intensities.  
 
2.3 Statistical analysis  
 
All quantified data was evaluated using the statistical software package GraphPad Prism®. 
Statistical test information can be found within figure legends. Data was deemed significant 
when p < 0.05. The number of experiments conducted is defined in each section.  
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3. Developing an ex vivo model of DIVI 
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3.1 Introduction 
 
DIVI has been shown to occur in rats, mice and dogs treated with compounds from various 
pharmacological classes39,53,76. The primary aim of this chapter was to develop an ex vivo 
model that could replicate the features of DIVI. The work was carried out on rat vessel 
explants, where multiple drug treatments or conditions could be undertaken from the same 
animal. In this way, the number of animals required could be reduced. Studies have reported 
that the rat superior mesenteric artery (SMA), which arises from the anterior surface of the 
abdominal aorta and supplies arterial blood to the organs of the midgut, is particularly 
affected by DIVI, and therefore was selected for these experiments76,203.  
 
Activation of EC stimulates the release of several proteins, including VWF. VWF has been used 
as a clinical biomarker for non-drug related endothelial dysfunction diseases, as increased 
circulating levels are associated to EC damage in patients with arteritis, diabetes, sepsis, or 
atherosclerosis344,345. An increase in plasma levels of VWF has also been observed in rats and 
dogs following administration of fenoldopam and a K+ channel opener, demonstrating the 
cross-species translation of VWF as a biomarker for EC dysfunction198,200. 
 
Assessment of VWF release from the endothelium of the rat mesenteric explants was 
conducted following 24 hours of treatment because this is usually the timeline for DIVI198,203. 
Four drugs with different mechanisms of action were selected (Table 1.1, Introduction): (1) 
bosentan, an endothelin (ET) receptor antagonist, (2) fenoldopam mesylate, a dopamine DA1 
receptor agonist, (3) minoxidil, an opener of KIR (inward rectifier) 6.X ATP sensitive K+ 
channels, which increases the permeability of K+ ions into the cell, and (4) rolipram, a 
phosphodiesterase (PDE) IV inhibitor.  
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3.2 Methods 
 
Animal handling and experiments conformed to the UK Animal Scientific Procedures Act – 
specifically schedule 1 procedures that cover methods of euthanasia appropriate for different 
species, weights and stage of development. A total of 4 rats (3 males and 1 female) were 
employed in this experiment. Gender has been closely associated with vascular disease and 
injury, e.g. female rodents demonstrate reduced vascular injury through reduced intimal and 
medial thickening. It would have been ideal to perform the study with a statistically powered 
number of animals (both females and males) to assess these gender differences but this could 
not be addressed in this thesis for limitations in the rats availability as well as time constraints. 
The superior mesenteric artery (SMA) was isolated and dissected away from the protective 
adipose tissue (Figure 3.1). In order to minimise variability across arteries, for each rat only 
the first part (branching from the aorta) of the SMA was used and no first or second order 
branches were taken. Vessel size ranged between 300 m and 500 m in inner diameter. 
Figure 3.2 schematically depicts the work-flow for this procedure. A detailed description of 
the protocol is given in Methods, section 2.2.1.  
 
Each SMA was cut into 6 segments, each 1 mm long, for separate drug treatments. For each 
experiment a segment was treated with 0.1 % v/v dimethyl sulfoxide (DMSO) (vehicle) to 
serve as a control. Segments were treated for 24 hours in a water bath at 37 C in Krebs 
solution and bubbled with oxygen, and subsequently fixed overnight in 4 % v/v PFA. Vessels 
were then cut to 10 µM thickness sections with a cryostat followed by permeabilisation with 
0.1 % v/v Triton X-100 for 5 minutes. Sections were stained (see below) and images were 
taken by laser scanning confocal microscopy at a 20x magnification. Images were processed 
and analysed using the imaging software Fiji (Image J). In these experiments 20x did not allow 
a complete cross section of the vessel. As such, several images were taken and stitched using 
the pairwise stitching Fiji plugin. One picture of a complete vessel cross section was analysed 
for every condition per experiment, for a total of 4 experiments conducted with different 
animals on separate days.  
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Figure 3.1 Extraction of the rat gut and localisation of the superior mesenteric artery (SMA). Scale bar in A represents 2 cm. 
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Figure 3.2 Flow diagram of the experimental procedure. (1) The rat gut was collected and the superior branch of the mesenteric artery 
carefully isolated. (2) The vessel was cut in six segments and (3) each segment treated with a drug (Table 1.1, Introduction) at 37 C for 24 
hours under oxygenated conditions. Subsequently, segments were fixed in PFA overnight and then promptly frozen in liquid nitrogen. (4) Each 
segment was then cut into 10 µM slices using a cryostat, and then (5) stained for VWF and CD31. Images were acquired on a Leica confocal 
microscope. Analysis was performed using ImageJ Fiji software.    
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3.3 Results 
 
Figure 3.3 shows a representative picture of a rat control vessel explant stained for VWF and 
the platelet endothelial cell adhesion molecule 1 (PECAM-1)/CD31, to mark the endothelium. 
CD31 is highly expressed at endothelial cell-cell junctions, where it functions as an adhesive 
protein to maintain cell junctional integrity (refer to Introduction, section 1.6.1.2). DAPI was 
used to stain DNA and thus locate the nuclei. As expected, CD31 stained the endothelium 
uniformly. VWF was also found in the endothelium and co-localised with CD31.   
 
To measure the degree of non-specific binding, both the secondary antibodies used (anti-
rabbit IgG for VWF and anti-mouse IgG for CD31) were incubated alone, as a control, to assess 
the background fluorescence levels (Figure 3.4). For each experiment the intensity of the 
background fluorescence was subtracted from the fluorescent intensity values of the 
experimental data.  
 
The CD31 signal that is prominent around the outside of the vessel in Figure 3.3 is not a 
consequence of non-specific binding of the secondary antibody. Its pattern of staining 
suggests that the primary antibody sticks to the fatty layer in the vessel. 
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Figure 3.3 Cross section (10 µM thickness) of the SMA in a control rat. Cell nuclei were 
stained with DAPI (A). VWF and CD31 (endothelial marker) are shown in B and C, 
respectively. D is a merged picture of DAPI (blue), CD31 (red) and VWF (green). Images 
were taken with a confocal microscope, using a 20x oil immersion objective and stitched 
together using the pairwise stitching Fiji plugin. Scale bars represent 100 µm. 
 
Figure 3.1 Cross section (10 µM thickness) of the SMA in a control rat.  
Cell nuclei were stained with DAPI (A). CD31 (endothelial marker) and VWF are shown in B 
and C, respectively. D is a merged picture of DAPI (blue), CD31 (red) and VWF (green). 
Images were taken with a confocal microscope, using a 20x oil immersion objective and 
stitched together using the pairwise stitching Fiji plugin. Scale bars represent 100 µm. 
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To quantify the fluorescent signal corresponding to VWF, the images were analysed with the 
image analysis software Fiji (ImageJ). The image was split into the different colour channels 
(DAPI-blue, VWF-green, CD31-red) and a grid was used to aid in visually identifying the centre 
of the vessel. To remove bias, four lines were drawn starting from the centre towards each 
corner of the picture, obtaining a top right, bottom right, top left and bottom left lines (Figure 
3.5). The line thickness was 20 pixels and was chosen because this width generated the peak 
with the least noise. The CD31 signal was used as a guide for two reasons; firstly to ensure 
that the endothelium was intact following the treatment, and secondly to accurately locate 
VWF. DAPI was used to mark the lumen and the outer edge of the vessel. 
 
Thus, a plot with three fluorescence intensities along the line corresponding to the blue 
(DAPI), green (VWF) and red (CD31) channels was generated for each of the four lines (Figure 
3.6). Fluorescence intensities from the VWF, CD31 and DAPI signals were converted to 
greyscale values between 0=black and 255=white. The range between black and white is a 
continuous spectrum of grey shades. The greater the greyscale value the greater the 
fluorescence signal intensity. To directly compare greyscale values between vessels, imaging 
parameters and microscope settings remained constant.  
anti-rabbit IgG 
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C 
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Figure 3.4 Assessment of the level of non-specific staining. Rat segments were stained with 
secondary antibodies alone. Images were taken with a confocal microscope, using a 20x oil 
immersion objective. Scale bars represent 100 µm. 
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Figure 3.5 Quantification of VWF. Each image was split into the different colour channels 
(DAPI-blue, VWF-green, CD31-red) (A, C, E). A grid tool was used to locate the centre of the 
vessel. From the centre, four lines 20 pixels width were drawn towards each corner of the 
image obtaining a top right, bottom right, top left and bottom left lines (B, D, F). Images were 
taken with a confocal microscope, using a 20x oil immersion objective. Scale bars represent 
100 µm. TL= top left, TR= top right, BL= bottom left, BR= bottom right. 
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Figure 3.6 Plot profile with three fluorescence intensities representing CD31 (red), DAPI (blue) and VWF (green). Fluorescence intensity is 
presented as grey values. 
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CD31 was used to accurately locate the endothelium. From the direction of the lumen 
outwards, the first peak corresponded to the endothelium. An interval of 20 pixels before and 
after the highest value was taken in the CD31 plot profile to define the thickness of the 
endothelium. The intensity of VWF staining in this region was quantified as the average of 
VWF greyscale values and was expressed as a percentage of the control vessel. CD31 
expression was used to quantify VWF and to qualitatively ensure that the endothelium 
remained intact after treatment but was not quantified. The smooth muscle region was 
identified using -smooth muscle actin (-SMA) staining and was detected directly beneath 
the endothelium (Figure 3.7).  
 
It was not possible to co-stain -SMA, CD31 and VWF due to antibody cross reactivity. The 
smooth muscle layer was determined as the area 20 pixels past the highest CD31 value 
moving further into the vessel and away from the lumen. To quantify VWF in the smooth 
muscle region, the interval of intensity values between the last value of CD31 and the last 
value of DAPI was taken and averaged and expressed as percentage of the control vessel. An 
example of this approach is shown in Figure 3.7.  
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Figure 3.7 VWF, CD31 and -SMA staining in a rat vessel explant. A represents a control 
vessel and B a zoomed-in region showing VWF (green), CD31 (red) and DAPI (blue).C and D 
(zoomed-in) represent -SMA staining in a different control vessel. Quantification of VWF in 
the endothelium and smooth muscle region is shown in E. Scale bars represent 100 µm. 
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3.3.1 Thrombin promotes VWF release from EC ex vivo   
 
VWF is stored in Weibel-Palade bodies (WPB) in EC346. The release of VWF from EC is mediated 
by both basal and stimulus-induced signalling pathways219 (refer to Introduction, section 
1.6.2.4.2). Regulated release occurs in response to several agonists including histamine and 
thrombin. Thrombin has been used in vitro and in vivo to stimulate VWF release218. For the 
purposes of this study, these findings were recapitulated so that VWF levels could be assessed 
in the vessel explants. Moreover, measuring this would allow to demonstrate that these 
vessel explants are functionally active and able to respond to stimulation.  
 
Vessels were stimulated with thrombin 10 U/ml for 24 hours. Thrombin induced significant 
VWF release from the endothelium, as shown qualitatively by the loss of VWF signal 
compared to the matched control (Figure 3.8, B and F). To ensure that the loss was not 
associated with loss of integrity, the endothelium was stained with CD31 and maintained its 
integrity after 24 hours, as shown by the CD31 signal that is no different from the control 
vessel (Figure 3.8, A and E).  
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Figure 3.8 VWF expression in a thrombin-stimulated and in a control vessel. I and J show a 
thrombin and a control plot, respectively. Scale bars represent 100 µm.  
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When data was quantified and expressed as normalised percentage compared to the 
matched control vessel, thrombin stimulation reduced endothelial VWF intensity to 39.32 ± 
8.52 % of control (N=4, p < 0.01) (Figure 3.9 and 3.10). This data confirms that thrombin is a 
robust positive control for endothelial cell VWF release.  
 
3.3.2 DIVI-related drugs induce VWF release from EC   
 
Vessel segments were treated with four drugs, all reported to actively induce DIVI in animal 
models, at 100 µM for 24 hours under oxygenated conditions. A total of 4 rats were used in 
these experiments. Bosentan, fenoldopam and minoxidil induced a significant VWF release 
from EC compared to the matched vehicle control, as shown by over 50 % reduction 
(bosentan stimulation reduced endothelial VWF intensity to 39.12 ± 3.46 % of control (N=4, p 
< 0.01), fenoldopam to 43.99 ± 6.44 % of control (N=4, p < 0.01), minoxidil to 46.78 ± 5.92 % 
of control (N=4, p < 0.05)) (Figure 3.9 and 3.10). Conversely, rolipram induced a lower, 
insignificant level of VWF compared to the matched control (reduction in VWF intensity to 
89.0 ± 23.20 (N=4, p > 0.05). No difference was observed between the drugs and the thrombin 
positive control; thrombin, bosentan, fenoldopam and minoxidil all induced a comparable 
amount of VWF release from the endothelium. The VWF staining detected in the SMC layer 
of the vessels was not altered by treatment with any of the DIVI drugs (Figure 3.10, B).  
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Figure 3.9 VWF and CD31 staining in rat mesenteric explants. The endothelium in control 
vessels stains uniformly for VWF and remains intact after treatment, as shown by CD31+ stain. 
Images were taken with a confocal microscope, using a 20x oil immersion objective. Scale 
bars represent 100 µm. 
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Figure 3.10 Quantification of VWF release in EC and SMC in the vessel. Data are expressed 
as percentage reduction of VWF intensity relative to matched untreated control (white bars) 
and represent mean ± SEM of 4 independent experiments, analysed by one-way ANOVA 
followed by Dunnett’s post test. *p < 0.05. Note that control VWF levels in SMC were very 
low. 
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3.4 Discussion 
 
The aim of this first set of experiments was to determine whether a DIVI-like phenotype could 
be recapitulated using a novel vessel explant approach. These data showed that DIVI can been 
recapitulated in vitro and demonstrated the utility of this approach in enabling parallel drug 
treatments to be carried out on the same vessel. Minimising the variation caused by animal 
heterogeneity increases experimental reproducibility and could contribute to the reduction 
of the number of animals required for preclinical evaluation studies.  
  
VWF was selected as a marker in this model because of a known association with DIVI. Several 
studies in rats and dogs employed VWF as a biomarker of vascular injury198–200,203. However, 
most DIVI studies have used conventional histopathological examination, such as H&E 
staining. In this study this was replaced with immunofluorescence imaging, which generated 
a greater dynamic signal range. Immunofluorescence has other important advantages, such 
as a higher sensitivity and accuracy.  
 
The endothelium in control vessels stained uniformly for VWF. Although the vessels are 
circular, they are not uniformly-shaped, which made it difficult to accurately quantify VWF in 
the endothelium. Here, an analysis method that enabled quantification of the VWF in the 
endothelium in an unbiased manner was developed, using nuclei to define the vessel and 
CD31 staining to define the endothelium. Defining the region of the endothelium was 
important since it was possible that some VWF may be released into the SMC layer (see 
below). This method is robust, however there is a limitation as this approach would not be 
suitable for vessels in which treatments cause endothelial loss (although this will be seen in 
the CD31 staining). However, this was not observed for the drug treatments or our positive 
control in this study.  
 
Thrombin was used a positive control as it is an effective activator of EC, inducing disturbance 
of the endothelial cell barrier, release of inflammatory mediators, adhesion of leukocytes on 
EC, and release of VWF from WPB347–349. In these experiments, thrombin treatment of vessel 
explants led to significant loss of endothelial VWF demonstrating that the EC in the vessel 
explants remain functional and capable of responding to stimulation.  
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To evaluate whether a DIVI-like phenotype could be generated in our ex vivo vessel model 
four drugs that have been reported to cause DIVI in animal models were tested: bosentan, 
fenoldopam, minoxidil, and rolipram (refer to Introduction, Table 1.1). The length of 
treatment (24 hours) was selected to recapitulate the time course of injury seen in vivo200. 
Shorter postdosing intervals demonstrated that drug-induced damage in the mesenteric 
artery did not always occur, in a rat study regardless of the dose, DIVI was only evident when 
fenoldopam was infused for longer than 12 hours100.  
 
Bosentan, fenoldopam and minoxidil caused significant loss of VWF from the CD31+ 
endothelium, to a comparable extent to the positive control, thrombin. In contrast, rolipram 
had no effect. Importantly, the endothelium remained intact following each of the drug 
treatments. Therefore, VWF loss is more likely to be a marker of activation rather than death 
of the endothelium. This however should be confirmed by staining for apoptotic markers 
(such as activated caspase-3). It should be noted that degradation as opposed to release may 
be responsible for the loss of VWF in these assays. There are reasons for the loss of expression 
which could be irrespective of VWF release. For example, endothelial autophagosomes 
contain abundant VWF protein and the drugs could increase degradation of VWF. 
Degradation of VWF has been described in the Introduction 1.6.2. 
 
It may be expected that VWF would be re-synthesised during the 24 hour treatment, such 
that increased release would be masked in our model, since total intracellular VWF was 
detected. Re-synthesis could be for example be measured by quantitative polymerase chain 
reaction (qPCR), which monitors the amplification of targeted DNA molecules in real-time. 
Conversely, since EC have limited VWF storage capacity204,350,351, repeated EC activation may 
cause depletion of the cytoplasmic pool of VWF from WPB. In this study, rolipram was the 
only drug that did not cause a reduction in VWF. However, although there are reports 
regarding VWF release with fenoldopam and a K+ channel opener in preclinical animals200, this 
is the first data investigating VWF expression after stimulation with bosentan and rolipram.  
 
Although previous histopathological imaging of arteries injured in vivo showed an 
accumulation of VWF in the SMC region200, the drugs used in this study did not induce 
retention of VWF within the SMC region in the ex vivo model. However, the VWF 
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accumulation observed in previous reports may represent plasma-derived VWF extravasating 
in the tunica media199, a level of complexity absent from this model. It is also known that the 
shear stress induced by blood flow (which was not present in this experiment) can alter the 
expression and release of proteins within EC and it is possible that VWF release and 
distribution are also affected352. Indeed, the absence of plasma and flow is a limitation of this 
ex vivo model.  
 
These data suggest that an ex vivo model could be used to evaluate whether early 
development compounds may cause EC activation. In this approach, several drugs were 
tested on the mesenteric artery of a single rat, significantly reducing the number of animals 
required for this assessment. Although time course and dose-response studies have not been 
conducted in this project, with this positive proof-of-concept work, these could also be readily 
performed. In addition, this method could also be used to investigate EC activation looking at 
other biomarkers, such as VCAM-1 and ICAM-1, and to investigate SMC necrosis. In the 
standard toxicology studies, each timepoint and dose requires sufficient group numbers to 
provide statistical power. Surely, this model would not replace toxicology studies, but it still 
may be relevant for informing on dose and time. 
 
There are several important differences to consider between an ex vivo approach and an in 
vivo drug dose. The ex vivo model does not include blood cells that might contribute to the 
extent of arterial injury. Leukocytes have been observed adhering to arteries injured in 
vivo39,61. Moreover, a characteristic sign of DIVI is focal haemorrhage. The red blood cells 
(RBC) that bleed into the vessel wall may promote further damage and inflammation as they 
break down39. The ex vivo model also lacks the contribution of haemodynamic forces, and the 
absence of flow (as mentioned above) is another limitation of this system. In vivo, the 
endothelium of the artery will be subjected to blood flow and wall shear stress. Vasodilatation 
and a local increase in blood flow have been proposed as major physical factors in the 
development of DIVI38. For example, significant increases in rat mesenteric blood flow have 
been observed with fenoldopam101 and with the PDE IV inhibitor CI-1044353 at doses that 
induce DIVI. It has been hypothesised that alterations in shear stress might be the mechanism 
for the development of the injury75. The endothelium is subjected to either a laminar or a 
turbulent force, and responds accordingly (refer to Introduction, section 1.7)354. EC exposed 
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to a laminar flow adopt a quiescent anti-inflammatory, anti-thrombotic and anti-apoptotic 
phenotype355,356, whereas EC exposed to turbulent flow display an activated phenotype 
implicated in the pathogenesis of vascular injury by promoting expression of proteins involved 
in inflammation, coagulation and proliferation356–358.  
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Some studies have attempted to add flow to EC to mimic in vivo hemodynamic and create a 
more physiological model. For instance, the American company HemoShear created a co-
culture platform with rat primary EC and SMC where the endothelium is exposed to in vivo-
derived hemodynamic waveforms. They found that a high dose (100 µM) of fenoldopam in 
the presence of drug-induced hemodynamic significantly increased vascular permeability and 
elevated several inflammatory pathways, suggesting that flow is important in the study of 
DIVI. 
 
This model did not involve blood and the data may suggest that an increase in blood flow is 
not required for DIVI, since three drugs produced an effect. Nonetheless, blood flow may 
contribute to the extent of the damage, in particular the status of the smooth muscle layer, 
which is known to be necrotic in DIVI. However, it could also be proposed that flow was 
important for fenoldopam, minoxidil and bosentan to induce release of VWF. In fact, even 
though the model did not involve flow, the vessel explants originally developed under flow 
and adapted to it in the animal. As a consequence, EC have been shear-conditioned in this 
model. It could be that rolipram needs flow during the drug treatment to generate a DIVI-
related phenotype, which did not happen in this model, or perhaps it is just altered flow that 
is important. However, it could also be that it is the drug specific mechanism of action that 
caused rolipram to not induce VWF release in this model.  
If flow is not a prerequisite for DIVI, this means that it is possible to take a step further in a 
NC3Rs approach to reproduce the model totally in vitro. This will be explained in the next 
chapter. 
 
In summary, it was successfully demonstrated that VWF is a sensitive morphological marker 
of EC activation in a rat model of DIVI, it is released from EC following stimulation. These 
experiments have also demonstrated that these drugs are active and induce a significant 
reduction of VWF expression in the vessel endothelium. The next chapters will explore VWF 
release in a human in vitro model under static conditions.  
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4. Investigating DIVI in vitro
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4.1 Introduction  
 
The primary aim of this chapter was to investigate whether it is possible to recapitulate DIVI 
in vitro. This in vitro set up would use human-derived primary cells that would eliminate 
species specificity translatability issues359. To investigate whether DIVI would occur in 
humans, EC and SMC from human pooled donors were used. Firstly, the effect of the drugs 
on VWF release was investigated, as loss of VWF from the endothelium in the rat vessel 
explants was clearly defined in all DIVI drugs except for rolipram (chapter 3). Subsequently, 
other known features of DIVI, such as cell death, vascular permeability and inflammation were 
investigated. 
 
4.2 Results  
 
HUVEC were selected as the source of EC, since they have been extensively characterised in 
the literature341. HCASMC were used as the source of arterial vascular SMC as they have also 
been widely described342. When grown to confluency, HUVEC had a cobblestone appearance, 
whereas HCASMC were characterised by an elongated appearance (Figure 4.1, A and B).  
 
 
Figure 4.1 Bright field images of EC and SMC. HUVEC are shown in A, and HCASMC in B. 
Cultured cells were imaged at passage 6. Scale bars represent 50 µM. Images were taken with 
a bright field microscope. 10x. 
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The junctional protein VE-cadherin, important in maintaining the integrity of the 
endothelium, was used as specific EC marker360,361. Calponin, a calcium-binding protein that 
is involved in the modulation of contraction by interaction with actin and inhibition of 
actomyosin Mg-ATPase activity, was used as a specific marker of SMC362. HUVEC stained 
positive for VE-cadherin (Figure 4.2, A and B), however no calponin was identified (C and D). 
By contrast, HCASMC showed positive expression of calponin (Figure 4.2, G and H), but an 
absence of VE-cadherin (E and F). DAPI was used to stain the cell nuclei (Figure 4.2). 
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Figure 4.2 Representative confocal images of specific HUVEC and HCASMC markers. VE-cadherin stain is positive in HUVEC (A and B) and 
negative in HCASMC (E and F). Calponin was detected in SMC (G and H) and was absent in HUVEC (C and D). DAPI (blue) was used to stain 
the nuclei. Scale bars represent 20 µM. 63x. 
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4.2.1 VWF release with DIVI-related drugs in HUVEC  
 
Firstly, VWF release from the endothelium was monitored, to understand if the observations 
in rat mesenteric artery explants in chapter 3 could be recapitulated in human EC in vitro. 
HUVEC were seeded in ibidi slides at 100,000 cells/well, grown for 24 hours, and treated with 
100 M fenoldopam mesylate, minoxidil sulfate, bosentan and rolipram. Two time points 
were selected: 1 hour, to assess a short-term effect (acute) and 24 hours, to reflect the time 
point of the vessel experiment. Thrombin 1 U/ml was used as a positive control in the 
experiments. Vehicle control cells were treated with 0.1 % v/v DMSO. Following treatment, 
cells were fixed with 4 % v/v PFA for 10 minutes then permeabilised for 5 minutes with 0.1 % 
v/v Triton X-100. Specific antibodies were used to detect VWF and CD31 (to mark cell 
junctions), and DAPI was used to label the nuclei. Cells were imaged with a confocal 
microscope using a 63x objective. Six images were taken for each treatment per repeat, four 
experiments were conducted in total. 
 
4.2.1.1 DIVI-related drugs induce VWF release after 1 hour and 24 hours  
 
VWF release was analysed (Figure 4.3, 4.4). Images in the green channel (VWF) were 
thresholded to remove background noise. Cells were counted as VWF-positive if they had 3 
or more spots/cell. This cut off point was selected as 3 was the minimum number of spots 
present when the positive control thrombin was analysed. DMSO control cells did not show 
100 % positivity, but rather around 80 % both at 1 and 24 hours. This was expected, as VWF 
is also secreted spontaneously from unstimulated cells through the constitutive secretory 
pathway363 (refer to Introduction, section 1.6.2.4.2).  
 
Thrombin 1 U/ml was chosen as positive control to match VWF release ex vivo (refer to 
chapter 3). Thrombin induced significant release of VWF compared to DMSO control after 1 
hour (% VWF-positive cells was reduced to 41.6 ± 5.5, N=4, p < 0.01) and after 24 hours (% 
VWF-positive cells was reduced to 55.8 ± 2.9, N=4, p < 0.001), (Figure 4.5). The mean 
percentages of cells that remained positive for VWF following thrombin stimulation at 1 and 
24 hours were not significantly different (41.6 vs 55.8). 
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Figure 4.3 Representative confocal pictures of VWF release in HUVEC at 1 hour. HUVEC were grown for 24 hours and then 
VWF (green) release was detected with a specific antibody after treatment with DIVI-related drugs for 1 hour. Arrows in (A) 
point at WPB which contain VWF. Arrow in (B) points at a cell which has secreted VWF. Cell junctions are stained with CD31 
(red). Scale bars represent 20 m.  
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Figure 4.4 Representative confocal pictures of VWF release in HUVEC at 24 hours. HUVEC were grown for 24 hours and 
then VWF (green) release was detected with a specific antibody after treatment with DIVI-related drugs for 24 hours. Cell 
junctions are stained with CD31 (red). Scale bars represent 20 m. 
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Bosentan induced significant VWF release after 1 hour (% VWF-positive cells was reduced to 
51.7 ± 2.6, p < 0.05) and 24 hours (reduction to 53.3 ± 6.9, p < 0.001). Similarly, fenoldopam 
caused significant VWF release at both time points. Minoxidil showed a trend but the release 
was not significant at 1 hour. However, at 24 hours minoxidil significantly expelled VWF (% 
VWF-positive cells was reduced to 63.5 ± 4.73, p < 0.01). Rolipram did not cause VWF release. 
All represent N=4 (Figure 4.5, A and B).  
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Figure 4.5 VWF release after 1 and 24 hours in HUVEC. HUVEC were treated with 1 U/ml 
thrombin and DIVI-related drugs at 100 M for 1 and 24 hours. Data are expressed as % of 
VWF-positive cells out of all cells in the field of view (six random fields of view per treatment), 
and represent mean ± SEM of 4 independent experiments, analysed by one-way ANOVA 
followed by Dunnett’s post test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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4.2.1.2 The particle size of WPB does not differ across treatments    
 
In order to analyse the particle size of WPB, which store VWF, images were thresholded to 
remove the background, made binary and then the total area of particles larger than 0.3 μm2 
was counted automatically. Using this method, all particles are counted, including the ones 
outside the cells and therefore this approach does not discriminate whether VWF has been 
released from the cell. The particle size of WPB did not differ across treatments at 1 hour or 
24 hours (Figure 4.6, A and B). 
 
These data showed that DIVI-related drugs (except for rolipram) induce significant VWF 
release compared to control both ex vivo in rat vessel explants and in vitro in human EC. VWF 
release is induced acutely (after 1 hour) and the effect is retained after 24 hours. In both 
experiments, thrombin caused VWF release, proving to be a robust positive control.  
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Figure 4.6 Average particle size of WPB at 1 and 24 hours. HUVEC were treated with 1 U/ml 
thrombin and DIVI-related drugs at 100 M for 1 and 24 hours. Data are expressed as area of 
WPB particles in the field of view (six random fields of view per treatment), and represent 
mean ± SEM of 4 independent experiments, analysed by one-way ANOVA followed by 
Dunnett’s post test. 
 133 
 
4.2.2 Assessment of disruption to EC monolayer 
 
Drug-induced disruption to the HUVEC monolayer was assessed via confocal microscopy, 
using CD31 to mark junctional integrity and disruption. The experiment was conducted as 
explained in section 4.2.1. Images taken with a confocal microscope at a 63x objective were 
processed using ImageJ software. 6 images were taken per treatment per repeat. Images 
were thresholded in order to remove background noise and enable clear visualisation of the 
junctions. The image was then converted to binary and the median fluorescence intensity 
(MFI) of the black pixels enumerated. The larger the area of black the greater disruption to 
EC monolayer (Figure 4.7, 4.8).  
 
4.2.2.1 Fenoldopam induces junctions disruption at 1 hour and minoxidil at 24 hours  
 
Thrombin 1 U/ml was used as positive control for inducing disruption in the junctions. 
Thrombin significantly disrupted the junctions at 1 hour (mean of 7.5 ± 1.2, p < 0.01), and the 
effect was reversed after 24 hours treatment (mean of 3.2 ± 1.7), (Figure 4.9).  
 
All drugs were tested at 100 μM and disruption was assessed at 1 (Figure 4.7, 4.9, A) and 24 
hours (Figure 4.8, 4.9, B). Fenoldopam significantly increased junction disruption at 1 hour 
(mean of 7.9 ± 3.3, p < 0.01), however the effect was not observed at 24 hours (mean of 1.2 
± 0.6). Minoxidil showed a trend to increase disruption at 1 hour (mean of 9.3 ± 3.4), and the 
effect reached significance at 24 hours (mean of 11.5 ± 1.9, p < 0.01). Bosentan and rolipram 
had no effect on junction disruption at 1 hour (mean of 2.1 ± 0.7 and mean of 0.9 ± 0.3, 
respectively) or 24 hours (mean of 2.7 ± 1.7). All data represent N=4. 
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Figure 4.7 Assessment of EC junctional integrity with DIVI-related drugs at 1 hour. HUVEC were grown for 24 hours and then junctional 
disruption was analysed after treatment with DIVI-related drugs for 1 hour. Cell junctions are stained with CD31. Scale bars represent 30 μm.   
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Figure 4.8 Assessment of EC junctional integrity with DIVI-related drugs at 24 hours. HUVEC were grown for 24 hours and then junctional 
disruption was analysed after treatment with DIVI-related drugs for 24 hours. Cell junctions are stained with CD31. Scale bars represent 30 μm.  
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Figure 4.9 Quantification of EC junctional disruption. HUVEC were grown for 24 hours and 
then junctional disruption was analysed after treatment with DIVI-related drugs at 1 ad 24 
hours. Data are normalised to DMSO control and expressed as MFI fold change and represent 
mean ± SEM of 4 independent experiments, analysed by one-way ANOVA followed by 
Dunnett’s post test. *p < 0.05, **p < 0.01.  
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4.2.3 Investigating cell death with an ATP viability assay 
 
A key feature of DIVI is cell death, which was assessed next. DIVI-related drugs have been 
shown to cause necrosis of the tunica media170. Furthermore, investigation of EC death has 
been suggested as potential biomarker of DIVI35.  
 
The ATP assay was used to measure the number of viable cells in culture. Cell injury and death 
leads to membrane permeability and results in a rapid decrease in cytoplasmic ATP, 
incubation of the substrate with viable cells results in a signal that is proportional to the 
number of viable cells present. The luminescence assay used here was selected because of its 
high sensitivity.  
 
Cells were seeded in 96 well plates at 15,000 cells/well and left to grow for 24 hours. They 
were treated with fenoldopam, minoxidil, bosentan, and rolipram. Four concentrations were 
used: 0.1, 1, 10, and 100 M. Saponin, a detergent that dissolves lipids in the cell membrane 
making it permeable, was used as positive control364. Three time points (1, 4 and 24 hours) 
were chosen. The assay was performed on HUVEC and HCASMC. The luminescence was 
detected by a plate reader (refer to methods, section 2.2.6 for a detailed description of the 
protocol).  
 
4.2.3.1 Fenoldopam causes cell death after 24 hours in HUVEC 
 
The luminescence for the vehicle was measured to ensure that DMSO would not induce cell 
death. No significant difference was observed at 1, 4 and 24 hours (Figure 4.10). For example, 
at 1 hour DMSO-treated HUVEC had a mean survival of 97.0 ± 0.6 % and HUVEC treated with 
media alone had a mean survival of 98.7 ± 0.9 % (N=5, ns).  
 
The positive control saponin induce a significant decrease in cell survival compared to control 
at all time points. At 1 hour, saponin reduced HUVEC survival by 89.0 ± 0.7 %. Similar effects 
were seen at 4 and 24 hours.  
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Figure 4.10 Investigating cell death with the ATP viability assay. HUVEC were grown for 24 
hours, and luminescence was measured using a plate reader at three time points. DMSO 
was used as the vehicle for the drugs. The detergent saponin was used as positive control 
for cell death. Data represent mean ± SEM of 5 independent experiments, analysed by two-
way ANOVA followed by Dunnett’s post test. **** p < 0.0001. 
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Across the drugs, only 100 M fenoldopam had a significant effect, inducing approximately 
50 % HUVEC cell death at 24 hours (mean survival, 48.4 ± 6.1 %; N=5, p < 0.05) (Figure 4.11). 
10 μM Fenoldopam induced only a small amount of death, displaying a mean of 89.2 ± 2.7, 
whereas 1 μM showed a mean of 93.3 ± 7.3, and 0.1 μM a mean of 94.8 ± 6.5 (N=5, ns). None 
of the drugs showed an effect on cell proliferation. In HCASMC none of the drugs had an effect 
on cell death (Figure 4.12).
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Figure 4.11 ATP viability assay in HUVEC. HUVEC were grown for 24 hours, treated with DIVI-related drugs at 0.1, 1, 10, 100 M for 1, 4 and 24 
hours. Luminescence was detected using a plate reader. Data are expressed as % survival compared to control. 100 % represents no death. Data 
represent mean ± SEM of 5 independent experiments, analysed by two-way ANOVA followed by Dunnett’s post test. *p < 0.05. 
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Figure 4.12 ATP viability assay in HCASMC. HCASMC were grown for 24 hours, treated with DIVI-related drugs at 0.1, 1, 10, 100 M for 1, 4 and 
24 hours. Luminescence was detected using a plate reader. Data are expressed as % survival compared to control. 100 % represents no death. 
Data represent mean ± SEM of 5 independent experiments, analysed by two-way ANOVA followed by Dunnett’s post test. *p < 0.05. 
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4.2.4 Exploring inflammation in DIVI 
 
Inflammation and leukocyte recruitment to the injuried artery wall has been extensively 
indicated as a hallmark of DIVI35,170,202. It was therefore tested whether DIVI drugs induced 
inflammation in EC. VCAM-1 and ICAM-1 were selected as markers of inflammation as they 
are upregulated in reponse to inflammatoty stimuli and are required for leuckoyte adhesion 
to the inflamed vessel wall. 
HUVEC were grown for 24 hours in 24-well plates, and treated with the drugs or TNF-α as a 
positive control for 24 hours. HUVEC were then washed with EDTA and incubated with 
accutase for cell detachment. Accutase was neutralised with M199 containing 20 % v/v FBS, 
cells were harvested, centrifuged and stained with specific antibodies (Methods, Table 2.3) 
and analysed by flow cytometry.  
 
4.2.4.1 TNF-α induces VCAM-1 and ICAM-1 expression in HUVEC in a concentration-
dependent manner 
 
HUVEC were gated using forward and side scatter (Figure 4.13, A). The cells stained positive 
for CD31, a specific marker for EC365 (B). An IgG isotype control was used to remove the non-
specific staining from the gating. TNF-α (10 U/ml) induced ICAM-1 and VCAM-1 expression in 
HUVEC after 24 hours (C and D), as seen by the shift to the right in the MFI.  
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Figure 4.13 ICAM-1 and VCAM-1 expression in HUVEC. HUVEC were grown for 24 hours in 24-
well plates, and treated with the drugs or TNF-α as a positive control for 24 hours. Cells were 
detached with accutase, stained with CD31 (specific EC marker), ICAM-1 and VCAM-1, and 
analysed by flow cytometry. IgG represents the isotype control.  
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To establish a suitable concentration of TNF-α to use as a postive control in subsequent 
experiments to investigate inflammation, HUVEC were treated with various concentrations of 
TNF-α for 24 hours (1-100 U/ml) (Figure 4.14, A, B; data are expressed as MFI fold change 
compared to control cells). TNF-α induced ICAM-1 and VCAM-1 expression in a concentration-
dependent manner. TNF-α 1 U/ml did not significantly increase ICAM-1 (mean fold change of 
1.3 ± 0.1, N=5, ns) nor VCAM-1 expression (mean of 1.0 ± 0.1, N=5, ns). TNF-α 5 U/ml 
significantly increased only ICAM-1 expression (mean of 3.6 ± 0.5, N=5, p < 0.01). TNF-α 10, 
20, 50 and 100 U/ml significantly increased both ICAM-1 and VCAM-1 expression. For example 
TNF-α 100 U/ml showed a mean of 12.6 ± 1.1 for ICAM-1 (N=5, p < 0.001) and 7.1 ± 1.2 for 
VCAM-1 (N=5, p < 0.001). TNF-α 10 U/ml was the lowest dose to induce a significant effect on 
both VCAM-1 and ICAM-1 and was therefore chosen as positive control for the next 
experiment with the drugs (sections 4.2.4.2 and 4.2.4.3). This concentration was selected, 
rather than the much stronger stimulation seen with 100 U/ml TNF-α, as it was considered 
that the DIVI drugs might have relatively weak effects on inflammation and this would be 
reflected in the control. 
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Figure 4.14 ICAM-1 and VCAM-1 expression in HUVEC after treatment with increasing 
concentrations of TNF-α. HUVEC were grown for 24 hours in 24-well plates, and treated with 
increasing concentrations of TNF-α for 24 hours. Cells were detached with accutase, stained 
with CD31 (specific EC marker), ICAM-1 and VCAM-1, and analysed by flow cytometry. Data 
are expressed as MFI fold change compared to unstimulated control, and represent mean ± 
SEM of 5 independent experiments, analysed by one-way ANOVA followed by Dunnett’s post 
test. *p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001.  
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4.2.4.2 Bosentan and fenoldopam induce ICAM-1 and VCAM-1 expression in HUVEC 
 
To test whether the DIVI-related drugs under investigation could induce inflammatory 
responses in EC, HUVEC were treated with each of the drugs (100 µM) for 24 hours. Bosentan 
significantly increased ICAM-1 expression after 24 hours with a mean fold change in MFI of 
1.8 ± 0.1 (N=5, p < 0.05) compared to control (Figure 4.15). However, the increase was not to 
the same extent as TNF-α 10 U/ml (mean fold change of of 5.0 ± 0.3). Bosentan also 
significantly increased VCAM-1 expression, with a mean of 1.5 ± 0.1 (N=5, p < 0.01), showing 
a similar increase as TNF-α (mean of 1.6 ± 0.2, N=5, p < 0.001). Fenoldopam significantly 
increased only VCAM-1 expression (mean of 1.3 ± 0.1, N=5, p < 0.05), with no significant effect 
on ICAM-1 expression. These data suggest that although some DIVI drugs can induce 
increased expression of ICAM-1 or VCAM-1 in HUVEC in vitro, their effects are relatively weak 
since even at 100 µM their effects are similar to (or less than) a threshold concentration of 
TNF-α.  
 
4.2.4.3 ICAM-1 and VCAM-1 expression is increased by bosentan under inflammatory 
conditions 
 
It has been suggested that DIVI might be facilitated by underlying inflammatory 
conditions35,202. In order to test this hypothesis, HUVEC were treated with the drugs alone at 
100 μM (no TNF-α) or in combination with the threshold concentration of TNF-α (10 U/ml) 
for 24 hours to mimic underlying inflammatory conditions that could facilitate DIVI (Figure 
4.16). It was observed that bosentan and TNF-α had an additive effect on ICAM-1 expression 
(mean of 8.3 ± 0.5, compared to 5.3 ± 0.1 of TNF-α alone, N=5, p < 0.01). The effect was 
greater than the sum of TNF-α alone and bosentan alone. However, the effect of bosentan 
with TNF-α on VCAM-1 expression was not statistically significant (mean of 2.6 ± 0.5, 
compared to 1.7 ± 0.4 of TNF-α alone, N=5, ns). The other drugs did not induce an additive 
effect on ICAM-1 or VCAM-1 when co-incubated with the threshold concentration of TNF-α. 
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Figure 4.15 Quantification of ICAM-1 and VCAM-1 expression in HUVEC. Data are 
expressed as fold change compared to control and represent mean ± SEM of 5 
independent experiments, analysed by one-way ANOVA followed by Dunnett’s post test. 
*p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Figure 4.16 ICAM-1 and VCAM-1 expression mimicking underlying inflammatory conditions. 
HUVEC were incubated with the drugs alone (no TNF-α) or together with TNF-α 10 U/ml for 
24 hours. Cells were stained with CD31 (specific EC marker), ICAM-1 and VCAM-1 and 
analysed by flow cytometry. Data are expressed as MFI fold change compared to 
unstimulated control and represent mean ± SEM of 5 independent experiments, analysed by 
two-way ANOVA followed by Dunnett’s post test. **p < 0.01 compared to TNF-α alone. 
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4.2.4.4 Bosentan only at high concentrations increases ICAM-1 and VCAM-1 expression 
 
The effect of bosentan on ICAM-1 expression with underlying inflammatory conditions was 
investigated further, since it was the only drug that had an effect on ICAM-1 expression under 
inflammatory conditions. The next step was to find the concentration of TNF-α that induced 
an effect on both VCAM-1 and ICAM-1 when incubated with bosentan, (since bosentan with 
TNF-α 10 U/ml showed an effect only on ICAM-1). The other were not investigated as these 
did not induce any effect in sections 4.2.4.2 and 4.2.4.3, and fenoldopam only induced an 
effect on VCAM-1 but not on ICAM-1. 
 
Various concentrations of TNF-α (0, 1, 5, 10, 20, 50, 100 U/ml) were tested to identify the 
concentration that had the greatest effect on induction of ICAM-1 and VCAM-1 expression 
when incubated with 100 μM bosentan for 24 hours (Figure 4.17). The concentrations that 
produced an effect on both ICAM-1 and VCAM-1 were 20 and 50 U/ml and these were 
therefore used in the subsequent experiments.  
 150 
 
 
 
 
 
Figure 4.17 Increasing concentrations of TNF-α incubated with bosentan 100 μM on ICAM-
1 and VCAM-1 expression in HUVEC. HUVEC were grown for 24 hours in 24-well plates, and 
treated with bosentan and TNF-α or TNF-α alone for 24 hours. Cells were detached with 
accutase, stained with CD31 (specific EC marker), ICAM-1 and VCAM-1, and analysed by flow 
cytometry. Data are expressed as MFI fold change compared to control on a logarithmic scale 
of concentrations of TNF-α (1, 5, 10, 20, 50, 100 U/ml). Data represent mean ± SEM of 5 
independent experiments, analysed by one-way ANOVA followed by Dunnett’s post test. *p 
< 0.05.  
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Having identified the concentrations of TNF-α that induced an effect on ICAM-1 and VCAM-1 
expression with bosentan, lower concentrations of bosentan were subsequently investigated. 
Bosentan (1, 10 and 100 μM) were incubated with TNF-α 20 or 50 U/ml (Figure 4.18). As 
shown previously, TNF-α 20 U/ml significantly increased ICAM-1 (mean of 5.1 ± 0.1, N=5, p < 
0.001) and VCAM-1 expression (mean of 1.9 ± 0.1, N=5, p < 0.01). TNF-α 50 U/ml also 
significantly increased ICAM-1 (mean of 7.8 ± 0.2, N=5, p < 0.0001) and VCAM-1 expression 
(mean of 3.1 ± 0.1, N=5, p < 0.001). Stars are not indicated on the graph as this effect was 
shown in the previous figures.   
 
HUVEC treated with bosentan (100 μM) and TNF-α (20 U/ml) showed significantly increased 
ICAM-1 (mean of 8.8 ± 0.5, N=5, p < 0.001) and VCAM-1 expression (mean of 3.9 ± 0.2, N=5, 
p < 0.001) compared to TNF-α 20 U/ml alone. Also, bosentan (100 μM) incubated with TNF-α 
50 U/ml increased ICAM-1 (mean of 11.4 ± 0.4, N=5, p < 0.001) compared to TNF-α 50 U/ml 
alone and VCAM-1 expression (mean of 4.7 ± 0.1, N=5, p < 0.0001). However, lower 
concentrations of bosentan did not have any effect on VCAM-1 and ICAM-1 expression. These 
data suggest that although co-stimulation with TNF-α increases the magnitude of the effect 
of bosentan, it does not increase the sensitivity of HUVEC to bosentan.
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Figure 4.18 Increasing concentrations of bosentan on VCAM-1 and ICAM-1 expression. 
HUVEC were grown for 24 hours in 24-well plates, and treated with bosentan 1, 10, 100 µM 
and TNF-α 20 or 50 U/ml for 24 hours. Cells were detached with accutase, stained with CD31 
(specific EC marker), ICAM-1 and VCAM-1, and analysed by flow cytometry. Data are 
expressed as MFI fold change compared to unstimulated control and represent mean ± SEM 
of 5 independent experiments, analysed by two-way ANOVA followed by Dunnett’s post test. 
***p < 0.001, ****p < 0.0001.  
 153 
 
4.2.4.5 Bosentan effect on ICAM-1 and VCAM-1 does not depend on ET receptor antagonism 
 
To understand the mechanism by which bosentan induces the effect on VCAM-1 and ICAM-1 
expression, interaction with the target receptors was investigated to determine whether the 
response depends on its primary target or is alternatively an off-target effect. Bosentan is an 
ET receptor antagonist, acting non-selectively on both ETA and ETB366. Therefore, cells were 
treated with the ETA selective antagonist, BQ123, and the ETB selective blocker, BQ788, both 
at 1 μM367,368. Neither BQ123 nor BQ788 produced a comparable effect to bosentan 100 μM 
(Figure 4.19). For example, bosentan incubated with TNF-α 20 U/ml increased the fold change 
in ICAM-1 MFI by 6.9 ± 0.4, whereas BQ123 or BQ788 plus TNF-α led to a fold change in MFI 
of 3.5 ± 0.1 or 3.2 ± 0.7, respectively. This suggested that the effect does not depend on a 
selective antagonism of ETA nor ETB. 
 
To understand whether the effect of bosentan is through a combined non-selective action on 
ETA and ETB, BQ123 and BQ788 were incubated together but again they did not have a 
comparable effect to that observed with bosentan alone. 
 154 
 
 
 
 
Figure 4.19 ET receptor antagonism effect on ICAM-1 and VCAM-1 expression. HUVEC were 
grown for 24 hours in 24-well plates, and treated with bosentan 100 μM, BQ123 1 μM, BQ788 
1 μM and TNF-α 20 or 50 U/ml for 24 hours. Cells were detached with accutase, stained with 
CD31 (specific EC marker), ICAM-1 and VCAM-1, and analysed by flow cytometry. Data are 
expressed as MFI fold change compared to unstimulated control and represent mean ± SEM 
of 5 independent experiments, analysed by two-way ANOVA followed by Dunnett’s post test. 
*p < 0.05, **p < 0.01.  
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4.3 Discussion 
 
In this chapter monocultured EC and SMC were investigated for DIVI-related phenotypes.  
Monocultured HUVEC and HCASMC were used. It is important to note that observations 
described in this chapter may differ across different vascular beds and further studies should 
be directed at investigating those differences. Specifically, HUVEC are derived from veins from 
immune-naïve foetal tissue and show differences from adult vascular endothelium.  
VWF release was measured in vitro in HUVEC. The cells were permeabilised to allow VWF 
intracellular levels to be measured. Thrombin was used as positive control. Thrombin induces 
VWF release in HUVEC369–371. Here, thrombin caused a significant VWF release at 1 hour and 
24 hours compared to DMSO (vehicle)-treated cells. The release of VWF from cells is not 
uniform in the field of view, and some control cells had completely released VWF. This could 
be explained as newly synthesised VWF is also secreted spontaneously from unstimulated 
cells through the constitutive secretory pathway363 (refer to Introduction, section 1.6.2.4.2). 
In addition, the HUVEC were derived from pooled donors and were at different stage of 
growth, which may also explain the non-uniformity between cells in the field of view. Using a 
single donor would have certainly decreased variability between cells and perhaps VWF 
expression in DMSO controls would have been more uniform but it would have been less 
useful and less representative of a large population. The way this could have been addressed 
would have been to use several single donor populations and compare VWF expression and 
release with pooled donors, as well as how VWF expression alters during the EC lifespan, but 
it would have been costly and not time efficient.  
 
Fenoldopam, bosentan and minoxidil caused significant VWF release at 24 hours, reflecting 
the effects observed in the rat mesenteric artery explant (chapter 3). Rolipram did not show 
VWF release, again recapitulating the vessel work. This might depend on the specific rolipram 
mechanism of action, but further experiments are required to prove this. Bosentan and 
fenoldopam also caused release of VWF after 1 hour in HUVEC, suggesting that the effect of 
the drug is acute and it would have been interesting to assess VWF release at this time point 
ex vivo to understand how it compared.  
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Fenoldopam has been previously shown to promote VWF release in vivo198,200. VWF levels 
were measured in rat plasma in these studies after 2, 6 and 24 hours post treatment. It was 
found that fenoldopam caused release of VWF acutely, but levels returned to baseline after 
24 hours. In a study from the same group in dogs, a K+ channel opener has also been found to 
increase plasma VWF levels acutely200. This transient increase might depend on differences 
between ex vivo/in vitro and in vivo work372. 
 
The average particle size of WPB containing VWF was measured to make sure the difference 
in VWF was only in the extent of release rather than a change in the shape or size. In line with 
this, results showed that the size of the particles did not change across treatments. This 
suggests that WPB do not fuse together. However, it was noticed (data not shown) that the 
intracellular location of the WPB changes across treatment and after treatment with 
thrombin WPB migrate towards the periphery of the cell. This may suggest that the drugs 
cause VWF release through a different mechanism compared to thrombin, as this was not 
observed with any of the DIVI drugs. It would be interesting to understand this more in detail, 
investigating the signalling pathways of the drugs by blocking receptors. Importantly, the 
change in WPB size was not observed with the positive control thrombin either. It is therefore 
unclear whether how valid these findings are without a control that significantly impacts on 
WPB size. For example, statins have been reported to decrease the size significantly and could 
have been used as a positive control. This is something that is worth investigation in the 
future. 
 
Following assessment of VWF release, other potential markers of DIVI were investigated. EC 
junctional integrity, as an indirect measure of permeability which is a feature of DIVI (refer to 
Introduction), was assessed by CD31 staining of the cell junctions. Junctional permeability 
could have been also studied using other approaches, e.g. VE-cadherin phosphorylation 
(Y658) or IP-IB with catenins. In this thesis, cells were defined as ‘permeable’ if there was 
disruption of the junctions, which led to an evident empty area between cells and a larger 
black area during the analysis. CD31 has been used as a marker to determine EC permeability. 
The rationale behind this relates to the extensive usage of CD31 to mark EC junctions to assess 
their integrity. Thrombin has been used as positive control for EC junctional disruption373. The 
mechanism by which thrombin causes disruption is well described and is dependent on 
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activation of protease-activated receptor (PAR)-1, a G protein-coupled receptor347. PAR-1 
activation is coupled to G-proteins, including Gi, which in turn causes a decrease in 
intracellular cAMP level, Gq, which leads to an increase in intracellular Ca2+ and diacylglycerol 
(DAG) concentration, and G12/13, which lead to activation of the small GTPase, Rho. 
Ca2+/calmodulin-dependent activation of myosin light chain kinase (MLCK) promotes 
phosphorylation of myosin light chains, together with Rho kinase-dependent inactivation of 
myosin phosphatases, stimulates stress fiber formation and triggers actomyosin 
contraction347. In our experiments, thrombin-induced disruption was observed at 1 hour. It 
may have occurred earlier than this, as thrombin-induced barrier disruption has been 
reported to occur more rapidly142. The time points in this study did not allow to look at this in 
detail and it is something worth investigating in the future, but it was beyond the scope of 
this study. The effect on the junctions was restored after 24 hours, suggesting that thrombin 
has only a rapid and reversible action on permeability. The reversible effect of thrombin on 
permeability has been previously shown374.  
 
The effect of fenoldopam was similar to the observed thrombin response, in that, following 
fenoldopam treatment gaps could be observed in the endothelial monolayer within 1 hour, 
which had reversed by 24 hours. A previous in vitro study, in which rat aortic EC were co-
cultured with SMC and exposed to in vivo-derived hemodynamics, showed that fenoldopam 
100 µM caused endothelial permeability79. Although not assessed here, future studies to 
investigate whether fenoldopam can induce similar intracellular signalling to thrombin would 
be interesting.  
In contrast, these studies showed that minoxidil induces a trend toward endothelial junctional 
disruption at 1 hour, which reached statistical significance at 24 hours. These results suggest 
that minoxidil has an effect on cell junctions that persists for at least 24 hours, however high 
variability in this data suggests additional experiments would be required for confidence. Of 
the drugs tested, minoxidil alone induced endothelial barrier disruption at 24 hours 
suggesting that potentially there may be differences in the intracellular signalling pathways 
triggered by minoxidil, fenoldopam and thrombin53,80,154.  
 
Rolipram, a PDE inhibitor, did not affect HUVEC junctions in these studies. Indeed, this is in 
agreement with previous studies that have suggested that PDE inhibitors may protect 
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endothelial barrier integrity. For example, a study in rats reported that the PDE IV inhibitor 
roflumilast suppressed histamine-induced permeability in rat mesenteric 
microvasculature373. In these experiments, rats were firstly administered FITC-labelled bovine 
albumin and roflumilast was given for 1 hour. The mesenteric artery was the superfused in 
situ with buffer supplemented with histamine (potent trigger of endothelial permeability) and 
the extent of leakage assessed by FITC-derived fluorescence. Roflumilast reversed histamine-
induced extravasation of FITC-albumin by approximately 85 %. Notably, the same effect could 
also be observed in vitro, where permeability was measured using a transwell assay. HUVEC 
were preincubated with the roflumilast, rolipram and another PDE IV inhibitor (cilomilast) at 
a range of concentrations (10 pM - 100 μM) for 15 minutes, and permeability was elicited by 
thrombin treatment (1 U/ml). The permeation of horseradish peroxidase was assessed after 
1 hour. In these assays all compounds were able to restore the HUVEC barrier integrity 
impaired by thrombin indicating that rolipram may have a repair function on cell contraction.  
The ability of PDE IV and PDE III inhibitors in protecting the EC barrier in vitro is supported in 
other studies375,376. These data demonstrate that rolipram does not have any effect on EC 
barrier permeability, either acutely or after 24 hours stimulation.  
It is possible that the effect of PDE inhibitors is due to an elevation in cAMP concentration. 
cAMP is involved in protecting the integrity of the EC junctions, through the involvement of 
protein kinase A and the exchange protein (Epac) that is directly activated by cAMP377–379. 
Epac-1/Rap1 and protein kinase A activate Rac resulting in an improvement of the integrity of 
the EC barrier. Other mechanisms are also involved, such as protein kinase A-dependent 
myosin light chain kinase (MLCK) phosphorylation and RhoA inactivation380. 
Bosentan did not disrupt endothelial junctions, despite being as effective as thrombin and 
fenoldopam at triggering the release of VWF. This suggests that there is a difference in the 
intracellular signalling pathway activated by bosentan treatment compared with fenoldopam 
or thrombin.  
In summary, endothelial junction disruption cannot be considered a robust indicator of DIVI 
in vitro, as only fenoldopam and minoxidil had an effect but all of them induce DIVI. It can be 
speculated that the effect of these drugs on EC junctions does not depend on the on-target 
mechanism of the compounds and is rather an off-target action that needs further 
investigation. 
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One of the features associated with DIVI is cell death, specifically SMC necrosis170. To 
investigate cell death a high-throughput assay was utilised, whereby ATP release from cells 
was used as an indirect measure for cell viability. The high-throughput ATP assay was ideal 
for detecting cell proliferation and cytotoxicity381–383.  
 
None of the drugs tested in these studies induced cell death at either 1 or 4 hours in HUVEC 
or HCASMC. However, ~50 % cell death in HUVEC was observed after 24 hours with 
fenoldopam at the highest concentration. There was no observed effect on cell death at lower 
concentrations.  
There is no evidence in the literature of cell death induced by fenoldopam or the other drugs 
used in these experiments. On the contrary minoxidil has been shown to promote cell 
proliferation in dermal papilla cells of human hair follicle. This has been shown to be regulated 
by activation of the ERK and Akt pathways, and by inhibiting cell death through increasing the 
ratio of Bcl-2/Bax384. As minoxidil had no effect on vascular cell proliferation this could 
possibly be attributed to the phenotypic differences in the cell types used, since dermal cells 
are highly proliferative cells.  
 
SMC necrosis is a feature of DIVI however none of these drugs were cytotoxic to SMC at any 
of the time points or concentrations in this study. This may be because a more physiologically 
relevant system is required to elicit this response, whereby for example EC and SMC interact 
together as a co-culture and/or are exposed to flow/shear stress385.  
In addition, these data showed that these drugs did not induce cell proliferation. However, it 
had been observed in the literature that minoxidil can inhibit proliferation of SMC both in vivo 
and in vitro386 and bosentan was reported to inhibit proliferation of pulmonary artery SMC387. 
In these experiments the cells were seeded to confluency and this may have limited the ability 
to accurately assess effects on proliferation. Perhaps seeding the cells at lower density would 
have allowed for the observation of growth curves in the presence and absence of treatment. 
It would be useful to compare cell death in these in vitro experiments with the vessel explant 
in chapter 3 to understand if translation occurs ex vivo/in vitro. From a qualitative point of 
view, these drugs did not appear to induce EC death. Although the endothelium was intact 
after all drug treatments, including fenoldopam, it was difficult to assess from confocal 
imaging whether the cells were functional. Moreover, SMC death cannot be ruled out in the 
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ex vivo worked conducted, since α-SMA was only used to detect the size of the smooth muscle 
layer but was not quantified.  
 
Finally, HUVEC were stained for markers of inflammation. It has been suggested that DIVI-
related drugs may promote inflammation through expression of adhesion molecules such as 
E-selectin, VCAM-1 and ICAM-1, as well as other cytokines and chemokines388. VCAM-1 and 
ICAM-1 aid in leukocytes recruitment and their expression represent a robust markers of EC 
activation during inflammation389–391. TNF-α is a powerful inducer of these adhesion 
molecules both in vivo and in vitro and was therefore chosen as positive control392–394. 
 
Treatment of cells with TNF-α for 24 hours increased the expression of ICAM-1 and VCAM-1 
in a concentration-dependent manner. Bosentan and fenoldopam increased VCAM-1 
expression after 24 hours treatment, and bosentan also increased ICAM-1 expression under 
the same conditions. It is interesting how fenoldopam only affects one of the cell adhesion 
molecules and not the other. The mechanism of action of the two compounds is very 
different, and this effect might depend on transcription factors and protein regulation. For 
example, it has been suggested that regulation of VCAM-1 gene expression may be coupled 
to oxidative stress through specific reduction-oxidation sensitive transcriptional or 
posttranscriptional regulatory factors395. Fenoldopam has been shown to act through the NO 
pathway, since the incidence and severity of fenoldopam-induced vascular injury were 
decreased when an NOS inhibitor or a scavenger of NO-generated free radicals were 
coadministered with fenoldopam100. Therefore, it is possible that VCAM-1 expression induced 
by fenoldopam depends on the drug producing free radicals through an increase in NO 
generation.  
 
The data presented here are in contrast with literature reports about the anti-inflammatory 
effects of bosentan396–398. However, the experimental differences (first of all in vivo versus in 
vitro) could account for the observed differences. They were also studies in patients with 
systemic sclerosis, making the experiments difficult to fully compare. Lower concentrations 
of bosentan were investigated for VCAM-1 and ICAM-1 activation but they did not show any 
effect. 
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DIVI has been suggested to be facilitated when underlying inflammatory conditions are 
present35,202. To recapitulate this inflammatory state, cells were incubated with TNF-α with 
the drugs at the highest concentration (100 µM) for 24 hours. Of the drugs tested, bosentan 
showed an additive effect on ICAM-1 expression when incubated together with TNF-α for 24 
hours. The other drugs showed no effect and were therefore not investigated further. These 
data suggest that underlying inflammatory conditions might enhance the effect of bosentan, 
by perhaps summation of signalling pathways, but this does not apply to the rest of DIVI-
related drugs. Further experiments investigating the signalling pathways of bosentan may 
help shed a light on this.  
 
The mechanism of the inflammatory effect observed with bosentan was investigated with 
respect to ET receptors antagonism or an off-target effect. To address this, BQ123, a selective 
ETA antagonist and BQ788, a selective ETB blocker, were used but they did not show a 
comparable effect in terms of ICAM-1 and VCAM-1 expression to bosentan, suggesting that 
this mechanism might be driven by an off-target effect. Using tools such as the Swiss Target 
Prediction from the Swiss Institute of Bioinformatics it is possible to predict the targets of 
small molecules. Apart from ET receptors, serotonin receptors and P2Y1 receptors, activated 
by ADP399, have been indicated to be the secondary target with the highest probability and 
could be investigated in the future in the same way used here.  
 
In conclusion, in this chapter, potential markers of DIVI were investigated in vitro. A summary 
of the effects of DIVI-related drugs is shown in Table 4.1. It was identified that VWF release 
in vitro was induced by the same drugs that induced VWF release ex vivo in the vessel explants 
(chapter 3), implying that the effect of DIVI-inducing drugs on VWF release can be successfully 
recapitulated in vitro. However, rolipram that has been classified as DIVI-related drug failed 
to show an effect in the vessel explant and in vitro in these studies. Therefore, it is possible 
to conclude that VWF release cannot be the only biomarker assessed to assess DIVI.  
 
DIVI is described as an event that induces vascular permeability, cell death and endothelial 
cell inflammation. However, these features were not observed ubiquitously in all drug 
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treatments. Perhaps this is due to the reductive approach of this in vitro work, which is a 
simple model and not necessarily indicative of an in vivo system. In the following chapter we 
shall increase the complexity of this in vitro assay to encompass physical and paracrine 
communications between SMC and EC. Furthermore, we will investigate whether endothelial 
cells respond differently to these drugs using a pharmacological agent to mimic shear stress, 
providing a more physiologically relevant model.   
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Effect Time course 
(hours) 
Bosentan Fenoldopam  Minoxidil Rolipram 
VWF release 1     
24     
EC junctional breakage 1     
24     
Cell death 1     
4     
24   (on EC)   
Inflammation 24  
ICAM-1     
VCAM-1     
 
Table 4.1 Summary of the effects of DIVI-related drugs in vitro. Attributes of DIVI were investigated in this chapter: (1) 
VWF release from EC; (2) disruption to EC monolayer was measured by disruption of the intercellular junctions; (3) EC 
and SMC death; and (4) inflammation, shown as increased expression of ICAM-1 and VCAM-1 in EC. = very 
significant effect (p < 0.001); = very significant effect (p < 0.01); = significant effect (p < 0.05); = no effect. 
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5. Exploring the effects of DIVI-related drugs in 
whole blood 
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5.1 Introduction 
 
The objective of this chapter was to determine whether bosentan, fenoldopam mesylate, 
minoxidil sulfate salt, and rolipram directly activate blood cells. DIVI has been reported to 
increase inflammation, through upregulation of cell adhesion molecules, including 
endothelial ICAMs and VCAMs, and the release of secreted factors, for example, NO, 
cytokines, cellular enzymes, and acute phase proteins2,34,124,400,401. Inflammation promotes 
the adhesion of leukocytes, particularly neutrophils, macrophages and lymphocytes2 to the 
vessel wall and into the perivascular space,  which may contribute to the DIVI phenotype. It 
has been reported that leukocytes adhere to endothelial junctions, and erythrocytes and 
platelets extravasate into the perivascular space contributing to the progression of the 
lesions76 (refer to Introduction, section 1.3). However, it is not clear whether these events 
are a consequence of the drug action on EC, or as a result of an additional direct activation of 
leukocytes or platelets that contribute to the progression of the injury. In this chapter, flow 
cytometry was used to specifically characterise platelet and leukocyte activation. This 
simplistic monoculture experimental design will establish whether interaction directly 
between blood cells and drug is sufficient to induce cell activation or whether a more complex 
physiological system is required.  
 
5.2 Methods 
 
Blood was taken from healthy volunteers from the Department of Pharmacology in 75 µM 
PPACK, a synthetic peptide derivative that irreversibly and specifically inhibits thrombin-
mediated platelet activation by binding with high affinity to the active site of thrombin and is 
therefore used as an anticoagulant. Blood was promptly stimulated with the drugs or positive 
controls at room temperature to avoid artefactual platelet activation. Following stimulation, 
blood was stained with the appropriate antibodies and then fix-lysed. This step allows lysis of 
only red blood cells (RBC) so that the other fixed blood components (platelets and leukocytes) 
can be easily visualised and quantified. Samples were then analysed by flow cytometry. Prior 
to the analysis, each channel was compensated to correct for fluorescence bleed-through. A 
detailed description of the protocol, compensation and antibodies concentrations are given 
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in Methods, section 2.2.3. The drugs were used at three different concentrations: 1, 10 and 
100 M. Two time points were selected at 20 and 60 minutes as blood cell activation happens 
rapidly and within this timeframe. As positive controls, the leukocyte-specific agonist fMLP at 
10 M and the protease-activated receptor-1 (PAR-1) agonist TRAP-6 amide at 100 M were 
used to induce leukocyte and platelet activation, respectively. It is accepted that some 
leukocytes (mainly monocytes and macrophages402) also express PAR-1, to a lesser extent 
compared to platelets403, and will also be activated by TRAP-6 amide.  
 
Platelet P-selectin expression (a marker of platelet granule secretion, which contributes to 
leukocyte recruitment via PSGL-1404) and integrin αIIbβ3 activation (a receptor for fibrinogen 
and VWF, monitored by PAC-1 antibody) were used to assess platelet activation. CD11b 
activation (monitored by CBRM1/5 antibody, which binds to the activated form of CD11b 
known as αMβ2, or Mac-1, involved in the migration of monocytes and neutrophils, as well as 
adhesion and phagocytosis405,406) served to assess neutrophil and monocyte activation. Refer 
to Introduction, section 1.6.5.3 for a detailed description of these molecules. Analysis was 
performed separately for each group of cells, using the median fluorescence intensity (MFI) 
as a measure for cell activation.  
 
5.3 Results 
 
5.3.1 TRAP-6 amide activates platelets, as shown by αIIbβ3 activation and increased P-selectin 
surface expression 
 
Figure 5.1 shows the acquisition and gating of platelets. Forward scatter (representing cell 
size) versus side scatter (representing cell granularity) of fix-lysed whole blood are shown in 
A (unstimulated) and C (blood stimulated with TRAP-6 amide). In this process RBC have been 
lysed. Platelets were identified using forward scatter and CD41 expression, a general surface 
marker for platelets but not expressed on leukocytes (B). After activation with TRAP-6 amide, 
there is an increase in size of platelets (C, D) compared to unstimulated blood (A, B), which 
likely indicates platelet aggregation. Histograms (E and F) show activation with TRAP-6 amide, 
which causes a shift to the right, in comparison to an unstimulated control sample, as 
indicated by αIIbβ3 activation and P-selectin surface expression.  
A. 
 
A. 
 
A. 
 
A. 
 
A. 
 
A. 
B. 
 
B. 
 
B. 
 
B. 
 
B. 
 
B. 
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Figure 5.1 Acquisition of platelets with flow cytometer. Whole blood was collected from 
healthy volunteers and stimulated for 20 or 60 minutes with TRAP-6 amide 100 M as positive 
control for platelet activation. A and C show forward scatter and side scatter plot of 
unstimulated (A) and TRAP-6 amide-stimulated (C) whole blood. Platelets were identified 
using forward scatter and CD41 expression (B and D). D shows platelets gated in a TRAP-6 
amide-stimulated sample. E and F show histograms representing platelet activation, as 
indicated by αIIbβ3 activation and P-selectin surface expression in unstimulated (black) and 
stimulated (red) blood. 
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5.3.2 fMLP activates leukocytes, as indicated by CD11b activation 
 
Figure 5.2 shows the acquisition and gating of leukocytes. Forward scatter versus side scatter 
of fix-lysed unstimulated whole blood are shown in A. Leukocytes were subdivided into 
monocytes (CD14+) and neutrophils (CD15+) (B). Histograms show CD11b activation of 
monocytes and neutrophils in unstimulated and fMLP-stimulated blood (C and D). Stimulation 
with fMLP causes a shift to the right which represents CD11b activation. 
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Figure 5.2 Acquisition and analysis of leukocytes with flow cytometer. Whole blood was collected from healthy volunteers and stimulated for 
20 or 60 minutes with fMLP 10 M as positive control for leukocyte activation. A represents forward and side scatter of a whole blood sample. 
Neutrophils and monocytes are identified by CD15 and CD14 expression, respectively (B). C and Dare histograms showing unstimulated (black) 
and fMLP-stimulated blood (red). Stimulation with fMLP causes an increase in CD11b activation in monocytes (C) and neutrophils (D). 
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5.3.3 DIVI drugs do not activate platelets, as shown by P-selectin expression and αIIbβ3 
activation 
 
TRAP-6 amide is used as positive control for platelet activation in whole blood407. TRAP-6 
amide markedly increased platelet integrin αIIbβ3 activation, with a difference between means 
of 1003 ± 206 compared to unstimulated samples after 20 minutes (N=5, p < 0.001) and 477.4 
± 63.4 after 60 minutes stimulation (N=5, p < 0.01) (Figure 5.3). TRAP-6 amide markedly 
increased P-selectin expression (8465 ± 840) compared to unstimulated samples after 20 
minutes (N=5, p < 0.001) and 6400 ± 974 after 60 minutes stimulation (N=5, p < 0.001). The 
effect is not significantly reduced after 60 minutes. fMLP did not induce platelet activation, 
as expected (Figure 5.4). 
 
Whole blood was treated with four drugs, as described in chapters 3 and 4, at 1, 10, and 100 
µM for 20 and 60 minutes. A total of 5 healthy volunteers were used in these experiments 
(N=5). Fenoldopam, bosentan, minoxidil and rolipram did not induce platelet activation, as 
no integrin αIIbβ3 activation or increase in P-selectin expression was observed at any 
concentration.  
 
For example, for the integrin αIIbβ3 activation, fenoldopam 1, 10, 100 µM is comparable to the 
unstimulated mean at 20 minutes: unstimulated is 257.5 ± 9.190, TRAP-6 amide is 1261 ± 
206.1, fMLP is 269.9 ± 9.341, fenoldopam 1 µM is 307.0 ± 45.19, 10 µM is 286.1 ± 30.49, and 
100 µM is 318.2 ± 65.18 (N=5, ns) (Figure 5.3). At 60 minutes fenoldopam 1, 10 and 100 µM 
mean is comparable to controls. All other drugs produced a comparable effect.  
 
For P-selectin at 20 minutes, unstimulated is 95.30 ± 12.36, TRAP-6 amide is 8560 ± 840.0, 
fMLP is 96.20 ± 29.18, fenoldopam 1 µM is 110.0 ± 28.96, 10 µM is 104.2 ± 23.25, and 100 µM 
is 109.9 ± 25.85 (N=5, ns). The other drugs produced a comparable effect. At 60 minutes 
fenoldopam 1, 10 and 100 µM mean is comparable to controls (Figure 5.4). Similar means 
were produced with the other drugs. These data show that no effect is produced with the 
drugs tested and that the experimental conditions were optimal as the positive control 
induced an effect.  
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Figure 5.3 Effects of the drugs on platelet integrin αIIbβ3 activation. Whole blood was 
collected from healthy volunteers and stimulated for 20 or 60 minutes with TRAP-6 amide 
100 M, fMLP 10 M, and DIVI-related drugs 1, 10, 100 M. Data are expressed as median 
fluorescence intensity and represent mean ± SEM of 5 independent experiments, analysed by 
one-way ANOVA followed by Dunnett’s post test. ***p < 0.001, **p < 0.01.  
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Figure 5.4 Effects of the drugs on platelet P-selectin expression. Whole blood was collected 
from healthy volunteers and stimulated for 20 or 60 minutes with TRAP-6 amide 100 M, 
fMLP 10 M, and DIVI-related drugs 1, 10, 100 M. Data are expressed as median 
fluorescence intensity and represent mean ± SEM of 5 independent experiments, analysed by 
one-way ANOVA followed by Dunnett’s post test. ***p < 0.001.    
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5.3.4 Minoxidil and bosentan activate leukocytes, as indicated by CD11b activation 
 
fMLP was used as positive control because it specifically stimulates neutrophils and 
monocytes but not lymphocytes and platelets408. CD11b was selected as a marker for 
leukocyte activation. CD11b forms a complex with CD18 called membrane-activated complex 
1 (Mac-1). Mac-1 binds ICAM-1 on EC409 and is therefore important for leukocyte attachment 
to EC and transmigration (refer to Introduction, section 1.6.5.3). TRAP-6 amide and fMLP 
induced a significant leukocyte activation at 20 and 60 minutes, as shown by increased CD11b 
expression (Figure 5.5). TRAP-6 amide increased CD11b activation after 20 minutes, with a 
difference between means compared to unstimulated samples of 18020 ± 2155 (N=5, p < 
0.01), and 60 minutes, with a difference of 19790 ± 5395 (N=5, p < 0.001). fMLP significantly 
increased activation after 20 minutes, with a difference between means of 32300 ± 2810 
compared to unstimulated samples (N=5, p < 0.001), and 60 minutes stimulation, with a 
difference of 42720 ± 4254 (N=5, p < 0.001) (Figure 5.5). As above, these data indicate that 
the experimental conditions were optimal as the positive control induced an effect.  
 
Bosentan increased CD11b activation at 60 minutes stimulation at both 100 µM (mean of 
52555 ± 6691 and at 10 µM (mean of 54239 ± 8406) (N=5, p < 0.05). 
 
Minoxidil significantly activated leukocytes, as shown by increased CD11b activation at 20 and 
60 minutes (Figure 5.5). There is a concentration-dependent effect, where 10 and 100 µM 
significantly affected leukocyte activation at 20 minutes (100 µM: mean of 34737 ± 2329) 
compared to unstimulated (20128 ± 1180) and 100 µM also at 60 minutes (46135 ± 2162) 
compared to unstimulated (33470 ± 2377) (N=5, p < 0.01).  
 
Fenoldopam did not significantly activate leukocytes. However, there is a trend towards 
activation at 20 minutes only. Rolipram had no effect on leukocyte CD11b activation.  
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Figure 5.5 Effects of the drugs on leukocyte activation. Whole blood was collected from 
healthy volunteers and stimulated for 20 or 60 minutes with TRAP-6 amide 100 M, fMLP 10 
M, and DIVI-related drugs 1, 10, 100 M. Data are expressed as median fluorescence 
intensity and represent mean ± SEM of 5 independent experiments, analysed by one-way 
ANOVA followed by Dunnett’s post test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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5.3.4.1 Minoxidil and bosentan activate neutrophils and not monocytes  
 
To identify whether the observed effect was in neutrophils, monocytes or both, the two 
groups of cells were separated during the analysis. In single cell populations, TRAP-6 amide 
increased CD11b expression in neutrophils, with a difference between means of 22580 ± 3030 
after 20 minutes (N=5, p < 0.01) and 25600 ± 4646 after 60 minutes stimulation (N=5, p < 
0.001). fMLP increased CD11b expression after 20 minutes with a difference between means 
of 35490 ± 3455 (N=5, p < 0.001), and after 60 minutes, with a difference of 46840 ± 6134 
(N=5, p < 0.001) (Figure 5.6).  
 
It was identified that the effect of bosentan and minoxidil on leukocyte activation was 
neutrophil driven, not monocytes (Figures 5.6). Bosentan (100 µM) activated neutrophils at 
60 minutes (N=5, p < 0.05). Minoxidil activated neutrophils at 20 minutes at 10 µM (N=5, p < 
0.05) and 100 µM (N=5, p < 0.01) compared to unstimulated. At 60 minutes stimulation, only 
100 µM activated neutrophils (N=5, p < 0.05). The activation at both time points however is 
not of the same extent as fMLP nor TRAP-6 amide.  
 
TRAP-6 amide increased CD11b expression in monocytes only at 60 minutes, with a difference 
between means compared to unstimulated samples of 29760 ± 8975 (N=5, p < 0.05). The 
effect was not significant at 20 minutes. fMLP increased CD11b expression in monocytes after 
20 minutes with a difference between means of 17140 ± 2641 (N=5, p < 0.05), and after 60 
minutes, with a difference of 45640 ± 12080 (N=5, p < 0.001) (Figure 5.7).  
 
Bosentan and minoxidil did not activate monocytes, however there is a trend towards 
activation for minoxidil at the highest concentration (Figure 5.7).  
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Figure 5.6 Effects of bosentan and minoxidil on neutrophils. Whole blood was collected from 
healthy volunteers and stimulated for 20 or 60 minutes with TRAP-6 amide 100 M, fMLP 10 
M, bosentan and minoxidil 1, 10, 100 M. Data are expressed as median fluorescence 
intensity and represent mean ± SEM of 5 independent experiments, analysed by one-way 
ANOVA followed by Dunnett’s post test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 5.7 Effects of bosentan and minoxidil on monocytes. Whole blood was collected from 
healthy volunteers and stimulated for 20 or 60 minutes with TRAP-6 amide 100 M, fMLP 10 
M, bosentan and minoxidil 1, 10, 100 M. Data are expressed as median fluorescence 
intensity and represent mean ± SEM of 5 independent experiments, analysed by one-way 
ANOVA followed by Dunnett’s post test. *p < 0.05, ***p < 0.001. 
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5.4 Discussion 
 
The aim of these experiments was to determine whether DIVI-related drugs would activate 
discrete blood cell populations. There are several reports of increased levels of inflammatory 
factors in DIVI2,124,400,401. Secretion of these factors during the inflammatory response would 
promote the recruitment of inflammatory cells in the vascular wall and perivascular space 
which contribute to the DIVI phenotype. This evidence would provide data that would enable 
to select and develop the ideal in vitro model for DIVI.  
 
The positive controls worked, as TRAP-6 amide and fMLP induced platelet and leukocyte 
activation, respectively. TRAP-6 amide markedly increased platelet P-selectin expression and 
integrin αIIbβ3 activation which was expected, since this has been previously reported by 
others via binding to PAR-1 and triggering downstream signalling causing -granule fusion 
with the plasma membrane410. This effect is still significant but is reduced after 60 minutes. 
The activation of the integrin is dependent on intracellular Ca2+ release and transient 
fluctuations might cause this decrease.  
 
A previous study reported that minoxidil prevented platelet aggregation in response to ADP 
and arachidonic acid and reduced the synthesis of prostaglandin E2 (PGE2) and thromboxane 
B2 (TxB2)411. These data showed that the effect on platelet aggregation was not associated 
with increased cyclic adenosine monophosphate synthesis. Therefore, it has been suggested 
that minoxidil functions primarily as a cyclooxygenase inhibitor in platelet metabolism. These 
data support these findings, in that, there was no observed platelet activation in the presence 
of drug treatment in these studies.  
 
Bosentan acts as an antagonist to both ETA and ETB. However the action on platelets has yet 
to be established with some studies reporting an activation of platelets and others inhibition 
of platelets412–414. The data in this chapter showed that bosentan had no effect on platelet 
function. 
 
A previous study used rolipram treatment to investigate platelet aggregation ex vivo415. Pre-
treatment of anaesthetised rabbits with rolipram did not impair the platelet aggregation 
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induced by ADP, collagen, arachidonic acid or thrombin. Furthermore in vitro studies 
demonstrated that fenoldopam had no effect on platelets following an in vitro study on whole 
blood416. Therefore, the data presented in this study are in agreement with these findings as 
rolipram and fenoldopam had no observed effect on platelets in these experiments.  
 
Leukocytes would be expected to be elevated in DIVI as there are reports of increased levels 
of inflammatory factors in DIVI2,124,400,401 and leukocytes are recruited during the 
inflammatory response.TRAP-6 amide caused activation of neutrophils and monocytes, as 
indicated by increased CD11b activation. However, it is unclear whether this is a direct 
response to TRAP-6 amide, or an indirect effect via activation of platelets which in turn 
activate leukocytes. fMLP induced marked activation of neutrophils and monocytes but no 
platelet activation. The effect of the positive controls was observed at two time points (20 
and 60 minutes). These time points were selected because DIVI studies reported that the 
effect of the drugs is generally acute and occurs within hours of administration34. In addition, 
60 minutes is considered a maximal amount of time for platelet degranulation417. 
Additionally, by selecting this time point, assessment of the effect of drugs on protein 
synthesis in leukocytes could be undertaken. Furthermore, this time interval is sufficient to 
assess autocrine activation of cellular subsets. At 60 minutes, CD11b expression was greater 
than at 20 minutes both for neutrophils and monocytes. This might be related to leukocytes 
sticking to the plastic of the tubes, or because the experiment was run in non-sterile 
conditions418.  
 
Minoxidil had an effect on leukocyte activation at both 20 minutes and 60 minutes. 
Interestingly, two doses of minoxidil (10 and 100 µM) induced the effect at 20 minutes and 
only the high dose at 60 minutes, indicating that minoxidil acts rapidly. There are no previous 
reports of using minoxidil in whole blood experiments. By identifying the distinct cell 
populations, the effect of minoxidil was determined to be on neutrophils and not on 
monocytes. This possibly depends on the specific mechanism of action of the drug and 
perhaps a different distribution of K+ channels on neutrophils and monocytes419. Minoxidil is 
a K+ channel opener and a vasodilator, which opens KIR (inward rectifier) 6.X ATP sensitive K+ 
channels. The mechanism by which DIVI is induced is unclear. These data and that presented 
from previous chapters suggests that minoxidil acts on both EC and circulating blood cells. 
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However, it is unclear whether it is the leukocyte activation that leads to the development of 
the vascular damage or rather the leukocyte recruitment is a secondary event to the initial 
damage. A study reported an anti-inflammatory effect of minoxidil, as evidenced by 
significant downregulation of IL-1α gene expression in human keratinocytes420. A further 
study showed that minoxidil has been found to not cause T-cells to infiltrate into skin upon 
topical application for alopecia421. However, it is difficult to compare these findings with ours, 
as there are differences in the cell types used and in the route of administration.  
 
Activation was observed following 60 minute treatment with bosentan. The effect, similarly 
to minoxidil, was on neutrophils and not monocytes. A previous in vivo study reported a 
reduction in leukocyte adhesion and inflammation in a mice in response to bosentan422. 
Another study observed anti-inflammatory effects of bosentan in mice423. The observed 
difference may be related to species-specificity (human vs. mice) or as a consequence of a 
lack of communication between blood cells and EC for example in vitro424.  
 
An in vivo study found that selective inhibition of PDE IV (the mechanism of action of rolipram) 
significantly reduced neutrophil recruitment at the site of vascular damage425. In addition, it 
has been reported in the same study that the effect of PDE IV inhibition on neutrophil 
adhesion was primarily mediated by downregulation of P-selectin-induced activation of Mac-
1. It has also been observed426 found that rolipram inhibited leukotriene B4 (LTB4) synthesis 
in neutrophils, produced from leukocytes in response to inflammation in vitro427,428. The 
compounds were inactive when LTB4 was triggered by the calcium ionophore A23187, 
suggesting that the compounds induce a receptor-mediated event. The compounds also 
inhibited TNF-α synthesis in monocytes suggesting that rolipram has an anti-inflammatory 
effect. The data presented in this chapter recapitulate these findings, as no activation of 
neutrophils nor monocytes was observed. Fenoldopam did not activate nor inhibit 
leukocytes.  
 
Additionally, other markers of leukocyte activation that have been reported in DIVI could have 
been investigated, for example IL-6, IL-8 and C-reactive protein2. Other biomarkers of 
inflammation include shedding of L-selectin, macrophage inflammatory protein-3β (MIP-3β), 
monokine induced by gamma interferon (MIG) and stromal cell-derived factor 1 (SDF1).  
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Longer time points could have been investigated, to monitor how the drugs affect protein 
processing, however storing whole blood for long periods of time is problematic as platelets 
and neutrophils get activated and degrade spontaneously with time in vitro429. One method 
would be to fractionate the blood or use white blood cells lines.  
As reported previously, platelets and leukocytes may form platelet-leukocyte aggregates 
mainly via platelet-expressed P-selectin and its receptor PSGL-1, as well as via fibrinogen 
bridging between integrin αIIbβ3 and CD11b/CD18430. However, data on platelet-leukocyte 
aggregation were not collected but it is something that could be investigated in the future. 
 
Collectively, these data suggest that DIVI-related drugs mostly affect vascular cells (EC and 
SMC) rather than circulating blood cells. One proposed mechanism is that the drug effect on 
blood cells is an indirect process following EC activation. EC would then induce the cascade of 
events whereby leukocytes are recruited to initiate the inflammatory response, and platelets 
activated triggering the typical DIVI phenotype. In the previous chapter (chapter 4, section 
4.2.4.2), it was found that fenoldopam and bosentan increase VCAM-1 expression on EC. This 
would likely lead to more leukocyte adhesion and possibly more transmigration. 
 
To finitely address whether the drugs affect blood cells in an ex vivo setup, the next step 
would be to cannulate blood vessels and perfuse blood inside the lumen. The drug treatment 
could happen before cannulation (as a pre-treatment), or during perfusion. It is possible to 
choose whether to perfuse human blood or animal blood from the different species affected, 
and then image leukocyte adhesion to the vessel wall or monitor released inflammatory 
factors in the perfused blood collected from the outlet.  
 
In conclusion, the effect of DIVI-related drugs was investigated in single EC and SMC (in 
chapter 4) and here on circulating blood cells (Table 5.1). The next chapter will assess whether 
a more physiological system, where EC and SMC interact together in a co-culture system, is 
important to elicit a DIVI phenotype.
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Effect  Time course (minutes) Bosentan Fenoldopam  Minoxidil Rolipram 
Platelets Integrin αIIbβ3 activation 20     
60     
P-selectin expression 20     
60     
Leukocytes Neutrophil CD11b 
activation 
20     
60     
Monocyte CD11b 
activation 
20     
60     
 
 
 
Table 5.1 Summary of the effects of DIVI-related drugs in vitro on blood cells. = very significant effect (p < 0.01); = significant effect (p < 
0.05); = no effect. 
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6. Investigating DIVI in a co-culture system  
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6.1 Introduction 
 
The aim of this chapter was to assess whether interaction between EC and SMC is required to 
give a DIVI-like phenotype in vitro. In the previous chapter, several biomarkers of DIVI were 
investigated in monocultured human EC and SMC. This chapter will address whether the 
presence of physical contact between EC and SMC increases the effect of the drugs, by 
culturing these two cell types in co-culture.  Two hallmarks of DIVI, as described in chapter 4 
were also selected to be investigated in the co-culture system. These are (1) release of VWF 
and (2) cell death. VWF release was selected as in the experiments presented in the preceding 
chapters 3 and 4 this was altered by all DIVI-related drugs except for rolipram. Therefore, 
these experiments aimed to assess whether rolipram induces VWF release from EC when SMC 
are present. Cell death was measured as SMC necrosis has been extensively described in DIVI. 
However, data shown in chapter 4 demonstrated that SMC death was not induced by any of 
the drugs. It is possible that interaction between EC and SMC may alter the cellular response 
to drug treatment.   
 
There are a number of  published methods for co-culture of EC and SMC: (1) culture of SMC 
and EC on opposite sides of a porous membrane to facilitate cell separation but allow cells 
communication through paracrine signalling431–434; (2) culture of EC on the surface of collagen 
or fibrin gels that contain embedded SMC435,436; (3) culture of EC directly layered over SMC to 
replicate the geometry in vivo in arteries and veins437,438; (4) culture of EC and SMC side-by-
side where EC and SMC are heterogeneously mixed together439,440. 
 
The system chosen in this chapter was to culture EC and SMC side-by-side. This was in order 
to have a rapid (in terms of both the optimisation and the experiment) way of assessing 
whether SMC are necessary for DIVI development. This co-culture system also allows physical 
communication and effective paracrine signalling by reducing diffusion distances of molecules 
between the cell types and is advantageous in the assessment of acute drug treatments.  
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6.2 Methods  
 
6.2.1 Optimisation of co-culture cell density 
 
The following protocol was used to optimise the seeding density for the co-culture system. 
HUVEC and HCASMC at passage 6 were grown in flasks separately until confluent. Cell trackers 
were used to visualise the two cell types. SMC were tracked with a deep red cell tracker, while 
EC were tracked in green with 5-chloromethylfluorescein diacetate. These tracking probes 
freely pass through the membrane into the cell and they are transformed into cell-
impermeant reaction products after loading. The green tracker contains a chloromethyl group 
that reacts with thiol groups, utilizing a glutathione S-transferase–mediated reaction, and the 
deep red tracker contains a succinimidyl ester reactive group, which reacts with amine groups 
present on proteins. The unique excitation/emission spectra for the two trackers allowed 
clear visualisation of the two cell types (green excites at 492 and emits at 517 nm, deep red 
excites at 630 and emits at 650 nm). The key features of the cell trackers are they; 1) are 
passed to dividing cells but do not transfer to neighbouring cells upon contact, 2) are stable, 
nontoxic to cells at working concentrations and 3) are brightly fluorescent. The working 
concentration was within the range suggested by the manufacturer, such that it would 
produce a bright enough signal to be imaged but would not be toxic to cells.  
 
Cells were washed with RPMI and incubated for 20 minutes with the trackers at 37 C.  Excess 
dye was removed, the cells seeded in ibidi slides for 24 hours, followed by fixation in 4 % v/v 
PFA before imaging (refer to Methods, section 2.2.2.2) for a detailed description of the 
protocol).  
 
Various seeding densities were tested to assess the number of cells per ibidi well and also the 
ratio between EC and SMC such that the EC would form a confluent monolayer and the cells 
would maintain viability (Figure 6.1). In this system, a proportion of SMC grew on top/bottom 
of the EC, but this did not appear to affect the results. Following optimisation 500,000 cells/ml 
were used in all subsequent experiments (Figure 6.1, B). At lower and higher densities the 
cells were either growing too sparsely or were too tightly packed, respectively (Figure 6.1, A 
and C). The optimal ratio between EC and SMC was found to be 2:1 because EC did not survive 
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when in a 1:1 ratio with SMC (Figure 6.1, D). This is may be due to differences in growth rates 
of EC and SMC and using the 2:1 ratio proved to be an efficient way to limit overgrowth of 
SMC. The cells were grown in their respective media until plated together, at such time EC 
media was used, it was observed that SMC could survive in EC media but not vice versa, 
potentially because the EC media contains VEGF and other growth factors that are essential 
for EC division and these were not present in SMC media. 
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Figure 6.1 Optimisation of co-culture seeding density. EC and SMC were seeded at 375,000 (A), 500,000 (B), or 750,000 cells/ml (C). B represents 
the optimal density, where SMC occupy the spaces between EC. Cells were seeded at a ratio 2:1 (EC to SMC) because when plated in equal ratio 
the EC survival was reduced (D). Images are representative confocal pictures taken with a 63x objective. Scale bars represent 20 µm. 
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6.3 Results  
 
6.3.1 Characterisation of EC and SMC in co-culture 
 
The first step was to assess whether EC morphology would be affected by co-culture with SMC 
(Figure 6.2). This was because previous reports have suggested that EC cultured with SMC 
changed the EC from the normal polygonal morphology to an elongated shape435. 
 
In order to assess this, cells were analysed in morphology using parameters related to the cell 
shapes. EC and SMC were evaluated according to the following descriptors in ImageJ: i) area, 
in square pixels; and ii) circularity, calculated as 4*area/perimeter2 where a value of 1.0 
indicates a perfect circle and 0.0 an elongated shape. Analysis was conducted on the 
brightfield images in ImageJ. The field of view was randomly selected to avoid bias, cell shape 
was manually defined with the freehand tool and the area and circularity were calculated. 
 
 
 
Monocultured EC did not differ from EC in co-culture in terms of area (difference between 
means of 0.1 ± 4.1, ns) or circularity (0.1 ± 0.1, ns). SMC also did not differ in co-culture, 
neither in area nor in circularity, suggesting that the method provided in this chapter does 
not alter EC-SMC morphology (Figure 6.3).  
Figure 6.2 Bright field image of monocultured EC and SMC and cells in co-culture. 
Monocultured HUVEC and HCASMC are shown in A and B, respectively; C shows cells in co-
culture. Cultured cells were at passage 6. Arrows point at either EC or SMC in co-culture. Scale 
bars represent 50 µM. Images were taken with a bright field microscope. 10x. 
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Figure 6.3 Shape descriptors in a co-culture of EC and SMC. The area (A) and circularity (B) of 
the cells. Data represent mean ± SEM of 4 independent experiments, analysed by one-way 
ANOVA followed by Dunnett’s post test. 
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6.3.2 VWF release with DIVI-related drugs in co-culture 
 
VWF release was assessed with the same drugs tested in the rat vessel explant (chapter 3) 
and in monocultured HUVEC (chapter 4): bosentan, fenoldopam mesylate, minoxidil sulfate 
and rolipram, at the highest concentration (100 µM). The same time points were chosen: 1 
hour to assess a short-term effect and 24 hours, to reflect the time point used in the ex vivo 
vessel experiment. Thrombin 1 U/ml was used as a positive control in the experiments to 
enable the comparison of VWF release ex vivo and in vitro in monocultured HUVEC. Vehicle 
control cells were treated with 0.1 % v/v DMSO. Prior to treatment, HCASMC were tracked 
with the deep red cell tracker, seeded together with HUVEC and grown for 24 hours. HUVEC 
were not tracked due to a lack of sufficient fluorescence channels in the confocal microscope. 
VWF is uniquely produced by EC and not SMC441 so tracking EC was not essential. Following 
treatment, cells were fixed with 4 % v/v PFA for 10 minutes, permeabilised for 5 minutes with 
0.1 % v/v Triton X-100 and a specific antibody was used to detect VWF (refer to Methods, 
Table 2.3) for antibody concentrations. The permeabilisation step was necessary to visualise 
VWF intracellularly, as in chapter 4. The deep red cell tracker allows cells to be permeabilised 
but still retain the tracker intracellularly, as the succinimidyl ester reactive group that it 
contains reacts with amine groups present on intracellular proteins, making the dye persist 
post fixation and permeabilisation. In addition, to avoid bleed-through and ensure the deep 
red tracker would only stain SMC, the excess stain was removed by repeated wash steps. 
 
DAPI was used to label all nuclei from both EC and SMC. Cells were imaged with a confocal 
microscope using a 63x objective. Six images were taken for each treatment per repeat, four 
experiments were conducted in total. Images were taken as a z-stack of 2 µm/slice to make 
sure all EC and SMC were all in focus and counted in the analysis.  
 
VWF release was analysed in EC cultured with SMC using the same parameters described in 
chapter 4: (1) the % VWF-positive cells; and (2) the particle size of WPB. As in chapter 4, the 
MFI was analysed (data not shown), but it did not prove to be representative of VWF release. 
For example, the MFI in thrombin-stimulated cells is expected to be low because VWF has 
been released, but sometimes this was detected and comparable to DMSO treated cells, 
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either because of fluorescent non-specific agglomerates or because an automated system 
cannot differentiate between intra or extracellular VWF. 
 
In order to count the % VWF-positive cells, an additional step was conducted compared to 
chapter 4 to account for the presence of SMC. It was assessed that SMC did not express VWF 
(Figure 6.4). Images from the different stacks were merged together as a maximum projection 
and separated into the different channels. Images in the green channel (VWF) were 
thresholded to remove background noise. SMC in the red channel were identified using the 
freehand tool in ImageJ and the contour was added into the region of interest manager. The 
selection was then opened in the correspondent image in the green channel. SMC were 
counted as VWF-positive if they showed more than 3 green spots/cell. It was found that SMC 
only expressed a very low % of VWF (around 2-3 %) and there was no difference across 
treatments. This was expected since VWF is uniquely produced by EC and platelets348.  
 
To assess VWF release from EC, the total nuclei (EC and SMC) were automatically counted. 
This was carried out by thresholding the images to remove the background and allow particles 
greater than 15 m2 to be counted as nuclei. The three channels were merged back together, 
SMC nuclei were counted manually and subtracted from the total nuclei to calculate only EC 
nuclei.  EC were determined VWF-positive if they showed more than 3 spots/cell in the green 
channel. This was conducted as described previously, after thresholding to remove 
background noise.  
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Figure 6.4 Assessment of VWF expression in SMC. HCASMC were tracked with a deep red cell tracker and seeded together with HUVEC, grown 
for 24 hours and then VWF (green) release at 1 and 24 hours was detected with a specific antibody. Six images of random field of view were 
taken for each treatment per repeat, four experiments were conducted in total. Images are representative confocal maximum projections 
pictures taken with a 63x objective. Scale bars represent 10 µm. 
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6.3.2.1 DIVI-related drugs induce VWF release in co-culture after 1 hour and 24 hours 
 
As observed in chapter 4, in these experiments the DMSO treated control did not 
demonstrate 100 % VWF-positive cells, but rather around 86 % at 1 hour and 88 % at 24 hours.  
This was expected since unstimulated cells release VWF through a constitutive pathway363. In 
addition, it may have also been due to the use of pooled donor cells, which show some 
variability in phenotype and growth characteristics, so also VWF expression might be 
different442. In addition, the prolonged treatment up to 24 hours did not affect this. 
 
Thrombin (1 U/ml) was used as a positive control to match VWF release ex vivo (refer to 
chapter 3). Thrombin induced significant release of VWF compared to DMSO control after 1 
hour (% VWF-positive cells was reduced to 54.4 ± 5.2, N=4, p < 0.01) and after 24 hours (% 
VWF-positive cells was reduced to 51.7 ± 3.9, N=4, p < 0.001), (Figure 6.5, 6.6, 6.7). The mean 
percentage of cells that were positive for VWF following thrombin stimulation at 1 and 24 
hours were not significantly different (54.4 ± 5.2 vs 51.7 ± 3.9) suggesting that the release is 
at constant rate or that VWF released at 1 hour does not get resynthesized and released.  
 
Bosentan induced significant VWF release after 1 hour (% VWF-positive cells was reduced to 
68.3 ± 3.8, p < 0.05) and 24 hours (% VWF-positive cells was reduced to 62.8 ± 3.7, p < 0.01). 
Similarly, fenoldopam caused significant VWF release at both time points (% VWF-positive 
cells was reduced to 57.9 ± 5.1 at 1 hour p < 0.01, and to 54.2 ± 3.2 at 24 hours, p < 0.001). A 
similar effect with these drugs was found in monocultured HUVEC in chapter 4. The effect 
with minoxidil was not statistically significant at 1 hour. However, at 24 hours minoxidil 
treated cells significantly released VWF (% VWF-positive cells was reduced to of 54.5 ± 8.8, p 
< 0.001). These data correlate with the minoxidil effect observed in chapter 4, whereby 
monocultured HUVEC treated with minoxidil exhibited significant release at 24 hours. 
Rolipram did not cause VWF release in these experiments. All represent N=4.
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Figure 6.5 Representative confocal images of VWF release in EC and SMC co-culture at 1 hour. HCASMC were labelled with a deep red cell 
tracker and seeded together with HUVEC, grown for 24 hours and then VWF (green) release was detected with a specific antibody after treatment 
with DIVI-related drugs at 1 hour. Six images of random field of view were taken for each treatment per repeat, four experiments were conducted 
in total. Images are maximum projections, taken with a 63x objective. Scale bars represent 20 m. 
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Figure 6.6 Representative confocal pictures of VWF release in EC and SMC co-culture at 24 hours. HCASMC were labelled with a deep red cell 
tracker and seeded together with HUVEC, grown for 24 hours and then VWF (green) release was detected with a specific antibody after 
treatment with DIVI-related drugs at 24 hours. Six images of random field of view were taken for each treatment per repeat, four experiments 
were conducted in total. Images are maximum projections, taken with a 63x objective. Scale bars represent 20 m. 
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Figure 6.7 VWF release from SMC and EC in co-culture after 1 and 24 hours treatment with DIVI drugs. VWF release from SMC (A and B), and 
EC (C and D). HCASMC were labelled with a deep red cell tracker and seeded with HUVEC, grown for 24 hours and then VWF release was detected 
with a specific antibody after treatment with DIVI-related drugs. Data are expressed as % of VWF-positive SMC or EC as a proportion of total 
cells in the field of view, and represent mean ± SEM of 4 independent experiments, analysed by one-way ANOVA followed by Dunnett’s post 
test. *p < 0.05, **p < 0.01, ***p < 0.001. 
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These data demonstrate that VWF release from EC in co-culture is similar to the levels 
observed in monocultured HUVEC, whereby the same drugs induced VWF release at 1 and 24 
hours. Therefore co-culturing EC with SMC did not influence VWF release.  
 
6.3.2.2 The particle size of WPB does not differ across treatments    
 
To analyse the particle size of WPB, which contain VWF, images were thresholded to remove 
the background noise, made binary and then the total area of particles bigger than 0.3 μm2 
was automatically counted. With this method, all particles are counted, including the ones 
outside the cells and therefore this approach does not discriminate between whether VWF 
has been released from the cell. The particle size of WPB did not differ across treatments at 
1 hour or 24 hours (Figure 6.8, A and B), indicating that WPB do not fuse together at the 
plasma membrane. The particle size is similar to the observations made in monoculture (see 
chapter 4).  
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Figure 6.8 Average particle size of WPB at 1 and 24 hours. Data are expressed as area of WPB 
particles in the field of view (six random fields of view per treatment), and represent mean ± 
SEM of 4 independent experiments, analysed by one-way ANOVA followed by Dunnett’s post 
test. 
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6.3.3 Investigating cell death by flow cytometry 
 
Subsequent experiments focussed on assessing DIVI in the context of cell death. Cell death in 
co-culture was assessed by flow cytometry. The ATP luminescent assay used in chapter 4 
would be unable to discriminate between changes in EC and SMC populations. Therefore, 
propidium iodide (PI) was used to assess cell death. PI is a membrane impermeant dye that is 
excluded from viable cells, that have intact membranes, and was therefore used to stain cells 
with damaged and permeable membranes. PI binds to double stranded DNA by intercalating 
between base pairs. PI is excited at 488 nm and emits at a maximum wavelength of 617 nm, 
these spectral characteristics mean that PI can be used in combination with other 
fluorochromes excited at 488 nm such as FITC. As a result, in these experiments EC were 
stained with CD31-FITC. As the size and granularity of cells change as cells die (live cells are 
larger and less granular) these will appear higher in forward and lower in side scatter and will 
have low PI fluorescence443.  
 
HCASMC were labelled with a deep red dye, and then HUVEC and HCASMC were seeded in a 
2:1 mixture in 24 well plates, incubated for 24 hours and subsequently treated with the DIVI-
related drugs used previously at 100 µM for 24 hours. Monocultured HUVEC and 
monocultured HCASMC were also seeded in parallel to serve as a control. Cisplatin (50 µM) 
was used as a positive control for cell death in both EC and SMC. Following treatment, cells 
were washed with EDTA and incubated with accutase for cell detachment. Accutase was 
neutralised with M199 containing 20 % v/v FBS, cells were harvested, centrifuged and and 
stained with PI 10 µg/ml. HUVEC were also stained with CD31. Cells were analysed by flow 
cytometry. 
 
6.3.3.1 Gating strategy 
 
Cells were gated using forward and side scatter using a log scale to gate out cellular debris 
(Figure 6.9). SMC were labelled with the red cell tracker, and EC were stained with the specific 
marker, CD31365. PI was used to assess cell death. An IgG isotype control was used to remove 
the non-specific staining from the gating. To prevent bleed-through of the red cell tracker in 
the other cell population, the samples were washed thoroughly.  
 200 
 
 
 
 
Figure 6.9 Gating of EC and SMC to assess cell death. Monoculture SMC, EC and cells in 
co-culture show up on forward and side scatter, which represent size and granularity, 
respectively (A, D, G). SMC are tracked in red (B) and do not show CD31 (C), which is a 
specific EC marker (F). Cells in co-culture appear as two separate populations, which are 
detected by a deep red cell tracker for SMC (H) and CD31 for EC (I).    
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6.3.3.2 Bosentan causes cell death in co-culture 
 
The positive control cisplatin induced death in monocultured EC and SMC (91 ± 3.4 and 94.2 
± 2.3 % death, respectively), and also to the same extent in EC and SMC in co-culture (94.9 ± 
2.5 and 94.4 ± 2.3 %) compared to DMSO control. The difference between monoculture and 
co-culture was not statistically significant. All represent N=4 (Figures 6.10 and 6.11). 
 
Bosentan did not cause any death in monocultured EC or SMC and this is in line with data 
from the ATP viability assay in monocultured HUVEC and HCASMC in chapter 4, section 
4.2.3.1. However, in co-culture bosentan induced significant death both in EC and SMC (15.9 
+ 0.5 % death, p < 0.05 and 16.6 + 0.5 % death, p < 0.01, respectively) compared to 
monocultured EC and SMC (3.9 ± 0.1 % death and 2.6 ± 0.3 % death, respectively). This 
suggests that the effect of bosentan on cell death is altered under co-culture conditions.  
 
Fenoldopam caused significant death in monocultured EC (8.6 ± 1.1 % death compared to 3.3 
± 0.1 % in DMSO control), similarly to ATP viability data shown in chapter 4, section 4.2.3.1, 
where fenoldopam induced death in monocultured HUVEC. However, the effect of 
fenoldopam was not affected by the co-culture. Rather, fenoldopam seemed to have a 
protective effect on EC death in co-culture, as it caused only 1.8 % EC death in co-culture 
compared to 8.6 % in monocultured EC (there is a trend, but the effect is not significant). Also 
on SMC the difference between monoculture and co-culture was not significant. The other 
drugs did not induce cell death, either in monoculture or co-culture. 
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Figure 6.10 Propidium iodide (PI) is used to assess cell death. Death was assessed in monocultured EC (A), monocultured SMC (B), in EC in co-
culture (C) and in SMC in co-culture (D) and analysed by flow cytometry. Cisplatin (red) caused cell death in monoculture and in co-culture, as 
shown by a shift to the right in the PI MFI. Among the drugs, only bosentan (black) induced cell death in EC and SMC in co-culture.  
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Figure 6.11 Cell death induced by DIVI-related drugs and analysed by flow cytometry using PI. Summary of the data from the previous figure 
(6.10). Data are expressed as % cell death after treatment with DIVI-related drugs for 24 hours. 100 % represents no death. Data represent mean 
± SEM of 5 independent experiments, analysed by one-way ANOVA followed by Dunnett’s post test. *p < 0.05, **p < 0.01. 
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6.4 Discussion 
 
Several hallmarks of DIVI have been explored, however as not all the drugs investigated in 
this study caused DIVI with the same mechanism they produced different phenotypes. 
Potentially, the processes regulating DIVI cannot be fully recapitulated in isolated cell models 
and a more complicated, physiologically relevant model that mimics the anatomy of the 
vessel wall is required. As a step toward achieving this, a more complex co-culture model was 
developed, whereby EC and SMC are mixed together in a side-by-side model. 
 
This method has several advantages; firstly, EC are in close proximity to SMC and therefore 
have physical and paracrine contact. This eliminates issues arising from some co-culture 
methods where EC are separated from SMC by a membrane and the direct contact between 
cells is prevented by the thickness of the membranes431. This model also allowed evaluation 
of the role of EC-SMC interaction in DIVI without characterising and optimising a complicated 
setup. Furthermore, this system could be easily be replicated and standardised allowing quick 
screening of drugs.  
 
However, it is accepted that there are some limitations to using this co-culture model. First of 
all, this system does not closely mimic the in vivo architecture where EC grow as a single 
monolayer on top of SMC layers. Here, the ratio of EC to SMC does not resemble a 
physiological setting, where the SM layer represents the majority of the vascular cells and the 
endothelium only forms a thin monolayer. However, this is the ratio that allows EC to survive 
in the presence of SMC in this system and it is a simple setup that can be easily replicated. It 
would have been interesting to use the data from the mesenteric artery in chapter 3 to 
investigate how this system matches to a physiological setting.  
A more sophisticated system that resembles the in vivo vessel architecture, would be, for 
example, tissue engineered blood vessels, which closely mimic the in vivo geometry444. An 
elegant co-culture system has been developed for the in vitro study of DIVI, where EC are 
cultured on top of SMC separated by a porous membrane mimicking the internal elastic 
lamina, and cells are exposed to in vivo-derived hemodynamics114 (refer to Introduction, 
section 1.8.1, where this model has been described in detail). Although this system allows 
retention of many of the in vivo features of a blood vessel, it is a complex and low throughput 
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model, which also has a high variability. Although the complexity and physiological relevance 
would have been optimal for the characterisation of DIVI, for the purposes of this study the 
goal was to optimise a vascular model in a less complex system. 
 
Several in vitro models of EC and SMC co-culture have been reported in the literature, which 
demonstrate the importance of EC-SMC interaction in the study of vascular diseases. It has 
been reported that EC co-cultured with quiescent SMC (differentiated) have a reduced 
inflammatory response to TNF-α compared with EC cultured alone, which is due in part to the 
EC interactions with the SMC-produced extracellular matrix (ECM)445. In addition, direct 
contact co-culture increases the expression of the EC-specific transcription factor KLF-2, 
which promotes an anti-oxidant and anti-inflammatory EC phenotype. 
 
Other models have also been described, that involved culturing EC and SMC on opposite sides 
of a microporous membrane in transwell models446,447. One of these studies showed that SMC 
co-cultured with EC exhibited a significant increase in the number of adherent and spreading 
cells, and greater messenger ribonucleic acid (mRNA) and protein expression of β1-integrin 
compared to SMC cultured alone447. 
 
Review of the literature has shown that the co-culture conditions can produce different 
results. For example, it has been reported that direct co-culture of EC on top of SMC leads to 
a reduction in the responsiveness of EC to TNF-α, whereas the effect is reduced when the cells 
are grown on the opposite sides of a porous membrane445. In addition, transforming growth 
factor-β1 (TGF-β1) release is greater when EC and SMC are cultured together in a single layer 
than on opposite sides of a membrane. It would be interesting to observe whether the results 
described in this chapter would be altered by a different co-culture system.  
 
EC and SMC morphology was analysed to understand whether the co-culture system affected 
these parameters. It has been reported that EC in co-culture tend to elongate, which is more 
representative of their morphology in vessels in vivo, as opposed to a polygonal morphology 
that is observed in the absence of SMC435. This is interesting, as it suggests that shear stress 
from blood flow is not the only determinant of the elongated EC morphology in vivo. In our 
system, the shape of EC and SMC was not altered when grown in a co-culture system perhaps 
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suggesting that the technical approach to co-culture can affect the phenotype of the EC and 
SMC. Cell density, the ratio between EC and SMC, culture medium constituents, and the type 
of EC and SMC are all likely to have an impact448. 
VWF release was assessed with the same drugs tested in the rat vessel explant and in vitro in 
monoculture. SMC did not express WPB containing VWF, and VWF released from EC did not 
adhere to SMC nor was it internalised by SMC. This is consistent with the data from the rat 
vessel explant shown in chapter 3, where VWF was not also retained within the smooth 
muscle region. Unstimulated (DMSO-treated) control cells were not 100 % VWF-positive. This 
was similar to monocultured HUVEC in chapter 4. VWF is constitutively released from 
unstimulated cells363 (refer to Introduction, section 1.6.2.4.2). Furthermore, cells were from 
pooled donors and at different stages of growth.  
 
In these experiments, thrombin served as a positive control for VWF release. Thrombin 
induced VWF release at 1 hour and 24 hours and it proved to be a robust positive control in 
the co-culture system, as it had been in isolated EC.  
Thrombin induced the release of VWF from approximately 30 % of EC after 1 hour and 35 % 
after 24 hours compared to no release from DMSO-treated control. The release was greater 
at 24 hours compared to monocultured cells, where thrombin induced release of 
approximately 25 % at 24 hours. This perhaps suggests that the interaction between EC and 
SMC plays a role in the mechanism of thrombin in releasing VWF. The signalling pathways 
could be investigated, by knocking down the receptor on these cell types and then look at the 
effect of thrombin on VWF release.  
 
In the ex vivo experiment thrombin stimulation reduced endothelial VWF intensity, indicative 
of release, by around 60 % compared to control. This suggests that the effect ex vivo is greater 
than in vitro in monoculture, and that studying DIVI in vitro might be too reductionist. 
However, it is hard to directly compare ex vivo with in vitro in this case, because the starting 
expression levels in the vessels compared with the cellular model are unknown, the thrombin 
might stick to the plastic, the expression levels of the thrombin receptor might be different, 
and also the serum used in cell culture may affect the release. 
The same drugs that induced VWF release in chapter 4, caused a similar effect in co-culture 
experiments. Specifically, bosentan and fenoldopam induced release at 1 hour and 24 hours. 
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Minoxidil caused VWF release only at 24 hours that was similar to the observed effect in 
monocultured HUVEC. Likewise, rolipram showed no effect on VWF release in either cells or 
the vessel. This might suggest that rolipram might need to be injected in the animal in order 
to produce injury or it might work with different mechanisms in different species.  
 
It would have been interesting to assess EC junctional integrity as in chapter 4. However, the 
setup of the co-culture model was not suitable as EC did not form complete intercellular 
junctions when cultured with SMC. This could have been addressed for example by using 
transwell assays where EC are cultured on an insert lateral to SMC. This system would allow 
EC junctions to be intact that could be visualised and analysed. Studies have reported that co-
culture of EC with SMC produced increased localisation of tight junction proteins to the 
junctions and increased permeability in a similar way to the effect of cAMP, indicating that 
SMC play a critical role in regulating EC permeability431,449. This may have been of particular 
interest for rolipram. In these studies, no DIVI related effects for rolipram have been 
observed, despite it being reported as an effective inducer of DIVI in vivo. As it is a PDE 
inhibitor, it would be expected to increase cAMP and so may have affected EC junctions. To 
confirm this, cAMP levels could be assessed after administration of rolipram and determine 
whether these are being altered.  
 
More complex studies conducted by HemoShear identified that fenoldopam (100 µM) in 
combination with in vivo-derived hemodynamics increase vascular permeability in a rat 
mesentery co-culture system79 and that fenoldopam treatment altered several inflammatory 
pathways. In order to understand the mechanism of DIVI, it would also be interesting to study 
inflammation to see whether the effect of bosentan and fenoldopam described in chapter 4 
is amplified in a co-culture system. For example, a co-culture flow system was developed to 
investigate the adhesion of flowing leukocytes, which have a crucial role in inflammation 
(refer to Introduction, section 1.6.5.3) to EC co-cultured with SMC432,450,451. It was 
demonstrated that co-culture of EC with SMC at opposite sides of a porous membrane 
markedly increased the adhesion of flowing leukocytes to EC and that the response of co-
cultured EC to TNF-α stimulation was amplified. 
Furthermore, it would have been useful to also assess the phenotype of SMC in co-culture 
before and after drug treatment. Within mature blood vessels, SMC usually have contractile 
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functions and express SMC-specific contractile markers such as calponin452 and α-SMA453 
(refer to Introduction, section 1.6.3). In disease states, for example in atherosclerosis, SMC 
repress expression of these genes and express a more proliferative, synthetic phenotype 
(Figure 6.12).  
It has been shown that EC can influence SMC phenotype expression, proliferation and 
migration454,455. For example, EC maintain SMC in a more contractile phenotype compared 
with SMC cultured alone. In addition, EC inhibit SMC type I collagen synthesis and promote 
SMC migration and proliferation in co-culture456. 
In response to injury, SMC switch from contractile to a proliferative phenotype capable of 
dividing in response to several mitogens, including platelet-derived growth factor (PDGF) and 
basic fibroblast growth factor (bFGF) and they also synthesise extracellular matrix 
components such as collagen, elastin, and proteoglycans457,458. Adhesion proteins such as 
fibronectin and laminin play an important role in determining the basic phenotypic state of 
the cells and exert their effects via integrin receptors458. Assessing whether the drug 
treatment alters the SMC phenotype could also be done in the future, both on monocultured 
SMC and in co-culture. This could be achieved by assessing the expression of SMC specific 
phenotypic markers by Western blot or measuring RNA levels of those proteins in untreated 
and stimulated samples.   
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Figure 6.12 Phenotype switching in SMC. Mature and healthy SMC show a contractile and 
differentiated phenotype, expressing markers like α-SMA and calponin. However, in disease 
states increased expression of TGFβ and PDGF can induce SMC switch to a synthetic and 
undifferentiated phenotype, characterised by high proliferation and migration of SMC. This 
phenotype can be promoted by and is characterised by decreased expression of α-SMA and 
calponin. Author’s own drawing. 
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Finally, cell death was investigated in co-culture by flow cytometry. This technique was used 
because it was an effective way to analyse separate EC and SMC populations in the same 
sample and could be used to rapidly analyse sufficient cells to make statistically powered 
conclusions459. SMC necrosis is a clear feature of DIVI, however the ATP viability assay in 
chapter 4 did not show death in monocultured SMC. Therefore, cell death was investigated 
in co-culture to understand whether the presence of EC would affect SMC death. PI has been 
reported to be a robust method to assess the viability of cells443. PI is considered a cell death 
indicator because loss of cell membrane integrity is a common event in all forms of cell death, 
however this method cannot be used to detect dying cells or to distinguish between different 
types of death460,461. Alternative methods can differentiate between necrosis and apoptosis, 
including caspase activation, cytochrome c release and oligonucleosomal DNA 
fragmentations (apoptotic parameters). 
 
Cisplatin was used as positive control for inducing cell death. It is well known that cisplatin 
akin to other antitumor drugs induces apoptosis primarily by damaging the DNA, whereby a 
nuclear signal generated in the initiation phase is directed to the cytoplasm subsequently 
returning to the nucleus to produce internucleosomal DNA degradation462. 
As expected, cisplatin induced monocultured SMC and EC death. 
 
Bosentan did not cause death in monocultures of EC and SMC, recapitulating what was 
observed in the ATP viability assay in chapter 4. However, unexpectedly bosentan caused EC 
and SMC cell death in co-culture, indicating that potentially the interaction between cells is 
an important effect of bosentan. How this could be happening remains to be explored, as well 
as whether it is an off-target effect, which is likely. As demonstrated in chapter 4, the effects 
of bosentan at this concentration may not be through its primary targets, the endothelin (ET) 
receptors. It is possible to hypothesise that bosentan activates EC to release a signalling 
molecule that acts on the SMC.  
 
Fenoldopam induced around 10 % death in monocultured EC and no additive effects was 
observed in co-culture. Of the other drugs tested no effect was observed in respect of cell 
death.  
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In summary, these data demonstrated that co-culturing EC and SMC is not sufficient to alter 
(increase or decrease) an existing or induce a novel DIVI phenotype for any of the drugs. Only 
bosentan caused both VWF release and EC and SMC death of all the drugs (Table 6.1). As it 
was not possible to induce features common to all DIVI-related drugs in this in vitro system 
perhaps this adds to the evidence from previous chapters suggesting a more complex 
physiological model needs to be explored. Co-culture flow systems that allow variation of flow 
and pressure to model physiological conditions may advance the understanding of the role of 
these factors in regulating DIVI. Indeed, work conducted by HemoShear has developed an EC-
SMC co-culture platform where the cells are separated by a synthetic internal elastic lamina 
and the endothelium is exposed to in vivo-derived hemodynamics79. In the proceeding 
chapters the role of flow in regulating EC function in DIVI will be investigated.  
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Effect Time course 
(hours) 
Bosentan Fenoldopam  Minoxidil Rolipram 
VWF release 1     
24     
Cell death 24     
 
 
Table 6.1 Summary of the effects of DIVI-related drugs in co-culture. Attributes of DIVI were investigated in this 
chapter: (1) VWF release from EC and SMC; (2) EC and SMC death. = significant effect (p < 0.05); = no effect. 
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7. The role of flow in DIVI
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7.1 Introduction 
 
In this thesis the impact of four drugs known to induce DIVI has been investigated to elucidate 
their effects in a rat vessel explant, blood cells, monocultured EC and SMC, and finally in a 
direct co-culture system. Several biomarkers including VWF release from EC, EC junctional 
disruption, inflammation and cell death were investigated but no common DIVI associated 
features were indicative of all the drugs. Indeed, bosentan was the only drug that had an 
effect on both VWF release and cell death in co-culture and conversely, rolipram failed to 
show a DIVI phenotype in any of the assays tested.  
 
It has been suggested that shear stress plays a role in the mechanism of DIVI and that localised 
changes in coronary blood flow is involved in the pathogenesis of DIVI (refer to Introduction, 
section, 1.5.1)203. Each of the drugs tested in these studies are vasodilators (though not all 
cause a drop in main arterial blood pressure) (Introduction, Table 1.1), and therefore 
investigating the effect of shear stress was the next step considered important in assessing 
the onset of DIVI.  
 
Although DIVI has been mostly studied in vivo in dog and rodents, one report of investigating 
DIVI in vitro is by HemoShear, who developed a system where EC and SMC are cultured on 
top of each other, separated by a membrane and EC are directly exposed to in vivo-derived 
hemodynamics through a miniaturised cone-an-plate viscometre79. Intellectual property 
restrictions have limited the information regarding the shear rate and time period over which 
the cells are exposed to flow. However, these studies showed that with hemodynamic 
regulation, fenoldopam (100 M) elicited effects on several parameters that are affected by 
flow, increasing EC layer permeability as measured by VE-cadherin expression, inflammation, 
oxidative stress, promotes cell death and cell remodelling. These findings demonstrate the 
potential importance of shear stress in the study of DIVI79.  
 
Several methods have been developed to apply shear stress to EC in vitro, such as 
microfluidics, parallel-plate flow chambers, cone-and-plate viscometers, and orbital 
shakers463. However, these systems are complicated and costly. One of the primary aims of 
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the thesis was to characterise a “simplistic” in vitro model that could derisk DIVI, therefore 
providing the closest physiological environment was important. A simple high-throughput 
screening model would mean that other laboratories could use this assay, reducing variability 
and increasing reproducibility, providing a robust methodology for safety assessment. 
 
Recently, Piezo-1 channels expressed on EC were identified as fundamental regulators in 
sensing the shear stress caused by changes in blood flow464. Piezo-1 are stretch-activated 
calcium permeable channels, that serve as sensors of mechanical stress in EC465. Complete 
knock down of Piezo-1 in mice is embryonic lethal, with embryos displaying vascular 
remodelling deficiencies336. The importance of this protein in transducing shear stress to a 
biological effect was displayed in gene silencing studies in HUVEC, where Piezo-1 -/- cells 
cannot align effectively in response to shear stress336. Therefore, this last chapter explores 
the addition of Yoda-1, which activates Piezo-1, as a potential ‘flow-mimetic’ that could be 
used as an alternative over more complicated microfluidics. Yoda-1 is a synthetic small 
molecule, which selectively activates Piezo-1 and not Piezo-2 channels (also expressed on 
EC464) was used. Yoda-1 activates Piezo-1 by stabilising channel in an open conformation 
without the mechanical stimulation of flow466. Yoda-1 has a binding affinity to the purified 
Piezo-1 protein in the range of 10-50 µM. The selectivity of Yoda-1 for Piezo-1 channels was 
demonstrated in artificial lipid bilayers, where Yoda-1 activated Piezo-1 without other 
accessory proteins467,468. Furthermore, activation of eNOS by shear stress on EC can be 
mimicked by acute administration of Yoda-1338. Besides Piezo channels, prior evidence 
supports a role for integrins as mechanotransuders in the endothelium by promoting 
phosphorylation of different targets though the activation of focal adhesion kinase464. 
Furthermore, different structures of EC, mainly primary cilia are also involved in 
mechanotransduction. 
 
In the previous chapters, the DIVI-causing drugs ex vivo in a rat vessel explant, in vitro in 
monocultured cells and in co-culture of EC and SMC did not produce a phenotype that was 
common to all the drugs. In this chapter, Yoda-1’s capability as a flow-mimetic was examined, 
comparing HUVEC phenotypes while stimulated under Yoda-1 against HUVEC experiencing 
laminar shear stress. Subsequently, EC and SMC VWF release and death were assessed in the 
presence of both Yoda-1 and the candidate drug. The hypothesis was that shear stress might 
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contribute and enhance the effects of the drugs. Although shear stress has been reported to 
have a protective effect from several damaging stimuli469,470, it can also increase cell toxicity 
in response to certain drugs. For example, it has been recently shown in our laboratory that 
Yoda-1 and laminar shear stress both enhanced cytotoxicity of doxorubicin in EC340. 
 
7.2 Methods 
 
In this chapter, the same four drugs tested previously (chapter 3-6) were assessed for 
hallmarks of DIVI. Cells were grown for 24 hours and pre-treated with Yoda-1. Subsequently, 
cells were then incubated with DIVI-related drugs. Refer to the Methods and to the specific 
sections in this chapter for a detailed description of the protocol (concentrations and time 
points) depending on each assay.  
 
7.3 Results 
 
7.3.1 Establishing a working concentration of Yoda-1 
 
Firstly, a working concentration of Yoda-1 was established. A concentration of Yoda-1 was 
required that would be present during long-term cell culture (24-48 hours), that produced no 
cytotoxic effects, and would thus model EC under continued shear. Cytotoxicity was 
conducted using two methods, the ATP luminescence assay (used in the previous chapters) 
and confocal imaging. The ATP assay was performed on HUVEC treated with Yoda-1 for 1, 4 
or 24 hours in a range between 0.1 M and 100 M (Figure 7.1). 1 M was the concentration 
that did not cause cell death at any of the time points and thus was used in the subsequent 
experiments, whereas higher concentrations (10-100 M) were substantially toxic to HUVEC, 
especially at longer periods of time. 
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To assess cell death using confocal imaging, HUVEC were treated with Yoda-1 for 24 hours 
and incubated with a cell viability dye (blue) prior to fixation (Figure 7.2). Nuclei (red) were 
stained with DAPI and cell junctions with VE-cadherin (green), a protein that maintains intact 
intercellular junctions. The detergent Triton X-100 was used as a positive control, to cause 
cell membrane disruption and ultimately cell lysis. After treatment with Triton X-100, the 
viability dye enters the nuclei and co-localises with the nuclei stain. None of the 
concentrations of Yoda-1 tested (up to 2 M) induced cell death after 24 hours, thereby 
confirming results from the ATP assay (described above). A working range of 0.05-2 µm was 
established. Additionally, in these experiments Yoda-1 did not alter cell division (Figure 7.2, 
C), as the number of the nuclei in random fields of view showed no difference. 
Figure 7.1 Assessment of cytotoxicity using an ATP viability assay. HUVEC were treated with 
increasing concentrations of Yoda-1 for 1, 4 or 24 hours. Data represent mean ± SEM of 5 
independent experiments. 
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Figure 7.2 Assessment of cytotoxicity using immunofluorescence. Representative confocal pictures show HUVEC incubated for 24 
hours with varying concentrations of Yoda-1. Nuclei were stained with DAPI (red), and EC junctions with VE-cadherin (green). Cell 
death was monitored through a fluorescent cell viability stain (blue) (A). B represents % dead cells normalised against 0.2 % v/v Triton 
X-100. C represents cell nuclei per field of view. Six random fields of view were quantified for each repeat, three independent 
experiments were conducted. Scale bars in A represent 20 m. Data in B and C represent mean ± SEM of 5 independent experiments, 
analysed by one-way ANOVA followed by Dunnett’s post test. 
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7.3.2 Yoda-1 mimics the effect of flow in static EC 
 
A working concentration range of Yoda-1 was used to assess whether phenotypes commonly 
observed under shear stress conditions could be observed. Incubation of HUVEC with Yoda-1 
(at concentration range between 0 and 2 M) for 24 hours increased the surface expression 
of ICAM-1 to 1.45 ± 0.11 fold higher than the DMSO control (N=5, p < 0.05) (Figure 7.3, B). 
This increase was not observed with the surface molecule, VCAM-1 (D). It was considered 
appropriate to model Yoda-1 effects to HUVEC under 5 dyn/cm2 shear stress, as HUVEC are 
derived from a vein,  and  this is the shear stress measured in small veins  and post capillary 
venules471,472.Under flow (5 dyn/cm2), expression of ICAM-1 (A) but not VCAM-1 (C) 
significantly increased, in a similar way to that observed with Yoda-1 (1 M). This has been 
previously reported, but following shorter incubation periods to those used in this study473.  
 
Phosphorylation of eNOS and its upstream kinase Akt (Figure 7.4) was also observed in Yoda-
1 (1 M) stimulated HUVEC at 24 hours.  HUVEC cultured under flow (5 dyn/cm2) for 24 hours 
displayed a comparable level of phosphorylation to those cells treated with 1 M Yoda-1. This 
effect was maintained for 24 hours. It has been previously described that Yoda-1 induces Akt 
and eNOS phosphorylation, and this effect is strongly reduced after knockdown of Piezo-1338. 
However, previous studies did not investigate the effect of Yoda-1 for periods exceeding 30 
minutes338. It was important to assess that the response to Yoda-1 response would be 
maintained post 24 hours in order to allow comparison with previous experiments conducted 
for this study. All the experiments described below were conducted at 24 hours.
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Figure 7.3 ICAM-1 and VCAM-1 expression in HUVEC under flow or using the flow-mimetic Yoda-1. Expression under flow (A and C), and 
static conditions (B and D) using a concentration range of Yoda-1 for 24 hours. Representative histograms from a single experiment are 
shown, followed by MFI normalised to their appropriate static culture control. Data represent mean ± SEM of 5 independent experiments, 
analysed by two-tailed non-parametric test and one-way ANOVA followed by Dunnett’s post test. *p < 0.05, ** p < 0.01. 
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Figure 7.4 Representative blots and quantification by densitometric analysis of phospho-eNOS and phospho-Akt. Phosphorylation of eNOS 
(A) and Akt (B) is shown under flow or in static conditions after 1 M Yoda-1 treatment for 24 hours. Data are normalised against their 
appropriate static (no Yoda-1) control lysate and represent mean ± SEM of 5 independent experiments, analysed by one-way ANOVA followed 
by Tukey’s post test. *p < 0.01, **p < 0.001. 
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These results indicate EC cultured under shear stress conditions compared to Yoda-1. The 
effect of Yoda-1 on HUVEC treated with DIVI-related compounds was then assessed. 1 M 
Yoda-1 was preincubated 24 hours prior to drug treatment to model a shear pre-conditioned 
endothelium, a phenomenon that would occur in vivo474. In all subsequent experiments when 
Yoda-1 was added it was at a concentration of 1 μM.  
 
7.3.3 DIVI-related drugs in the presence of Yoda-1 do not induce VWF release  
 
First, VWF release from the endothelium was assessed, to identify if the effect of the drugs 
observed in previous chapters could be altered by exposing HUVEC to the flow-mimetic. 
HUVEC were seeded in ibidi slides at 100,000 cells/well, grown for 24 hours, treated with 1 
M Yoda-1 for 24 hours and then treated with bosentan, fenoldopam mesylate, minoxidil 
sulfate, and rolipram all at 100 M. The same two time points from chapters 4 and 5 were 
chosen: 1 hour, to assess a short-term effect and 24 hours, to reflect the time point used in 
the vessel experiment. 0.1 % v/v DMSO was the vehicle for all the drugs. Following treatment, 
cells were fixed with 4 % v/v PFA for 10 minutes and then permeabilised for 5 minutes with 
0.1 % v/v Triton X-100. Specific antibodies were used to detect VWF and CD31 (to mark cell 
junctions), and DAPI was used to label the nuclei. Cells were imaged with a confocal 
microscope using a 63x objective. Six images were taken for each treatment per repeat. Four 
experiments were conducted in total.  
 
Over 24 hours, VWF release was not significantly different in control cells, where 87.4 ± 2.8 % 
were VWF-positive and at 24 hours this was relatively unchanged at 93.0 ± 1.5 % (Figure 7.5, 
7.6, 7.7). This observation was consistent with the release observed in previous chapters.  
 
Yoda-1 control-treated cells induced some VWF release at 1 hour, as the % of VWF-positive 
cells was 79.5 ± 6.0 %, and the release was significantly increased at 24 hours to 63.9 ± 1.90 
%. Shear stress has been shown to release VWF from the endothelium, this could explain 
these findings471,472. However, none of the drugs appeared to increase the VWF release from 
EC following pretreatment with Yoda-1 at either 1 hour or 24 hour time periods. In the 
previous chapters (chapter 4 and chapter 5), bosentan and fenoldopam showed a significant 
effect and induced VWF release in monocultured HUVEC and in HUVEC in co-culture at 1 hour 
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and at 24 hours, whereas in these studies this effect was not apparent. Yoda-1 may be 
masking the effect of the drugs in inducing VWF release.  
 
Rolipram showed a trend for a reduction in VWF release, but the effect was not significant. 
Again, these results are in contrast with previous chapters 4 and 5, where bosentan, 
fenoldopam and minoxidil induced a significant VWF release at 24 hours. All represent N=4. 
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Figure 7.5 Representative confocal pictures of VWF release in HUVEC pre-treated with Yoda-1 1 M at 1 hour. HUVEC were grown for 24 
hours, treated with Yoda-1 (1 µM) for 24 hours and then the drugs at 100 µM. VWF (green) release was assessed at 1 hour. Cell junctions are 
stained with CD31 (red), and nuclei with DAPI (blue). Six images were taken in random fields of view, four experiments were conducted in total. 
Scale bars represent 20 m. 63x. 
DMSO Yoda-1
Bosentan + Yoda-1 Fenoldopam + 
Yoda-1
Minoxidil + Yoda-1 Rolipram + Yoda-1
A B
D E FC
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Figure 7.6 Representative confocal pictures of VWF release in HUVEC pre-treated with Yoda-1 at 24 hours. HUVEC were grown for 24 hours, 
treated with Yoda-1 1 µM for 24 hours and then the drugs at 100 µM. VWF (green) release was assessed at 24 hours. Cell junctions are stained 
with CD31 (red), and nuclei with DAPI (blue). Six images were taken in random fields of view, four experiments were conducted in total. Scale 
bars represent 20 m. 63x. 
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Figure 7.7 VWF release after 1 (A) and 24 (B) hours in HUVEC pre-treated with Yoda-1 1 μM.  
HUVEC were grown for 24 hours, treated with Yoda-1 1 µM for 24 hours and then with the 
drugs at 100 µM for 1 and 24 hours. Data are expressed as % of VWF-positive cells out of all 
cells in the field of view (six random fields of view per treatment), and represent mean ± SEM 
of 4 independent experiments, analysed by one-way ANOVA followed by Dunnett’s post test. 
**p < 0.01, ***p < 0.001, compared to Yoda-1. 
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7.3.4 The particle size of VWF does not differ across treatments    
 
The particle size of intracellular VWF was monitored to understand if Yoda-1 affected the 
packaging and distribution of VWF into WPB. The size was analysed as described in chapter 
4, section 4.2.2. The particle size of VWF did not differ across treatments at 1 hour or 24 hours 
(Figure 7.8, A and B), indicating that WPB do not fuse together at the plasma membrane. This 
is consistent with findings from monocultured HUVEC and also co-culture, where the average 
particle size did not alter with treatments.  
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Figure 7.8 Average particle size of VWF at 1 (A) and 24 hours (B). HUVEC were grown for 24 
hours, treated with Yoda-1 (1 µM) for 24 hours and then with the drugs at 100 µM for 1 and 
24 hours. Data are expressed as area of VWF particles in the field of view (six random fields 
of view per treatment), and represent mean ± SEM of 4 independent experiments, analysed 
by one-way ANOVA followed by Dunnett’s post test compared to Yoda-1.  
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7.3.5 The drugs do not affect EC junctional integrity 
 
Drug-induced disruption to the HUVEC monolayer was assessed using confocal microscopy as 
described in chapter 4, section 4.2.2, using CD31 to visualise junctional integrity and 
disruption. The experiment was conducted as described in this chapter, section 7.3.3. The 
greater the black area, the more disruption to the EC monolayer (Figure 7.9). Cells were pre-
treated with Yoda-1 and the effect of the drugs was assessed at 1 and 24 hours (Figures 7.9, 
7.10 and 7.11). The MFI for each drug treatment was measured and normalised against the 
Yoda-1 control. At 1 hour, Yoda-1 control significantly disrupted the junctions as shown by a 
larger black area between cells (and a higher MFI) compared to DMSO control (mean of 0.45 
± 0.07; N=4, p < 0.05). The drugs did not significantly affect the junctions, however bosentan, 
fenoldopam and minoxidil showed a trend towards disruption (score for bosentan, 
fenoldopam and minoxidil compared to Yoda-1 control were 4.9 ± 2.8, 7.7 ± 4.9, and 3.4 ± 
2.0, respectively). Previously, in monoculture experiments, in the absence of Yoda-1, 
fenoldopam induced significant disruption of the junctions at 1 hour, and minoxidil at 24 
hours (refer to chapter 4, section 4.2.2.1).  
 
After 24 hours, Yoda-1 control induced significant EC monolayer disruption compared to 
DMSO control, which showed a mean of 0.3 ± 0.04 (N=4, p < 0.01). This is not surprising as 
flow can affect the EC permeability, allowing the exchange of molecules with the tissues. 
Among all the drugs, only bosentan showed a trend towards disruption but it was not deemed 
significant (mean of 21.0 ± 5.0, N=4, ns). 
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Figure 7.9 Representative confocal pictures of assessment of EC junctional integrity with DIVI-related drugs in the presence of Yoda-1 (1 
M) at 1 hour. HUVEC were grown for 24 hours, treated with Yoda-1 1 µM for 24 hours and then with the drugs at 100 µM for 1 hour. Cell 
junctions are stained with CD31. Six images were taken in random fields of view, four experiments were conducted in total. Scale bars represent 
20 μm. 63x. 
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Figure 7.10 Representative confocal pictures of assessment of EC junctional integrity with DIVI-related drugs in the presence of Yoda-1 1 M 
at 24 hours. HUVEC were grown for 24 hours, treated with Yoda-1 1 µM for 24 hours and then with the drugs at 100 µM for 24 hours. Cell 
junctions are stained with CD31. Six images were taken in random fields of view, four experiments were conducted in total. Scale bars represent 
20 μm. 63x. 
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Figure 7.11 Assessment of junctional disruption at 1 hour (A) or 24 hours (B) in HUVEC. 
HUVEC were grown for 24 hours, treated with Yoda-1 1 µM for 24 hours and then with the 
drugs at 100 µM for 1 and 24 hours. Data are normalised to Yoda-1 control and expressed as 
MFI fold change, and represent mean ± SEM of 4 independent experiments, analysed by one-
way ANOVA followed by Dunnett’s post test. *p < 0.05, **p < 0.01, compared to Yoda-1. 
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7.3.6 Bosentan and fenoldopam in the presence of Yoda-1 cause EC but not SMC death  
 
To investigate the effect on cell death, the drugs were incubated with Yoda-1 and the same 
ATP viability assay used in chapter 4, section 4.2.3 was used. The assay was performed using 
three drug concentrations (1, 10 and 100 µM) at 24 hours, as data from chapter 4 showed no 
effect at shorter time points. The same protocol used in chapter 4 was used with the 
exception that cells were pre-treated with Yoda-1. Cells were seeded in a 96 well plate and 
grown for 24 hours. Then they were treated with Yoda-1 (1 µM) for 24 hours and then drugs 
for a further 24 hours.  
 
In EC, 100 μM bosentan (in the absence of Yoda-1) induced 17.6 ± 2.4 % cell death (p < 0.001, 
N=5) (Figure 7.12). This differs from data observed in monocultured HUVEC, where bosentan 
did not induce cell death. Bosentan with Yoda-1 caused 37.1 ± 3.8 % cell death (p < 0.01, N=5). 
This is novel and suggests that the effect of the drug is enhanced by flow. Bosentan was also 
the only drug causing an effect on cell death on both EC and SMC when co-cultured.  
 
Fenoldopam at 100 μM alone induced 24.1 ± 2.9 % cell death compared to DMSO control (p 
< 0.0001, N=5). This aligns with data in single HUVEC from chapter 4, section 4.2.3. 
Fenoldopam with Yoda-1 induced 72.6 ± 4.9 % cell death (p < 0.0001, N=5), indicating that 
the effect of fenoldopam is greatly increased by flow. Fenoldopam was not found to increase 
cell death on EC and SMC in co-culture. The other drugs had no effect on cell death.  
 
In SMC, none of the drugs induced cell death at 24 hours (Figure 7.13). This is in line with data 
from chapter 4, section 4.2.3 where in single cells none of the drugs was cytotoxic to SMC.  
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Figure 7.12 Assessment of cell death using an ATP assay in HUVEC pre-treated with Yoda-1 1 μM. HUVEC were grown for 24 hours, pre-treated 
with Yoda-1 1 µM and then treated with the drugs at 1, 10 and 100 µM for 24 hours. Data are expressed as % survival compared to control. 100 
% represents no death. Data represent mean ± SEM of 5 independent experiments, analysed by two-way ANOVA followed by Dunnett’s post 
test. **p < 0.01, ****p < 0.0001. 
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Figure 7.13 Assessment of cell death using an ATP assay in HCASMC pre-treated with Yoda-1 1 μM. HUVEC were grown for 24 hours, pre-
treated with Yoda-1 1 µM and then treated with the drugs at 1, 10 and 100 µM for 24 hours. Data are expressed as % survival compared to 
control. 100 % represents no death. Data represent mean ± SEM of 5 independent experiments, analysed by two-way ANOVA followed by 
Dunnett’s post test. 
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In summary, these data have demonstrated that flow affects only bosentan and fenoldopam 
and not the other drugs.  
 
7.4 Discussion 
 
In this final chapter, the effects of DIVI-related drugs were investigated in HUVEC in the 
presence of a molecule, Yoda-1, that mimics shear stress, the frictional force that blood flow 
exerts on EC in the vessel (refer to Introduction, section 1.7). It has been suggested that shear 
stress plays a role in DIVI203. Alterations in shear stress can result in leukocyte adhesion, 
endothelial junctional breaks, breakdown of the vessel wall integrity, breaks in the internal 
elastic lamina, and haemorrhage475,476. 
 
Flow is studied in vitro using microfluidic devices, which have three-dimensional complexity, 
enable cell-cell interactions and the relevant extracellular environment that is typical of living 
tissues. These devices, composed of submillimetre-scale channels through which liquid flows 
in a controlled manner, are an attractive way for the investigation of blood vessel function477. 
Precast three-dimensional micro networks can be engineered using different polymers and 
EC seeded on top of which blood flow can be mimicked and regulated. For example, in the 
production of a system that replicated aspects of angiogenesis, where micro vessels when 
activated produced new branches and recruited mural cells previously seeded in the 
device478. Nonetheless, although these models resemble the cellular arrangement and 
responses of in vivo vessels, for drug discovery in early safety these may not be optimal.  
Complicated in vitro models have also used a parallel plate design479. An innovative co-culture 
model utilising a combination of parallel plates with flow and a transwell with EC and SMC co-
culture has also been developed480. In this study, EC were either cultured alone or co-cultured 
with SMC under static conditions or subjected to normal levels of laminar shear stress of 15 
dyn/cm2 by using a parallel-plate co-culture flow chamber system. It was demonstrated that 
both shear stress and SMC could increase EC migration, and was associated with the increased 
expression of histone deacetylase 6 (HDAC6) and low level of acetylated tubulin. Another 
system focussed on the study of platelet aggregation by flowing whole blood and RBC and 
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leukocyte entry into the underlying tissue. It has been shown in the same study that adding a 
pro-inflammatory stimulus induced EC activation, promoted platelet aggregation and the 
formation of a blood clot339.  
 
All these models are complicated to construct and difficult to be standardised across different 
laboratories. The scope of this thesis is to create a simple in vitro system to allow quick 
screening of a large set of compounds. Therefore Yoda-1, a small molecule activator of Piezo-
1 cation channels, was used to mimic flow. Piezo-1 mediates flow-induced release of ATP from 
EC, leading to the activation of the Gq/G11-coupled purinergic P2Y2 receptor and subsequent 
phosphorylation of Akt and eNOS leading to NO production338. siRNA-mediated knockdown 
of Piezo-1 was shown to inhibit shear stress-induced increases in Ca2+ and also blocked 
phosphorylation of Akt and eNOS in response to shear stress in human umbilical arterial EC 
(HUAEC)338. In addition, several studies demonstrated that EC fail to align to the direction of 
flow when Piezo-1 is knocked down or partially removed336,337,481,482. 
 
Yoda-1 was chosen because 1) it selectively activates Piezo-1 channels, which have been 
shown to be important in the regulation of shear stress on EC; 2) it mimics in vivo flow without 
requiring a complex flow device.  
 
Yoda-1 induces effects similar to those generated by Piezo-1 in response to flow338. Yoda-1 
increases Ca2+ and the effect is reduced after knockdown of Piezo-1. Yoda-1 also induces Akt 
and eNOS phosphorylation, increases nitrate formation and causes ATP release, similarly to 
the effects of Piezo-1 in response to flow. All these responses are reduced after knockdown 
of Piezo-1. In addition, it was confirmed that Yoda-1-induced effects were dependent on 
ATP338. Knockdown of P2Y2 or Gq/G11 or incubation of HUAEC with apyrase, the enzyme that 
degrades ATP, or with an antagonist of P2Y2 receptors resulted in inhibition of Ca2+ increases 
and Akt/eNOS phosphorylation. These experiments demonstrate that Yoda-1-induced 
signalling pathways align with Piezo-1-mediated pathways induced by flow and involve P2Y2 
and Gq/G11. 
 
The first step was to find a working concentration of Yoda-1 that could be used in investigating 
hallmarks of DIVI. This was carried out using two methods: 1) the ATP luminescent assay used 
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in the previous chapters; and 2) confocal imaging, to have an additional confirmation. The 
ATP luminescent assay showed that 1 M Yoda-1 is not toxic to the cells at 1, 4 or 24 hours, 
however higher concentrations did cause cell death in HUVEC. Using immunofluorescence, 
concentrations up to 2 M were tested and were found to be non-cytotoxic in HUVEC.  
 
It was then confirmed that Yoda-1 mimicked the effects seen with shear stress in vivo 
reported in the literature. An important step was also to make sure that Yoda-1 would have 
a continued and sustainable effect (for 24 hours or more), similar to those seen in EC 
undergoing long term flow conditioning483. VWF endothelial release and cell death were 
assessed at this time point. In accordance with the literature338, it was observed that 
phospho-eNOS and phospho-Akt levels were increased by Yoda-1 treatment, to a similar 
degree to the shear stress control experiments. It was also confirmed that Yoda-1 increases 
expression of ICAM-1 and not VCAM-1 similarly to flow. In the control experiments shear 
stress has a similar effect on these proteins and these results had been previously reported473. 
 
Subsequent experiments focussed on investigating the same hallmarks of DIVI described in 
previous chapters in the presence of the flow mimetic, Yoda-1. There is evidence that VWF 
release is modulated by flow and it has been shown that laminar shear stress increases VWF 
release within few hours of exposure484,485. As such, VWF release from EC was measured and 
showed that Yoda-1 caused a slight VWF release at 1 hour and a significant release at 24 hours 
compared to DMSO control. The drugs that had in previous experiments induced significant 
VWF release both acutely and at 24 hours did not induce an effect in the presence of the flow-
mimetic. In monocultured HUVEC in the absence of Yoda-1 and in co-culture with SMC 
bosentan and fenoldopam caused VWF release. Interestingly, in the presence of shear stress 
the effect of these drugs on VWF release is reduced.  This discrepancy with data from 
monocultured HUVEC in the absence of Yoda-1 (chapter 4) could relate to variability in the 
assay, an effect driven by the low n values used in the study. 
 
Similarly to what has been discussed in chapter 4, the change in WPB size was not observed 
with the drugs nor with the positive control thrombin. It would have been useful to add a 
control e.g. statins which are reported to significantly decrease the size of WPB and this is 
something that is worth investigation in the future. 
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Following assessment of VWF release, focus was redirected to investigating endothelial 
junction integrity. Yoda-1 induced significant EC junctional disruption at 1 hour and 24 hours 
compared to DMSO control monolayers. As discussed earlier, flow affects EC permeability486 
however in these studies none of the drugs caused significant EC monolayer disruption in the 
presence of Yoda-1. Although an observed trend to increase EC disruption was observed for 
bosentan and fenoldopam at 1 hours, bosentan at 24 hours. This finding differed from 
monocultured cells in which fenoldopam at 1 hour and minoxidil at 24 hours induced 
disruption. In these studies, it appears as though Yoda-1 is having a protective effect. This is 
contradictory to all reported DIVI studies where the lesions were found in vivo and had been 
exposed to flow. This may suggest that SMC play a crucial role in the interaction with EC in 
generating lesions when exposed to the drugs under physiological flow in vivo, or it conversely 
it may indicate that more evidence is required to demonstrate that DIVI occurs humans. 
 
Finally, the effect of a shear-stress mimetic on cell death was assessed by ATP luminescent 
assay at three drug concentrations at 24 hours. Bosentan and fenoldopam alone were 
cytotoxic at the highest concentration. The toxic effect of fenoldopam had been shown 
previously in EC (chapter 4), however fenoldopam induced cell death to a greater extent. 
Experimental conditions were different, and this may account for the observed differences. 
It is possible that cell density plays a role in this and growing the cells for one more day to 
allow pretreatment with Yoda-1 affected this result. To confirm this, assessment of 
expression markers could be performed to understand if 24 hours more in culture make a 
difference. 
 
Both fenoldopam and bosentan induced greater cytotoxicity at the highest concentration 
when incubated with Yoda-1 compared with when they were administered alone. This 
suggests that flow plays an important role in their mechanism of action, by inducing cell 
markers that alter the response to these drugs.  
 
Bosentan did affect SMC cell death in co-culture. This suggests that the EC-SMC interaction 
plays a fundamental role in bosentan mechanism of causing DIVI and has a stronger influence 
on determining SMC cell death than flow. 
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The observation that bosentan induced cytotoxicity to both EC and SMC in co-culture 
indicates that the effect of bosentan is greatly influenced by EC-SMC interaction and flow. 
Conversely, as no SMC cytotoxicity was observed following treatment with fenoldopam it is 
possible to summarise that flow is a more important regulator of this effect than the presence 
of SMC. 
 
A summary of the effects of the drugs under flow is given in Table 7.1. The addition of the 
flow-mimetic failed to show an effect with rolipram and as for the co-culture it was not able 
to elicit the same DIVI phenotype for all the drugs. It is accepted that the experimental 
approach explored in these studies may be too reductionist, in terms of model complexity, 
and in the future there might be the need of investigating more complete systems (this will 
be discussed in chapter 8). However, using more complex systems was beyond the scope and 
aims of this work. In the general discussion (chapter 8), other approaches will be explored in 
order to find a physiological model that is simple enough so that would allow quick screening 
of drugs in development. 
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Effect Time course 
(hours) 
Bosentan Fenoldopam  Minoxidil Rolipram 
VWF release 1     
24     
EC junctional breakage 1     
24     
Cell death 24     
Table 7.1 Summary of the effects of DIVI-related drugs in the presence of the flow-mimetic Yoda-1. The following 
hallmarks have been investigated in this chapter: (1) VWF release from EC, (2) disruption of the EC monolayer and (3) EC 
and SMC death. = very significant effect (p < 0.0001); = very significant effect (p < 0.01); = no different to 
Yoda-1 treatment alone. 
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8. General Discussion 
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The aim of this PhD thesis was to define a toxicological limit around which the therapeutic 
index (TI) of a drug can be set, in order to reduce in the future the number of DIVIs seen in 
the clinic.  
Within this body of work, DIVI has been investigated in monocultured EC and SMC, in co-
culture (EC-SMC) and in a model that mimics flow in vitro under static conditions. However, 
no classical model could be developed that consistently recapitulated the major features of 
DIVI (apoptosis, barrier permeability, adhesion molecule upregulation) using drugs with a 
range of mechanisms of action that are known to cause DIVI in pre-clinical animal models. 
Importantly, DIVIs are likely to be mediated by an off-target toxicity rather than an on-target 
action of the drug. This is suggested by the fact that DIVI-related drugs have all different 
mechanisms of action and investigation on which off-target receptors might be implicated 
still has to be conducted. The drugs have been tested in the assays presented within this thesis 
at a limit concentration (100 µM) that would not be administered to humans but was 
important to define limits of off-target toxicity. In the future, more studies should be aimed 
at confirming the on vs. off-target effects either by using other compounds with comparable 
mechanism of actions but developed from different chemical templates or antagonism of 
specific sites of action. 
This Discussion will consider some of the factors that may have contributed to these findings, 
and the learnings that can be applied to our understanding of DIVI, and suggest directions for 
future research that may be to address these issues.  
 
8.1 VWF release with DIVI-related drugs ex vivo and in vitro 
 
DIVI is an in vivo phenotype in specific blood vessels described in pre-clinical studies. One 
reason for the difficulties in generating a reductionist, humanised model in vitro might thus 
have been cross species translatability. It was therefore necessary to first recapitulate DIVI ex 
vivo in relevant animal tissue, in a vessel in which DIVI has been widely described. For this, 
the rat mesentery artery was chosen as it has been reported as a site of DIVI by numerous 
groups124,198,203,400. Four drugs each with different mechanisms of action (refer to 
Introduction, Table 1.1), were selected from compounds that are known to cause DIVI in 
preclinical species, that are approved in the clinic.  
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Here, vessel explants were treated with the drugs and investigated for features of DIVI. 
Endothelial release of VWF was used as a DIVI biomarker, since its release signifies both EC 
activation and damage. It has often been described in the literature as a potential marker of 
DIVI in animals and a possible marker of vascular injury in patients35,198,201,203. Additionally, 
other properties make it a suitable target biomarker include the release into the blood that 
allows assessment through routine blood monitoring, and a short half-life (12 hours) that 
gives a definitive timestamp for acute damage.  
 
Most DIVI studies involve drug treatment in vivo, with separate animals for control and drug 
treatment, which requires four animals per group for the study to produce power. In this 
study however, for each replicate an explant from one animal was sectioned to enable 
multiple drug conditions to be carried out in parallel. This greatly reduced experimental 
variation and produced a more accurate vehicle control response. 
 
Using this technique, it was demonstrated that a response seen in vivo (VWF release from EC 
into plasma) can be reproduced ex vivo (albeit not release into plasma but loss from EC) for 
three of the drugs tested (bosentan, fenoldopam and minoxidil) however this was not 
observed following rolipram treatment.  
VWF release in the ex vivo experiments appeared similar between all three drugs excluding 
rolipram, as subsequent expression of VWF within the tunica media as localised by the SMC 
stain α-SMA was not present.  
 
Rolipram has previously been reported to effectively enter HUVEC. Incubation for 2 minutes 
with 50 µm of rolipram induced a 85 % increase in cAMP production487. The inability of 
rolipram to release VWF is surprising given that both rises in cAMP and cytosolic calcium have 
been documented to stimulate WBP membrane fusion488. Perhaps for a rolipram-dependent 
VWF release in these experiments, complementary cellular signals are required, for example, 
shear stress has been documented to increase cAMP levels in cultured HUVEC489; it is 
plausible that this synergistic effect is necessary to induce release. 
 
Previous studies have described acute VWF release (monitoring within initial 24 hours) in vivo 
with fenoldopam and ZD6169, a K+ channel opener198,201. Conversely, bosentan and rolipram 
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VWF release in vivo has never been reported (Table 8.1). In fact, bosentan was reported to 
not affect VWF release in patients with systemic sclerosis and pulmonary hypertension397, a 
condition characterised by high levels of VWF490. However, in these trials, VWF plasma levels 
were monitored as an end stage, perhaps after resolution, following 12 months of bosentan 
treatment, which makes the comparison with the study reported here more challenging.   
 
Studies have reported that fenoldopam induced VWF release into plasma at 2 hours and 6 
hours, but returned to baseline at 24 hours when lesions were identified by 
immunohistochemistry in vivo in rats198,201. Minoxidil has not been investigated for VWF 
release but another K+ channel opener that released VWF in dogs is ZD6169201. ZD6169 was 
associated with transient increases in VWF plasma levels at 1, 3 and 6 hours post-dosing in 
dogs. However, plasma VWF levels declined at all doses, in all dogs, 24 hours post-dose when 
histopathology confirmed morphologic evidence of medial necrosis and haemorrhage. 
 
There are several implications from the observations in this ex vivo model. First, it is possible 
to recapitulate at least one feature of DIVI with some drugs in a rat vessel explant. This ex 
vivo model uses the most relevant tissue, rat mesenteric artery, but lacks two potentially 
important in vivo features, namely drug-induced increases in local blood flow, and the actions 
of leukocytes, erythrocytes and platelets. In addition, there is no nervous system influences 
in this model, which may alter the vascular physiology (e.g. blood pressure). As described in 
the Introduction, section 1.5.1, one hypothesis regarding the mechanism of DIVI suggests 
that global or local increases in blood flow lead to vascular damage, with direct toxic effect of 
the drug on the vessel cells themselves. However, these data indicate a direct effect of three 
drugs on the EC themselves in the absence of changes in blood flow, at least for VWF release. 
Other key features of DIVI may still require increased blood flow, and this deserves further 
attention in the future. One approach may be to use cannulated, perfused vessels (as used in 
pressure myography, for example). A limitation with a significant increase in the complexity 
of the model however is a reduction in the throughput for drug screening, a consequence we 
were keen to avoid. A second implication of the data present with this ex vivo model is that, 
even with what was considered to be the most relevant tissue/animal model, this DIVI 
phenotype could not be recapitulated following rolipram treatment. It is possible that a local 
increase in blood flow is a necessary prerequisite for the effects of rolipram therefore making 
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it unlikely that the rolipram phenotype could be mimicked in an in vitro model – exactly as 
was ultimately found in the models tested in these studies. A further implication is that there 
must be some mechanistic difference between DIVI induced by rolipram, and DIVI induced by 
the other drugs that were tested, as rolipram was the only drug that induced no effect in all 
the assays tested, ex vivo and in vitro. Consequently, it may be difficult to ever generate a 
screening model that will reliably predict all drugs that cause DIVI. However, pharmaceutical 
industries generally aim for a 70 % accuracy in their safety screens, and it is unlikely to 
produce a biological assay that is 100 % accurate. In assay development, sensitivity and 
specificity are the most important factors.  
 
Following ex vivo investigation of DIVI, the drugs were tested for endothelial VWF release in 
vitro, using (1) monocultured EC; (2) a co-culture of EC-SMC; and (3) monocultured EC 
exposed to the flow-mimetic Yoda-1. These effects are summarised in Table 8.1. The 
experiments conducted within this thesis are highlighted in the red box, to compare with 
previous in vivo studies showing VWF release in animals or patients. 
It was observed that for bosentan, VWF release at 1 hour is not affected by more complex in 
vitro systems. In fact, using monocultured EC, co-culture or the flow-mimetic Yoda-1 did not 
increase VWF secretion. In monoculture and co-culture, but not when Yoda-1 was added, 
bosentan induced VWF release from EC acutely.  At 24 hours, bosentan induced VWF release 
in monoculture and co-culture, the monocultured EC produced a higher (around 25 % 
reduction in % VWF-positive cells at 1 hour and 25 % at 24 hours compared to DMSO control) 
effect compared to co-culture (15 % reduction at 1 hour and 25 % at 24 hours compared to 
DMSO control), suggesting that interaction with SMC does have a role in reducing the VWF 
released from EC. Interestingly, Yoda-1 did not induce release (acutely or at 24 hours) when 
added with bosentan. Thus, perhaps it is possible to infer that EC-SMC interaction plays a 
more important role in bosentan induced VWF release than flow. 
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Drug Time 
course 
(hours) 
In vivo 
(previous 
studies) 
Ex vivo  In vitro 
 Rat vessel 
explant 
Monocultured EC Co-culture EC-SMC EC with Yoda-1 
Bosentan 1 No change in 
patients with 
systemic 
sclerosis397 
n/a  
 
 
 
 
 
24  
 
    
Fenoldopam 1 Release at 2,4,6 
hours in 
rats198,201 
n/a  
 
  
24  
 
   
Minoxidil 1 Release at 1,3,6 
hours with 
ZD6169201 
n/a    
24  
 
   
Rolipram 1 n/a n/a    
24     
 
Table 8.1 Comparative effects of VWF release seen in vivo in previous studies with ex vivo and in vitro investigation conducted within 
this thesis.  = very significant effect (p < 0.001); = very significant effect (p < 0.01); = significant effect (p < 0.05); = no effect. 
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Fenoldopam induced VWF release acutely in monoculture and co-culture, but not in the 
presence of Yoda-1, with the greatest effect observed in a co-culture model, suggesting that 
EC-SMC interaction plays an important role in its mechanism. At 24 hours, VWF secretion was 
induced again only in monocultured EC and in co-culture, but not with Yoda-1.  
 
Minoxidil did not induce VWF secretion in monoculture, nor in co-culture at 1 hour, release 
was seen however at the 24 hour time point. As observed for the other drugs, Yoda-1 caused 
no significant release compared to the Yoda-1 control. 
 
Rolipram did not induce VWF secretion in any of the biological systems. It may be useful to 
use a different compound in the same pharmacological class as rolipram, such as the PDE IV 
inhibitor cilomilast, to understand whether absence of VWF release with rolipram relates 
uniquely to this drug or is a common factor for the entire class.  
 
Unfortunately, the rat vessel explant was only tested at 24 hours because of limited 
availability of tissue, and thus a comparison with the acute in vitro studies cannot be 
determined. At 24 hours the in vitro systems replicated the effect on VWF release observed 
in the vessel, except for when Yoda-1 was added, as Yoda-1 in vitro at 1 or 24 hours in 
combination with the drugs did not induce significant release compared to the Yoda-1 control.  
In order to build on our understanding, the next steps would be to undertake these 
experiments in a true shear stress environment. Furthermore, using in vitro assays to 
investigate DIVI resolution would also add to our understanding. Drug could be incubated for 
the above 24 hour period, then removed and after 7 days of culture VWF release from the 
endothelium re-probed.  
 
The vessels used in the rat explant had been conditioned by flow in the animal, however 
during the ex vivo drug treatment experiments flow was absent. Release of NO, which occurs 
when EC are exposed to flow (and also when EC are exposed to Yoda-1340), affects VWF 
secretion491. It has been suggested that endogenously produced NO may dampen the 
regulated pathway (i.e. stimulus-induced) of VWF secretion. In a study in humans, healthy 
subjects received placebo or an infusion of the NOS inhibitor N-monomethyl-k-arginine (L-
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NMMA), which decreases the production of endogenous NO491. After this pre-treatment all 
volunteers received a histamine infusion and blood samples were collected for determination 
of VWF plasma levels. It was demonstrated that the stimulatory action of histamine on VWF 
release could be induced in vivo, as demonstrated by the increased plasma VWF-antigen 
levels, and that it may be inhibited by endogenous production of NO, as shown by an 
enhanced effect of histamine-induced VWF release during NOS inhibition. Given this finding, 
it is possible that stimulation of NO production by Yoda-1 on EC inhibits drug-induced VWF 
release. The vessel explant, where flow is absent and thus production of NO may also be 
reduced, induced VWF release. However, this has not been investigated and would need 
confirmation. 
 
It may be then questioned as to why previous in vivo studies (thus under flow) have been able 
to demonstrate VWF release in rats and dogs with the same drugs tested here198,201 (Table 
8.1). These studies showed that release occurred only acutely up to 6 hours after drug 
treatment and that VWF plasma levels returned to baseline at 24 hours, when vascular 
damage was also detected histologically. These in vivo studies could suggest that either 
physiological flow (rather than a flow-mimetic) is required, or perhaps both flow and a co-
culture are needed in vitro to accurately determine DIVI risk.  
 
In the experiments presented in this thesis continuous VWF release, which would help 
understand how the drugs affect the kinetics of the release, was not monitored and is 
something worth investigation in the future. Cells could be either treated with inhibitors of 
the clathrin-mediated exocytosis pathway or treated with inhibitors of protein synthesis to 
prevent de novo production of VWF214,492. Finally, VWF secretion could be tested using drugs 
from the same families, to understand whether there is a common mechanism underlying 
one entire class of compounds or whether it is a drug-specific effect.  
 
8.2 Investigation of other markers of DIVI in vitro 
 
Next, the reported features of DIVI was investigated in vitro using human cells model systems. 
Clear histopathological features of DIVI, as mentioned in 1.3.1, are (1) activation and injury of 
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EC and SMC; (2) inflammation; and (3) extravasation of RBC due to disruption of vascular 
integrity. Cell activation (measured by assessment of EC junctional integrity), inflammation 
and death have been investigated in monocultured EC and SMC, in circulating blood cells and 
in co-culture. The third feature, extravasation of RBC, is something worth investigating in the 
future and will be discussed in section 8.3.  
 
8.2.1 EC junctional breakage 
 
As mentioned in the Introduction, section 1.6.1, under physiological conditions the 
endothelium forms a selective barrier with adherens, tight and gap junctions. However, this 
selective membrane can be altered in pathological situations and the monolayer disrupted. A 
marker investigated in DIVI in monocultured EC and in EC using the flow-mimetic Yoda-1 was 
EC junctional breakage and a summary of the effects of the drugs is depicted in Table 8.2, 
where also the responses of the drugs in previous in vitro/vivo studies are presented. 
Disruption of the EC barrier can facilitate transendothelial migration of immune cells to the 
arterial intima and induction of vascular inflammation. Depending on the stimulus, activated 
EC can return to the quiescent non-activated phenotype or can progress to apoptosis.
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Drug Time course 
(hours) 
In vitro/vivo (previous 
studies) 
In vitro  
 Monocultured EC EC with Yoda-1 
Bosentan 1  No effect in humans493   
24   
Fenoldopam 1 Increased permeability in 
vitro79 
 
 
 
24  
 
 
Minoxidil 1 Increased permeability in 
vivo and in vitro494 
 (trend) 
 
 
24  
 
 
Rolipram 1 Inhibition permeability 
induced by thrombin in 
vitro373 
  
24   
 
Table 8.2 Comparative effects of EC junctional breakage seen in vitro/vivo in previous studies with in 
vitro investigation conducted within this thesis. = very significant effect (p < 0.01); = significant 
effect (p < 0.05); = no effect. 
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In these studies, bosentan did not cause EC junctional breakage in monocultured EC with, or 
without Yoda-1. Bosentan has been shown in vivo to not induce significant changes in capillary 
permeability assessed in patients with systemic sclerosis using laser Doppler fluxmetry 
combined with iontophoresis and fluorescence microscopy493. The data presented here are 
in line with these reports. 
 
In monocultured EC, fenoldopam caused breakage of the junctions acutely at 1 hour. 
However, the effect was not observed at 24 hours and this pattern mimicked the response of 
the positive control thrombin, which also caused disruption at 1 hour but not at 24 hours. 
This suggests that fenoldopam acts rapidly on EC junctions but its effect is short lived. 
Fenoldopam at a high concentration (100 M), combined with in vivo-derived hemodynamics, 
has been shown in vitro to increase permeability at 28 and 48 hours using a co-culture of rat 
EC and SMC79. Unfortunately, because of intellectual property the details of the study are not 
available. The addition of Yoda-1 inhibited the effect on junctional breakage seen at 1 hour 
with fenoldopam, suggesting that flow may exert a protective effect.  
 
Minoxidil showed a trend toward junction disruption in monocultured EC at 1 hour but the 
effect was not significant. However at 24 hours, minoxidil caused a significant response (more 
than 10-fold compared to DMSO control) on junctional disruption, suggesting that the 
mechanism of action may require hours to induce EC monolayer disruption but the effect is 
sustained for at least one day. This suggests that secondary pathways and downstream 
effectors may be regulating the observed effect. These data are agreement with previous in 
vivo observations in rodents and in vitro in Caco-2 cells, where minoxidil was found to increase 
permeability494. 
To understand DIVI resolution, which is still unclear, it would be interesting to know whether 
the effect of minoxidil is irreversible on the junctions. However, this is not likely to be the case 
because, as mentioned above, irreversible EC activation would lead to cell death and in the 
cell death assays (discussed in section 8.2.3 and 8.2.4) minoxidil did not cause any EC nor SMC 
death. Interestingly, Yoda-1 inhibited the effect on the junctions at 24 hours. 
 
Rolipram did not cause EC monolayer disruption in monocultured EC and this was unaltered 
with the addition of Yoda-1. Rolipram has been reported in vitro in HUVEC to restore the EC 
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barrier after disruption with thrombin373. Roflumilast, a PDE IV inhibitor like rolipram, was 
reported in vivo in rats to restore the EC monolayer in a similar manner373. These experiments 
are discussed in detail in chapter 4. 
 
8.2.2 EC inflammation  
 
The drugs were then tested for their ability to induce inflammation in EC, which is a marker 
of DIVI170. Table 8.3 summarises the effects seen in this thesis.  
 
Bosentan increased both ICAM-1 and VCAM-1, compared with fenoldopam that only 
increased VCAM-1 expression at 24 hours. However, these effects were relatively small when 
compared with the ICAM-1 and VCAM-1 expression induced by TNF-α. Previous studies have 
suggested that bosentan has no effect on VCAM-1 or ICAM-1 expression in patients with 
systemic sclerosis493,495. This discrepancy with previous reports may be related to differences 
between in vivo and in vitro studies372, where binding to plastic, binding to proteins and 
interaction between the culture medium and the cells are factors that may affect the results. 
In addition, patients with systemic sclerosis have very different vasculature and physiological 
conditions compared with an in vitro model496.  
 
Fenoldopam has been reported to elevate several inflammatory pathways in vitro using a co-
culture of rat EC and SMC and in vivo-derived hemodynamics79. It has been shown that the 
hyaluronan-related signalling, which plays a key role in inflammation by recruiting 
inflammatory cells and releasing pro-inflammatory cytokines496, is upregulated after 
treatment with fenoldopam.
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Drug Time course 
(hours) 
In vitro/vivo (previous studies) In vitro  
 Monocultured EC  
ICAM-1 VCAM-1 
Bosentan 24 No effect in patients with systemic 
sclerosis493,495 
 
 
 
 
 
Fenoldopam 24 Increase in several inflammatory pathways 
in vitro79 
 
 
 
 
 
Minoxidil 24 Increased inflammation in dogs52    
 
Rolipram 24 Downregulation of pro-inflammatory 
cytokines in the central nervous system in 
rats497 
 
 
 
 
Table 8.3 Comparative effects of EC inflammation seen in vitro/vivo in previous studies with in vitro investigation 
conducted within this thesis. = very significant effect (p < 0.01); = significant effect (p < 0.05); = no effect. 
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Minoxidil and rolipram did not affect VCAM-1 nor ICAM-1 expression in EC. There is evidence 
of inflammation with minoxidil reported in DIVI in dogs in the tunica adventitia in coronary 
arteries, but these effects have been described only in dogs and not in humans52. Rolipram 
has been shown to have an anti-inflammatory effect in rats in the central nervous system, 
where it inhibits TNF-α at both the mRNA and protein levels, and downregulates IL-13, a pro-
inflammatory cytokine of T cell origin497. In addition, rolipram has been found to 
downregulate antigen-driven proliferation and cytokine gene expression for IL-5 and IFN-γ in 
human peripheral blood mononuclear cells497. 
 
8.2.3 EC death 
 
Drug-induced EC death (Table 8.4) was investigated using ATP release as a marker for viability. 
No drug-dependent cell death was observed at the 1 hour and 4 hour time points in 
monoculture and therefore only the 24 hour time point was investigated in co-culture and in 
the presence of Yoda-1. Bosentan did not induce toxicity in EC, but did affect EC death in the 
presence of SMC or Yoda-1. Fenoldopam did induce cell death after 24 hour drug incubation, 
with approximately 50 % of the cells showing death. Although fenoldopam-induced 
cytotoxicity has been observed in vivo in the rat mesenteric artery, however only 1 in 6 rats 
tested positive for EC caspase activation after 24 hours of 100 mg/kg dosage41. Death may be 
exaggerated in our in vitro set up as catabolism of the drug is severely reduced compared to 
in vivo372. In addition, caspase activation (apoptotic cell death) is different to ATP release 
(viability). In the future, TUNEL and caspase-3 immunohistochemistry could be conducted in 
the ex vivo set up to access EC and SMC specific cell death profiles. Endothelial cytotoxicity 
was not observed using any of the other 3 drugs.  
 
Uniquely, fenoldopam induced cytotoxicity was significantly increased in the presence of 
Yoda-1 after 24 hours (75 % death in the presence of Yoda-1 compared to 50 % death alone). 
The chemotherapy agent doxorubicin also increases cytotoxicity under shear stress and Yoda-
1 conditions through increased production of ROS and consequent mitochondrial stress and 
DNA damage498. Perhaps, fenoldopam acts through a similar mechanism since a link between 
fenoldopam and increased NO production (which stimulates RNS and ROS) has been 
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reported100. Again, to ultimately conclude that this is a biological phenomenon due to 
mechanosignalling, HUVEC should be treated with fenoldopam under shear stress conditions 
and monitored for cell viability.    
Minoxidil and rolipram were not cytotoxic in either of the systems used. In previous in vivo 
studies in DIVI, these drugs showed mostly necrosis of SMC and not EC52,53,127.  
 
It is possible that the differences between cytotoxicity observed in vivo and in vitro could 
relate to different expression levels of the drugs known protein targets372. This could be 
quantified through western blot and densitometry analysis. Additionally, different cell species 
may have different off-target effects. One way to monitor this would be to incubate the drugs 
with the HUVEC in the presence of inhibitors of the protein targets. Further, secondary 
pharmacology binding assays/proteomics and stable isotope labelling by amino acids in cells 
culture (SILAC), a powerful method to investigate the proteomic change under differential 
treatment, could be performed.
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Drug Time course 
(hours) 
In vitro/vivo (previous studies) In vitro  
 Monocultured EC Co-culture EC-
SMC 
EC with Yoda-1 
Bosentan 24 n/a  
 
 
 
 
 
 
Fenoldopam 24 Increased activated caspase-3 in rats41  
 
 
 
 
 
 
Minoxidil 24 Necrosis of SMC and not EC52,53    
 
 
 
Rolipram 24 Necrosis of SMC and not EC127  
 
 
 
 
 
 
Table 8.4 Comparative effects of EC death seen in vitro/vivo in previous studies with in vitro investigation conducted within this thesis.  
 = very significant effect (p < 0.0001); = very significant effect (p < 0.01); = significant effect (p < 0.05); = no effect. 
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8.2.4 SMC death 
 
SMC death is summarised in Table 8.5. None of the drugs caused SMC death in monocultured 
SMC, and this effect was unaltered by addition of Yoda-1. This is perhaps surprising as a clear 
histopathological feature of DIVI is apoptosis and necrosis of SMC (refer to Introduction, 
section 1.3.1).  
 
Bosentan has been suggested to prevent apoptosis and inflammation in rats499, conversely 
data presented in this thesis showed a cytotoxic effect of bosentan on SMC when co-cultured 
with EC. This effect was absent when Yoda-1 was added to monocultured SMC. This might 
relate to the differences between in vivo and in vitro models, and especially the complexity 
of the latter. A previous study in rats with fenoldopam showed evident SMC apoptosis, 
measured using activated caspase-3 and TUNEL staining41. 
 
Another study using a PDE IV inhibitor, CI-1018, in rats showed prominent activated caspase-
3 and TUNEL staining in SMC, associated with active inflammation127. However, it has been 
suggested that SMC apoptosis may not be a primary event but rather secondary to the 
inflammatory response127. This suggests that the system used in this thesis may be too 
reductionist and perhaps a more complex system using a combination of EC-SMC interaction 
and flow, is required. It is known that both EC and SMC are altered by the effects of flow in 
vivo500,501 and this was absent in the system described here which may have limited the 
findings.  
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Drug Time course 
(hours) 
In vivo (previous studies) In vitro  
 Monocultured SMC Co-culture 
EC-SMC 
SMC with Yoda-1 
Bosentan 24 Anti-apoptotic effects in rats499  
 
 
 
 
 
 
 
Fenoldopam 24  Increased activated caspase-3 in rats41  
 
 
 
 
 
 
Minoxidil 24 Necrosis in dogs shown by H&E staining53,57    
 
 
 
Rolipram 24 Apoptosis in tunica media in rats with CI-
1018127 
 
 
 
 
 
 
 
Table 8.5 Comparative effects of SMC death seen in vitro/vivo in previous studies with in vitro investigation conducted within this 
thesis. = significant effect (p < 0.05); = no effect. 
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8.2.5 Platelet and leukocyte activation 
 
Finally, the final DIVI feature investigated was whole blood cell activation following drug 
treatment. The effects of the drugs are summarised in Table 8.6. It has been shown that 
platelets adhere to EC and also form aggregates with leukocytes in DIVI199,502. However, in 
these experiment the drugs had no effect on platelets and only bosentan and minoxidil 
induced an effect on neutrophil activation. The effects seen in previous studies have been 
described in chapter 5.
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Drug Time 
course 
(hours) 
In vitro/vivo (previous studies) In vitro  
 Platelets Leukocytes 
Integrin αIIbβ3 P-selectin Neutrophils Monocytes 
Bosentan 20 Effects on platelets unclear412–414, 
reduction in leukocyte adhesion and 
inflammation in mice422 
 
 
 
 
 
 
 
 
 
 
 
 
60     
Fenoldopam 20 No effect on platelets416     
60     
Minoxidil 20 Prevention of platelet aggregation411     
60     
Rolipram 20 Reduction in neutrophil recruitment in 
vivo and in vitro425 
    
60     
 
Table 8.6 Comparative effects of inflammation seen in vitro/vivo in previous studies with in vitro investigation conducted within this thesis.  
= very significant effect (p < 0.01); = significant effect (p < 0.05); = no effect. 
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In summary, the four drugs tested have been reported to cause DIVI in preclinical species, 
even though the exact mechanisms driving the injury are still unclear. In this study, when 
investigated in vitro for classic biomarkers of DIVI, no common patterns emerged and they 
each had different effects on the features explored. This suggests that the somewhat 
simplistic approach taken here is not ideal for the assessment of DIVI and additional elements 
need to be added to generate a more complex in vitro model for DIVI. In addition, it has to be 
noted that the assays investigated in this thesis are mostly phenotypic and not mechanistic. 
As such, future investigation should focus on understanding in detail the cellular and 
mechanistic aspects of DIVI. The subsequent sections will provide hypotheses on markers that 
could be investigated in the future to increase the understanding of the mechanisms 
underlying DIVI. The next sections will explore (1) other potential DIVI biomarkers that are 
worth investigation and (2) the construction of a more complex model system to study DIVI. 
 
8.3 Exploring other potential markers of DIVI in vitro 
 
A popular DIVI theory is that these compounds induce lesions by triggering vasodilation 
(described in Introduction, section 1.5.1). For example, it has been reported that 
administration of minoxidil, an opener of KIR (inward rectifier) 6.X ATP sensitive K+ channels, 
to rats at an equipotent hypotensive dose to SK&F 95654, a PDE III inhibitor, led to arterial 
lesions that were macroscopically, microscopically, and ultrastructurally identical to those 
induced by the PDE III inhibitor76. This suggests that the lesion may be caused by the 
haemodynamic effect of these compounds rather than an underlying cytotoxic effect. This 
finding is important for the understanding of the mechanisms underlying all drugs implicated 
in DIVI. Both compounds also induce a comparable and long-lasting increase in mesentery 
blood flow in rats, which is expected to produce an increase in endothelial shear stress.  
 
These observations suggest that a useful potential marker of DIVI that has not been 
investigated in this thesis is NO, which is fundamental in maintaining vascular tone. Previous 
studies have implicated NO as a potential regulator involved in the pathogenesis of 
DIVI35,100,127,128,171, particularly for phosphodiesterase IV inhibitors, where the upregulation of 
cAMP causes SMC relaxation503. For example, an elevation in eNOS phosphorylation at S615 
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has been shown after administration of the PDE IV inhibitor CI-1044, accompanied by 
overproduction of NO and vascular injury125. These elevations were higher in the mesenteric 
arteries in rats compared to the aorta, which is not damaged in response to PDE IV inhibitors. 
This finding was not specific to PDE IV inhibitors, since each of the other classes of drugs 
examined (PDE III inhibitor, adenosine agonist and a K+ channel opener) produced similar 
results. These findings support the hypothesis that NO may underlie DIVI and it will warrant 
further investigation. 
 
Transcriptional profiling of specific elements of blood vessels from animal models of vascular 
toxicity is an approach to gain insight into molecular mechanisms of vascular injury41. A study 
using fenoldopam in rats used laser capture microdissection to assess differential gene 
expression in the mesenteric arteries. RNA was then isolated, linearly amplified and 
hybridized to Affymetrix GeneChips®. It was found that fenoldopam resulted in differential 
expression of 333 versus 458 genes in EC and 371 versus 618 genes in SMC at the 1 hour or 4 
hour time point, respectively. 
 
Microarray technology to detect circulating microRNAs is able to screen a large set of 
components in the plasma and might also be a useful approach to gain insights into DIVI. 
Further, -omic approaches can be used to assess pathways that change with DIVI-related 
drugs in the presence or absence of Yoda-1 (such as eNOS and Akt phosphorylation, VCAM-1 
and ICAM-1 expression) in the model used here and compare them with traditional flow. 
Blood vessels on a chip to study DIVI metabolites and biomarkers using BIOCORE analysis of 
the media/blood that is flowed through the device may also be of help504.  
 
A model to study extravasation of RBC would also be useful to understand DIVI. It has been 
described in dogs treated with a PDE III inhibitor that erythrocytes fill the space previously 
occupied by SMC that undergo necrosis76. A microfluidic vascular device where EC and SMC 
are co-cultured together has been developed to study this phenomenon that is still unclear 
in DIVI114. This in vitro system is made using poly(dimethylsiloxane) (PDMS), where primary 
rat EC and SMC are co-cultured on opposite sides of a porous membrane mimicking the 
internal elastic lamina and then whole blood perfused in the EC chamber with the possibility 
of studying extravasation of RBC into the smooth muscle region114. The endothelial chamber 
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was designed to be 200 µM in diameter in order to replicate the size of rat mesentery vessels 
affected by DIVI. It was found that administration for 8 hours of a candidate drug (CI-1044) 
known to cause DIVI induced extravasation of RBC, which was suggested to be due to the 
deleterious effects of the compound on EC junctions or other responses such as vascular 
oxidant stress and inflammation reported in previous in vivo studies with CI-1044. 
 
8.4 The optimum device to study DIVI 
 
A human in vitro model of DIVI has been developed in this study, where several markers that 
play a crucial role in the development and progression of the lesions in DIVI have been 
investigated. A factor that has not been investigated is the addition of Yoda-1 to EC-SMC co-
culture rather than studying the effects of Yoda-1 only on EC. In addition, SMC inflammation 
has not been explored and is something that is worth doing in the future as inflammation is 
an important sign of DIVI. 
 
This in vitro system provided the following advantages: (1) it is a simple model to construct 
as the parameters investigated have been well-characterised in the past and are relatively 
simple and quick to measure; (2) it is a model that can be replicated across different 
laboratories and does not involve the use of complicated and expensive machinery nor 
equipment. In drug development the aim is to have reproducibility, low cell number, robust 
endpoint, plate format, sensitivity and specificity and these requirements have been met with 
the model presented here. 
 
However, there are a few limitations using this model: (1) absence of flow. Flow might be a 
crucial component in the development of DIVI and the use of real flow with blood rather than 
a flow-mimetic would allow the study of RBC extravasation, because although Yoda-1 mimics 
some of the biological effects of flow, the physical forces are likely the elements that cause 
RBC extravasation, although this has not been established yet114; (2) complexity and 
physiological relevance. The model did not include the study of the effect of the drugs using 
a combination of EC-SMC co-culture and flow.  
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It has been suggested that a key element in RBC extravasation may be the porous internal 
elastic lamina, where the diameter of its holes is large enough to allow extravasation of RBC114 
as it has been hypothesised that this is their route of passage into the tunica media in DIVI. 
Therefore consideration in designing an optimal future device would be incorporating a 
porous membrane that separates the EC and the SMC layer, mimicking the naturally porous 
internal elastic lamina. 
The optimal device would also allow cells to be cultured for long periods of time, in order to 
investigate the phenomena demonstrated in animals, where drugs are administered for 
months. This would enable an understanding of the resolution of the lesions that have been 
observed with some of the drugs that is still a matter for debate (refer to Introduction, section 
1.3.1). Moreover, the ideal device would allow isolation of different cell types to perform end 
stage testing and also to assess whether SMC undergo the phenotype switch to the synthetic 
or proliferating one, that has been reported in vascular diseases such as atherosclerosis236. 
Isolation of plasma or cell supernatant to monitor biomarkers released from the cells at 
different time intervals would also be optimal. Investigating DIVI in an assay format has 
proven to be difficult and perhaps a low throughput/high sensitivity option in a device (rather 
than a high-throughput/low sensitivity) is the way forward. The benefit of this as opposed to 
an in vivo model would still be the reduction in the use of animals in research. 
In summary, this PhD aimed at studying a toxicological event in human cells. Further studies 
are needed in the future to understand the exact mechanism by which drugs cause vascular 
injury. Likely, as mentioned previously, the drugs act through off-target actions and possibly 
the on-target effect has little implication in the development of the injury. Mechanistically, 
this could be achieved by studying the molecular structure of the drug to understand which 
receptors could be implicated in the DIVI pathology and then blocking those receptors to 
assess whether the effect of the drug is reduced. Most likely, one assay will not be sufficient 
and multiple assays are required for these studies. 
 
8.5 Limitations and concluding remarks 
 
Several limitations affect the studies presented in this thesis. First of all, the low sample size 
(n=4), which is usually appropriate for initial/pilot experiments, is a very limited number for 
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in vivo studies. As mentioned in chapter 2, previous studies in the field describe similar 
experiments using a comparable number of animals. In addition, considerations related to 
the Replacement, Refinement and Reduction of Animals in Research (3Rs) have been made 
and the number of rats used kept to the minimum. 
Furthermore, it would have been ideal to use for the studies endothelial and smooth muscle 
cell lines originating from arteries usually affected by DIVI. HUVEC are derived from veins from 
immune-naïve foetal tissue and show differences from adult vascular endothelium. However, 
HUVEC were selected as the source of EC since they have been extensively characterised in 
the literature341 and HCASMC were used as the source of arterial vascular SMC as they have 
also been widely described342. Limitations related to the sensitivity to drugs and shear stress 
should be taken into considerations and have been described more in detail in the specific 
chapters sections. 
A further limitation relates to the fact that degradation as opposed to release may be 
responsible for the loss of VWF in the assays presented. There are reasons for the loss of 
expression which could be irrespective of VWF release. For example, endothelial 
autophagosomes contain abundant VWF protein and the drugs could increase degradation of 
VWF. This should be taken into consideration and further investigated in the future. 
 
In conclusion, the aim of the work presented in this thesis was to develop a simple cellular 
system that would facilitate future screening of a large number of compounds for DIVI risk 
during drug development. In such an underinvestigated area it has been difficult to develop 
a predictive assay. A human in vitro model has been generated, whereby drugs known to 
cause DIVI in preclinical animal species were used to identify whether a DIVI phenotype could 
be detected in human cells. The approach was limited by variability in DIVI features following 
drug treatment and the utilisation of high doses that poorly correlated with a human 
efficacious dose. 
 
The limitations associated with the model may indicate that a more complex system needs to 
be developed for the in vitro study of DIVI, or that the absence of DIVI markers in human cell 
models means that there is limited cross species translation and that this is a 
pathophysiological effect that only occurs in animals and not humans. In order to fully confirm 
this hypothesis, in the future improvements must be added to the assay in order to have a 
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tool that reproduces in the best possible way the in vivo physiology, and at the same time is 
easy to use and cost-effective. Drug attrition at present is still high, and safety assessment is 
of fundamental importance. Thus, the need for robust predictive assays remains. With further 
development, this model will have utility as an in vitro screening test of candidate drugs for 
DIVI. 
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Appendix 
 
The following tables summarise the effect of the drugs in the assays tested. 
CHAPTER 3 (Rat vessel) 
VWF release (N=4) 24 hours 
Untreated control 100 % 
Thrombin 10 U/ml 39.32 ± 8.52 % 
Bosentan 100 µM 39.12 ± 3.46 % 
Fenoldopam 100 
µM 
43.99 ± 6.44 % 
Minoxidil 100 µM 46.78 ± 5.92 % 
Rolipram 100 µM 89.0 ± 23.20 
 
CHAPTER 4 (Monocultured EC and SMC) 
VWF release (N=4) 1 hour 24 hours 
DMSO control 80 % 80 % 
Thrombin 1 U/ml 41.6 ± 5.5 % 55.8 ± 2.9 % 
Bosentan 100 µM 51.7 ± 2.6 % 53.3 ± 6.9 % 
 
EC junctional disruption 
(N=4) 
1 hour 24 hours 
DMSO control 1 1 
Thrombin 1 U/ml 7.5 ± 1.2 3.2 ± 1.7 
Bosentan 100 µM 2.1 ± 0.7 2.7 ± 1.7 
Fenoldopam 100 µM 7.9 ± 3.3 1.2 ± 0.6 
Minoxidil 100 µM 9.3 ± 3.4 11.5 ± 1.9 
Rolipram 100 µM 0.9 ± 0.3 - 
 
EC death (N=5) 1 hour 4 hours 24 hours 
DMSO control 97.0 ± 0.6 % - - 
Saponin 11.0 ± 0.7 % - - 
Fenoldopam 100 µM - - 48.4 ± 6.1 % 
Fenoldopam 10 µM - - 89.2 ± 2.7 % 
Fenoldopam 1 µM - - 93.3 ± 7.3 % 
Fenoldopam 0.1 µM - - 94.8 ± 6.5 
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CHAPTER 5 (Whole blood) 
Platelets 20 minutes 20 minutes 
Integrin (N=5) P-selectin (N=5) 
Untreated control 257.5 ± 9.190 95.30 ± 12.36 
TRAP-6 1261 ± 206.1 8560 ± 840.0 
fMLP 269.9 ± 9.341 96.20 ± 29.18 
Fenoldopam 1 µM 307.0 ± 45.19 110.0 ± 28.96 
Fenoldopam 10 
µM 
286.1 ± 30.49 104.2 ± 23.25 
Fenoldopam 100 
µM 
318.2 ± 65.18 109.9 ± 25.85 
 
CHAPTER 6 (EC-SMC co-culture) 
VWF release (N=4) 1 hour 24 hours 
DMSO control 86 % 88 % 
Thrombin 1 U/ml 54.4 ± 5.2 % 51.7 ± 3.9 % 
Bosentan 100 µM 68.3 ± 3.8 % 62.8 ± 3.7 % 
Fenoldopam 100 µM 57.9 ± 5.1 % 54.2 ± 3.2 % 
Minoxidil 100 µM - 54.5 ± 8.8 % 
 
Cell death (N=4) EC  EC mix SMC  SMC mix 
24 hours 24 hours 
DMSO control 3.3 ± 0.1 % - - - 
Cisplatin 91 ± 3.4 % 94.9 ± 2.5 % 94.2 ± 2.3 % 94.4 ± 2.3 % 
Bosentan 100 µM - 15.9 ± 0.5 % - 16.6 ± 0.5 % 
Fenoldopam 100 µM 8.6 ± 1.1 % 1.8 % - - 
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CHAPTER 7 (Yoda-1) 
VWF release (N=4) 1 hour 24 hours 
DMSO control 87.4 ± 2.8 % 93.0 ± 1.5 % 
Yoda-1 1 µM 79.5 ± 6.0 % 63.9 ± 1.90 % 
Minoxidil 100 µM - 72.9 ± 2.2 % 
 
EC junctional disruption 
(N=4) 
1 hour 24 hours 
DMSO control 1 1 
Yoda-1 1 µM 0.45 ± 0.07 0.3 ± 0.04 
Bosentan 100 µM 4.9 ± 2.8 21.0 ± 5.0 
Fenoldopam 100 µM 7.7 ± 4.9 - 
Minoxidil 100 µM 3.4 ± 2.0 - 
 
EC death (N=5) -Yoda-1 +Yoda-1 
24 hours 24 hours 
DMSO control - - 
Yoda-1 1 µM - - 
Bosentan 100 µM 17.6 ± 2.4 % 37.1 ± 3.8 % 
Fenoldopam 100 µM 24.1 ± 2.9 % 72.6 ± 4.9 % 
 
 
